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Abstract
Endoribonucleases are messenger ribonucleic acid (mRNA)-degrading enzymes that have 
been determined to be key players in post-transcriptional regulation o f mRNA. These unique 
enzymes are known to cleave mRNA transcripts via the deadenylation-independent pathway, 
thus providing a method of controlling gene expression by regulating the relative abundance of 
mRNA within the cytoplasm at any given time; a process collectively referred to as mRNA 
turnover. The c-myc gene is a transcription factor that plays important roles in growth 
regulation, differentiation, and cell death in virtually all mammalian cells, c-myc can also act as 
a proto-oncogene, and overexpression of the c-myc protein product has been linked to over 14% 
of annual cancer mortalities; a statistic that emphasizes the importance of studying enzymes 
capable of cleaving the c-myc protein precursor mRNA.
Our lab has discovered and purified a novel mammalian liver endoribonuclease from rats 
that is capable of degrading the coding region determinant (CRD) of c-myc mRNA in vitro. Five 
proteins were found to co-purify with this endoribonuclease activity, with one of these proteins 
having a molecular weight of ~35 kDa. Trypsin digestion of this ~35 kOa protein, followed by 
MALDI-mass spectroscopy and subsequent database searching, found a protein, referred to here 
as recombinant protein p35 (Rpp35), that matched four of the -35  kDa protein's tryptic peptides.
The main goal of this thesis was to characterize human Rpp35. The first aim of this 
thesis was to generate, purify, re fold, and then test Rpp35 for endoribonuclease activity. Aim I 
was a success in that the full-length human Rpp35 was generated and purified, and successfully 
shown to exhibit endorihonucleolytic activity against the CRD of c-myc mRNA in vitro. The 
second aim of this thesis was to perform five main characterization experiments on Rpp35 in an 
attempt to confirm whether it is in fact the -35  kDa protein that co-purified with the native
11
mammalian endoribonuclease. The endoribonucleolytic activity of Rpp35 against the CRD of c- 
myc mRNA was demonstrated to be distinct to that of the native mammalian endoribonuclease. 
Cleavage site mapping experiments conducted on Rpp35 determined that Rpp35 specifically 
cleaves the CRD of c-myc mRNA at single-stranded AA, AG, and GU dinucleotides, as well as 
double-stranded GG dinucleotides found in stem-loop regions. While both Rpp35 and the 
partially purified native mammalian endoribonuclease successfully reacted witb a polyclonal 
antibody source specific to Rpp35, neither the immunoprécipitation and/or the subsequent 
enzymatic-depletion experiments generated conclusive data. It is still not definitively known 
whether Rpp35 and the ~35 kDa protein associated with the native mammalian endoribonuclease 
are, in fact, the same protein, as this thesis generated data that both supports and opposes this 
hypothesis.
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CHAPTER 1: INTRODUCTION
1.0 Messenger RNA Turnover
To fully appreciate the complexity of the processes involved in mRNA turnover, and to 
gain insights as to the emerging role that endoribonucleases play in these processes, it is 
necessary to first review our current knowledge of mRNA turnover. This section provides an 
overview for the processes and steps involved in mRNA turnover in prokaryotes, as well as in 
lower (yeast) and higher (vertebrate) eukaryotes.
1.0.1 Messenger RNA Turnover - Overview
Messenger RNA degradation plays vital roles in the control of gene expression, 
regulating the quality of mRNA synthesis, the processing of pre-mRNAs, and in anti-viral 
defences (Dodson and Shapiro 2002; Baker and Condon 2004; Parker and Song 2004). mRNA 
degradation influences gene expression by controlling the amount of time the mRNA transcript 
remains in the cytosol; the longer the mRNA transcript persists in the cytosol, the more that 
protein gets translated (Dodson and Shapiro 2002). mRNA degradation also plays a role in 
recognizing and eliminating aberrant mRNAs that contain premature stop codons (PTCs), 
referred to as nonsense-mediated decay (NMD) and mRNAs lacking translation termination 
codons, referred to as non-stop decay (NSD), thus regulating the quality of the mRNA (Parker 
and Song 2004). The anti-viral role is a defence mechanism against double-stranded viral RNA 
or RNA interference (RNAi) (Van Hoof and Parker 1999; Dykxhoorn et al. 2003).
There are many challenges when studying mRNA decay. One of the major challenges is 
that mRNA is not very abundant, and only represents a small fraction (<10%) of total RNA 
within a cell at any given time (Kushner 2002). Another challenge in studying mRNA
degradation is the stability of the mRNA itself; mRNA is very unstable compared to tRNA, 
rRNA, and complex structures (Rauhut and Klug 1999).
There are two main proposed pathways for mRNA decay. One is termed the 
deadenylation-dependent pathway, in which removal of the poly(A) tail at the 3' terminus is a 
pre-requisite for 5 '^ 3 ' or 3 '^ 5 ' exoribonucleolytic degradation (Guhaniyogi and Brewer 2001). 
The second pathway, called the deadenylation-independent pathway, does not require removal of 
the poly(A) tail. This type of mRNA degradation is initiated by endoribonucleases that 
recognize highly specific sequences within the transcript, or in a response to micro RNAs 
(miRNAs) or small interfering RNAs (siRNAs) (Guhaniyogi and Brewer 2001; Dodson and 
Shapiro 2002; Parker and Song 2004). Once the initial endonucleolytic cleavage event has 
occurred, the remaining mRNA transcript is rapidly degraded by various exoribonucleases.
Many of the ci5-acting RNA elements that control the mRNA decay rates as well as the 
tran^-acting proteins that enzymatically carry out the degradation have now been characterized 
(Grunberg-Manago 1999). CA-determinants, which are essentially stability determinants, can 
occur anywhere within a mRNA transcript, but are usually found within the 3'-untranslated 
region (UTR) and within coding region determinants (CRDs) (Lee et al. 1998; Guhaniyogi and 
Brewer 2001; Dodson and Shapiro 2002). CA-determinants include the poly(A) tail, iron- 
responsive elements (IREs), and AU-rich elements (AREs) typically found in the 3 -UTR (Ross 
1995). Tmm-acting factors include RNA-binding proteins and ribonucleases (Ross 1995). 
Ribonucleases (RNases) represent the most direct tran^-acting factors involved in mRNA 
stability (Baker and Condon 2004), and play crucial roles in both the processes of cellular 
metabolism and in the control of gene expression (Condon and Putzer 2002).
Ribonucleases, which are present within a cell or secreted as extracellular enzymes, are 
small heat-stahle proteins that cleave in a site-specific manner (Mishra 2002). They can act on 
single or douhle-stranded RNA, or on the RNA present in DNA-RNA hybrids (Mishra 2002). 
RNases are divided into two categories, termed exoribonucleases and endoribonucleases, based 
on their mode of RNA cleavage. Exoribonucleases are capable of degrading nucleic acids at one 
end of the molecule, while endoribonucleases are RNases that can degrade an RNA transcript 
from within its sequence, attacking an internal phosphodiester bond, with or without a free 
terminus (Condon and Putzer 2002). Both will produce either a 3'- or 5'-phosphorylated 
nucleolytic product (Mishra 2002).
In addition to cA-determinants and trans-acting factors, elaborate secondary structure 
features are also believed to play roles in mRNA stability by making the transcript more or less 
accessible for cleavage by exo- and endoribonucleases (Mackie 1998; Coburn and Mackie 1999).
1.0.2 Messenger RNA Turnover in Prokaryotes (Bacteria)
Much of our understanding of mRNA turnover comes from the extensive work carried 
out on simple bacteria, such as Escherichia coli (E. coli). The study of E. coli as a model for 
mRNA degradation has dominated mRNA decay research, so it is important to recognize that 
observations and discoveries made in E. coli mRNA degradation might not hold true for other 
prokaryotes and eukaryotes. This realization has become apparent by various inconsistencies 
and conflicting data found between E. coli. Bacillus subtilis, Streptomyces coelicolor, and 
Synechocystis species (Condon 2003; Baker and Condon 2004). Nevertheless, the study of 
E.coli mRNA decay has provided numerous insights, and led to significant advances in our 
understanding of prokaryote mRNA decay (Rauhut and Klug 1999).
While over 20 different RNases have been identified in E. coli, only 9 are now known to 
be implicated in mRNA decay; 6 of these RNases act as endoribonucleases (summarized in 
Table 1, Section 1.2.1, pg. 30) and 3 act as exoribonucleases (Steege 2000; Cheng and Deutscher
2005). The three main mRNA decaying RNases, referred to as site-specific endoribonucleases, 
are named RNase E, RNase G (an RNase E orthologue), and RNase III (which are discussed in 
greater detail in Chapter 1, Section 1.3.1) (Nicholson 1999; Steege 2000; Kushner 2002). The 
three main exoribonucleases (RNase II, Polynucleotide phosphorylase, and oligoribonuclease) 
have been shown to degrade mRNA in a 3 '^ 5 ' fashion (Cheng and Deutscher 2005). There are 
also several newcomers to the scene, MazF, PemK, and RNase R. MazE is a highly conserved 
toxin gene found in E. coli that has been reported to act as sequence-specific endoribonuclease 
capable of cleaving cellular mRNAs (Zhang et al. 2005). PemK is also believed to be an 
endoribonuclease that blocks protein synthesis by sequence-specific cleavage of cellular mRNAs 
(Zhang et al. 2004b). RNase R is another proposed exoribonuclease involved in mRNA decay, 
which acts by removing repetitive extragenic palindromic (REP) sequences in both prokaryotes 
and eukaryotes (Deutscher 2003; Baker and Condon 2004; Cheng and Deutscher 2005). RNase 
P has also recently been added to the list of mRNA degrading enzymes as it was found that 
RNase P is capable of endonucleolytically cleaving several polycistronic operon mRNAs in vitro 
in E. coli (Ei and Altman 2003). Other endoribonucleases have also been proposed to exist, such 
as RNase M, RNase IV, and RNase E, but studies illustrate that these are most likely mutant 
forms of RNase I (Subbarayan and Deutscher 2001).
Prokaryotes degrade mRNA via the deadenylation-independent pathway. It is currently 
believed that mRNA degradation in bacteria is predominately initiated by endoribonucleolytic 
attack, thought to be by RNase E, or less commonly, RNase III or RNase G (Jiang and Belasco
2004), and that the remaining monophosphate degradation products are quickly degraded from 
their resulting 3' end by the 3'-^5' exoribonucleases polynucleotide phosphorylase (PNPase) and 
RNase II (Grunberg-Manago 1999; Nicholson 1999; Rauhut and Klug 1999; Steege 2000; 
Condon and Putzer 2002; Kushner 2002; Baker and Mackie 2003; Deutscher 2003). It has been 
speculated that the majority of mRNA in E. coli are degraded unidirectionally in a successive net 
5’->3’ direction (Mackie 1998); an interesting hypothesis considering that no exoribonucleases 
that degrade in the 5 '^ 3 ' direction have yet been discovered amongst prokaryotes (Grunberg- 
Manago 1999; Nicholson 1999; Kennell 2002; Condon 2003). While this net 5 '^ 3 ' directional 
decay makes sense from an efficiency and evolutionary standpoint, it is, however, important to 
note that there is currently very little physical proof to support this theory (Condon 2003). 
Cohen and colleagues further complicated this issue and raised more questions when they 
reported that RNase E has inherent 3 '^ 5 ' directionality in cleavage site selection (Feng et at. 
2002; Kennell 2002).
The first step in mRNA degradation in E. coli, endoribonucleolytic cleavage by RNase E, 
is considered the rate-limiting step in the degradation pathway and is highly dependant on the 
phosphorylation state of the 5' end (Condon 2003). The original site-specific cleavage is 
frequently found to be in the 5 -terminus region, often very close to the translation initiation site 
(Coburn and Mackie 1999; Nicholson 1999). The strong preference of RNase E for 5'- 
monophosphates ensures that once initial mRNA decay has commenced, the continued 
degradation of the previously cleaved 3' fragment has priority over cleavage of a yet untouched 
5'-triphosphate (Baker and Condon 2004; Jiang and Belasco 2004). It is now generally accepted 
that 5'-triphosphates act to help stabilize mRNA transcripts by blocking the activity of RNase E 
(Baker and Condon 2004). These hypotheses are coneurrent with the observations that RNA
secondary structures located in proximity to the 5' terminal can help to further stabilize 
downstream RNA sequences (Grunberg-Manago 1999; Baker and Mackie 2003). The mRNA 5' 
terminal is not the only determinant of stability, however, and it is believed that the 3' terminal 
also plays a critical role in regulating mRNA decay through the presence or absence of 
polyadenylation (Grunberg-Manago 1999; Baker and Condon 2004).
It is believed that E. coli mRNA transcripts are destabilized by a poly(A) tail, and that the 
presence or absence of this poly(A) tail does, in fact, have an effect on the degradation of mRNA 
(Bini et al. 2002). When coming to conclusions regarding the relative significance of 3'- 
polyadenylation, it is important to remember that only a very small proportion (1 to 2%) of the 
total mRNA population actually have poly(A) tails (Kushner 2002). Nevertheless, prokaryote 
mRNAs are polyadenylated at the 3' terminus (Bini et al. 2002), which has the suggested effect 
of destabilizing the mRNAs because it represents a single-stranded region which is highly 
susceptible to exonucleolytic digestion by 3'-^5' exoribonucleases (Coburn and Mackie 1999; 
Grunberg-Manago 1999); an interesting direct contrast to what is believed to be the case in 
eukaryotes, where the poly(A) tail is thought to help stabilize mRNA (Grunberg-Manago 1999; 
Bini et al. 2002; Baker and Condon 2004). It has also been observed that the presence of 3’ stem 
and loop structures also contribute to overall stability by blocking the degradation of the mRNA 
transcript by various exoribonucleases (Grunberg-Manago 1999).
Further helping to clarify the mRNA decay process in bacteria is the discovery and 
characterization of a multi-component enzyme complex called the degradosome, which is 
believed to choreograph mRNA decay in E. coli (Coburn and Mackie 1999; Nicholson 1999). 
The degradosome, which was discovered when full-length RNase E was first purified, was found 
to be highly associated with PNPase and other, at the time, unknown proteins that co-precipitated
with the RNase E antibodies (Rauhut and Klug 1999). The degradosome is now believed to be 
composed of RNase E, PNPase, R hlB  RNA helicase, a glycolytic enzyme enolase, and several 
other enzymes that require ATP as a cofactor (Grunberg-Manago 1999; Kushner 2002; Redko et 
aZ. 2003).
It is believed that the degradosome is similar to other multi-enzyme complexes such as 
the proteasome, ribosome, spliceosome, and nuclear pore (Rauhut and Klug 1999). Complexes 
such as these orchestrate a number of distinct proteins in a coordinated effort to carry out the 
most vital and critical of cellular processes (Rauhut and Klug 1999). The degradosome may be 
implicated in numerous enzymatic processes as it has also been shown to degrade rRNAs in vitro 
(Deutscher 2003). It is still highly debated whether the degradosome formation actually 
increases the catalytic cleavage of RNase E (Lee et al. 2003).
1.0.3 Messenger RNA Turnover in Lower Eukaryotes (Yeast)
The majority of our current knowledge of mRNA decay in eukaryotes comes primarily 
from work carried out on yeast (reviewed in Parker and Song 2004) and mammals (Dodson and 
Shapiro 2002). In yeast, such as Saccharomyces cerevisiae, the deadenylation-dependent 
pathway appears to be the dominant mode of mRNA decay.
The first step in eukaryote mRNA decay is the polysome-associated deadenylation of the 
3'-poly(A) tail by mRNA deadenylases, such as Ccr4 and/or Pop2 in yeast (Cougot et al. 2004; 
Parker and Song 2004). In the major pathway in S. cerevisiae, a decapping pyrophosphatase 
enzyme composed of two subunits, Dcpl and Dcp2, then effectively removes the 5'-cap structure 
rendering the now unprotected mRNA transcript vulnerable to exoribonucleolytic attack by the 
5 '^ 3 ' exoribonuclease X rnip (Brewer 1999; Wagner and Lykke-Andersen 2002; Cougot et al. 
2004; Parker and Song 2004). This process also requires decapping activators, such as D hhlp,
Lsm l-7p, and Pat Ip, although their exact role in yeast mRNA decay is not yet fully understood 
(Long and McNally 2003). The 5’^ 3 ' mRNA decay pathway is regulated through control of the 
rate of deadenylation and the decapping efficiency (Cougot et al. 2004).
In an alternative, less active pathway, deadenylation is followed by 3 '^ 5 ' exonucleolytic 
degradation by the exosome, a multi-protein complex consisting of at least seven 3 '^ 5 ' 
exonucleases, which then ensures 3 '^ 5 ' degradation (Brewer 1999; Liu et al. 2002; Wagner and 
Lykke-Andersen 2002; Lehner and Sanderson 2004; Parker and Song 2004). The 5'-cap of the 
resulting oligonucleotide, in this case, would then be hydrolyzed by the DcpS scavenger 
decapping enzyme (Parker and Song 2004).
It is becoming apparent that yeast mRNA can also be degraded via the deadenylation- 
independent pathway, as several endoribonucleases have now been identified in yeast that are 
capable of degrading mRNA. These include an RNase III orthologue called R ntlp (Chanfreau 
2003; Danin-Krieselman et al. 2003; Lee et al. 2005), and RNase mitochondrial RNA processing 
(RNase MRP) (van Eenennaam et al. 2001b; Gill et al. 2004). These endoribonucleases and 
their mode of attack will be discussed in greater detail later (Chapter 1, Section 1.2.2).
1.0.4 Messenger RNA Turnover in Higher Eukaryotes (Vertebrates)
mRNA degradation in vertebrate cells is very similar to that observed in yeast. 
Vertebrate mRNA degradation is believed to occur primarily through the deadenylation- 
dependent pathway, although there is also evidence that suggests degradation via the 
deadenylation-independent pathway.
As is the case in 5. cerevisiae cells, vertebrate mRNA utilizing the deadenylation- 
dependent pathway must first exonucleolytically degrade the poly(A) tail (Brewer 1999; Parker 
and Song 2004). The enzymes that accomplish this in vertebrates are either the same, or
paralogous to those that exist in yeast, and include Ccr4p, pop2, Pan2p, and Pan3p (Parker and 
Song 2004). An additional poly(A)-specific exonucleolytic deadenylation enzyme also exists, 
called poly(A) ribonuclease (PARN), which appears to be responsible for the major deadenylase 
activity observed in mammalian mRNA decay systems (Parker and Song 2004). While PARN 
homologues have been found in numerous eukaryotes (Caenorhabditis elegans, Arabidopsis 
thaliana, mosquito, Schizosaccharomyces pombe, and Neurospora crassa), it is not found 
ubiquitously (5. cerevisiae and Drosophila melanogaster) (Parker and Song 2004). Once the 
poly(A) tail has been successfully removed, the now unprotected transcript is rapidly degraded in 
the 3 '^ 5 ' direction by various 3 '^ 5 ' exonucleases contained within the exosome (Parker and 
Song 2004). The 5 '-cap structure (m^GMP) is then released via the scavenger decapping 
enzyme, DcpS (Liu et al. 2002).
Also similar to yeast, the 5'-»3' exonucleolytic decay pathways have recently been 
implicated in mammals (Wang and Kiledjian 2001; Liu et al. 2002; Mukherjee et al. 2002). In 
this pathway, the rate-limiting step of deadenylation is followed by removal of the 5'-cap 
structure by mammalian homologues of Dcpl (D cplA  and DcplB), and then rapidly degraded 
exonucleolytically in the 5 '^ 3 ' direction by mammalian homologues of X rnlp (Long and 
McNally 2003; Lehner and Sanderson 2004). It was recently found that factors implicated in 
5 '^ 3 ' decay in mammals appear to colocalize, and were found to be concentrated in specific 
cytoplasmic structures (GW bodies) believed to be the actual site of mRNA decay (Cougot et al. 
2004). These GW bodies will be discussed in more detail in Chapter 4, Section
In contrast to what is observed in yeast, the major mRNA degradative pathway in 
mammals appears to be 3 '^ 5 ' exoribonucleolytic decay, while degradation from the 5' termini is 
believed to be a minor contributor (Liu et al. 2002; Rodgers et al. 2002) These hypotheses are
supported by numerous studies that have shown that c-myc mRNA can be degraded via 
deadenylation followed by 3’^ 5 ’ decay governed by adenosine and uridine (AU)-rich elements 
at its 3’ untranslated region (UTR) (Brewer 1999; Doyle et a l  2000; Bremer et a l  2003).
The deadenylation-independent pathway is also believed to play a role in vertebrate 
mRNA decay; a hypothesis based on the identification of endonuclease cleavage sites in many 
mRNAs, including mammalian (Dodson and Shapiro 2002; Bremer et a l 2003; Baker and 
Condon 2004; Parker and Song 2004). Endoribonucleases have been implicated in the mRNA 
degradation of: human a-globin (Wang and Kiledjian 2000a), human [3-globin (Stevens et a l  
2002), mouse (Tharun and Sirdeshmukh 1995) and Xenopus albumin (Hanson and Schoenberg 
2001), human transferrin receptor (Binder et a l  1994), human insulin-like growth factor II (IGF- 
II) (Meinsma et a l  1992), human c-myc (Lee et a l  1998; Tourriere et a l  2001 ; Bergstrom et a l
2006), Xenopus vitellogenin (Cunningham et a l  2001b), cell cycle regulator p27*^ '*’' (Zhao et a l
2000), Xlhbox2B (Brown and Harland 1990; Brown et a l  1993), Hepatitis B virus (Heise et a l
2001), apolipoprotein II (Binder et a l  1989), interleukin-2 (Hua et a l  1993), numerous viral 
RNAs (Everly et al. 2002; Mishra 2002; Zhang et a l  2004a), and PTC-containing mRNAs in 
Drosophila (Gatfield and Izaurralde 2004). Only a few of the endoribonucleases responsible for 
cleavage of these mRNAs have been purified and/or identified, and to date, no true mammalian 
mRNase (RNase devoted only to the degradation of mRNA) has been identified (Lee et a l  
1998). A comprehensive review of known vertebrate endoribonucleases and their respective 
characteristics are discussed in detail in Chapter 1, Section 1.2. Our current lack of knowledge 
regarding mammalian RNases, specifically mRNA endoribonucleases, underlines the importance 
of continued investigation and research in this field.
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Eukaryotes have also evolved special pathways designed to deal with problematic 
mRNAs, such as nonsense-mediated decay (NMD) and nonstop decay (NSD). In the conserved, 
post-transcriptional NMD process, mRNAs that contain premature stop codons (PTCs) are 
recognized and degraded prior to translation to prevent truncated proteins from harming the cell 
(Wagner and Lykke-Andersen 2002; Coller and Parker 2004; Gatfield and Izaurralde 2004). The 
degradation process in NMD can be initiated from both the 5' and 3' terminals. When 
degradation is initiated from the 5'-terminus, it involves removal of the 5 '-cap, and then 
subsequent 5'-»3' exonucleolytic degradation by X rnlp (yeast) or X rnlp vertebrate homologues 
(Wagner and Lykke-Andersen 2002; Coller and Parker 2004; Gatfield and Izaurralde 2004). 
When NMD is initiated from the 3' terminus, accelerated deadenylation is observed, followed by 
3 '^ 5 ' exosome-mediated decay (Coller and Parker 2004; Gatfield and Izaurralde 2004). Recent 
studies have shown that the predominant NMD pathway in Drosophila cells is an 
endonucleolytic cleavage event that occurs in the vicinity of PTCs (Gatfield and Izaurralde 
2004), which further supports the hypothesis that endonucleases play a vital role in mRNA decay 
in eukaryotes. In the NSD pathway, mRNAs that lack in-frame termination codons are 
recognized and degraded exonucleolytically by exosome-containing 3 '^ 5 ' exonucleases 
(Wagner and Lykke-Andersen 2002; Coller and Parker 2004; Parker and Song 2004).
The pathways of mRNA decay utilized by eukaryotes can be seen summarized on the 
next page (Figure 1 )
Deadenylation-independent 
decmpping 
(nonsense-mediated 
decay)
m ^ Q p p p  1 AUG UAA I a a a a a a a
I”Deactonylation Endonuclease cleavage
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Gppp LjiiSi—  yaflOAoiigo
lAAAAAAAygr Decapping/m^GpppI Atkk UÀA la  „1 S' -> 3‘
\  Exonucleolytic
V  decay
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;
■"^GPP  ÜÂA....
Nonstop 
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Exonucleolytic
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Figure 1. mRNA decay pathways utilized by eukaryotes (Parker and Song 2004). 
1.1 c-myc
1.1.1 c-myc Gene: Structure and Function
The c-myc proto-oncogene was first discovered 25 years ago through its cellular 
homology with the transforming gene (v-myc) of a group of avian acute leukemia retroviruses, 
MC29 avian myelocytomatosis virus, known to induce myelocytomatosis and chicken tumours 
(Ryan and Birnie 1996; Dang 1999; Hermeking 2003). c-myc is a member of the myc oncogene 
family, which also includes L-myc, 'N-myc, S-myc, and B-myc (Dang 1999). Only c-myc, L-myc 
and N-myc, however, have been shown to have neoplastic potential (Dang 1999).
The c-myc gene structure, which is located in human chromosome 8q24, has been highly 
conserved throughout evolution, from Drosophila to vertebrates (Wickstrom et al. 1988; Gazdar 
and Carbone 1994; McEwan et al. 1996; Dang 1999; Flinn et al. 2002; Gardner et al. 2002). 
Members in the myc oncogene family were originally grouped together based on their
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characteristic 100 residue sequence containing a basic region (BR), a leucine zipper (LZ) motif, 
and a helix-loop-helix (HLH) motif at the carboxyl-terminus (Brugge et al. 1991; De Vita et al. 
1993; McEwan et al. 1996; Ryan and Birnie 1996; Dang 1999; Flinn et al. 2002). The bHLH 
and LZ motifs play important roles in the formation of a heterodimer between c-myc and a 
second bHLH-LZ protein, referred to as Max (Hermeking et al. 2000; Hermeking 2003). The 
formation of the heterodimer Myc/Max was found to be a prerequisite for c-myc to be able to act 
as a transcription factor (Ryan and Birnie 1996; Hermeking 2003). The bHLH-LZ motifs are 
known to recognize and bind with high-affinity to the DNA sequence 5 -CACGTG-3', referred to 
as the E box motif (Boyd et al. 1998; Hermeking et al. 2000; Kim et al. 2000; Hermeking 2003).
c-myc function can vary widely, as its activity is highly dependent on the interactions 
with other co-factors, c-myc plays essential roles in everyday cellular processes including the 
regulation of normal cell growth, differentiation, and apoptosis (Nanbru et al. 1997; Flinn et al. 
2002; Wang et al. 2005). c-myc has also been implicated in stress response, amino acid 
transport, and cell adhesion (Flinn et al. 2002). Acting as a transcription factor, c-myc interacts 
with many different genes and proteins which can lead to constitutive cell-cycle progression, cell 
immortality, and to the blocking of differentiation (Ryan and Birnie 1996; Dang 1999).
There are currently two main proposed hypotheses to explain how c-myc proteins actually 
function at the molecular level. They either (1) play direct roles in DNA replication, and/or (2) 
play roles in transcription (Brugge et al. 1991). Evidence that c-myc proteins play direct roles in 
DNA replication is supported by several findings, c-myc expression is strongly correlated with 
cell proliferation, and is down-regulated following terminal differentiation (Brugge et al. 1991). 
Constitutive expression of c-myc has been demonstrated to block differentiation in several cell 
types, suggesting that c-myc plays an important role in the switch from proliferation to
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differentiation (Brugge et al. 1991). Other evidence can be seen in studies employing antisense 
c-myc mRNA, which causes a reduction in the number of cells capable of entering the S phase 
(McKinnell et al. 1998). In contrast, cells expressing high levels of c-myc traverse to G, more 
rapidly and are more efficient in supporting replication of SV40 DNA (McKinnell et al. 1998). 
Evidence that c-myc plays roles in transcription can be seen in trans-activation experiments in 
which c-myc is co-transfected into cells along with different promoters coupled to reporter genes 
(Brugge et al. 1991). While these experiments demonstrate moderate activation or repression, it 
is difficult to directly link these effects with specific sequence elements in the promoter (Brugge 
et al. 1991). Not only is c-myc capable of inducing transcription, but it can also repress 
transcription in vitro and in transient-transfection assays (Dang 1999).
1.1.2 Regulation of c-myc Gene Expression
In normal cellular conditions, c-myc is very tightly regulated and usually only present in 
proliferating cells at very low, almost undetectable levels (Facchini and Penn 1998; Gardner et 
al. 2002). When these resting cells are stimulated by growth factors, a dramatic immediate 
increase in c-myc expression is observed (Gardner et al. 2002). While c-myc overexpression 
does continue into the cell cycle, it eventually returns to basal levels in resultant resting daughter 
cells (Facchini and Penn 1998; Gardner et al. 2002).
c-myc gene expression is regulated at the transcriptional, post-transcriptional, and post- 
translational levels. Regulation at the transcriptional level involves the signal transduction 
pathway and/or the negative feedback autoregulation of c-myc (DeVita et al. 1993; Facchini and 
Penn 1998). In the signal transduction pathway, internal and external signals influence 
regulatory elements of the c-myc gene (Facchini and Penn 1998). As c-myc mRNA and its 
protein products have very short half-lives (<30 minutes), it is necessary for c-myc mRNA and c-
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myc proteins to be continuously synthesized. The negative feedback autoregulation, therefore, 
controls the relative levels of cellular c-myc mRNA and protein product within the cell at any 
given time (DeVita et al. 1993; Facchini and Penn 1998). Post-transcriptional level regulation, 
which is investigated in this thesis, is believed to involve the activity of ribonucleases (Brewer 
1998; Lee et al. 1998; Brewer 1999). Post-translational regulation involves numerous protein- 
protein interactions and the phosphorylation of serine and threonine sites (Facchini and Penn 
1998).
1.1.3 c-myc and Cancer
Genetic rearrangements within the c-myc locus will result in deregulation of c-myc gene 
expression (DeVita et al. 1993). This deregulation can lead to the activation of the c-myc gene, 
resulting in over-expression of the c-myc protein product. The activation of the c-myc gene has 
been observed in many species through gene amplification, chromosomal translocation, and 
proviral insertion (Wickstrom et al. 1988; Hermeking 2003). Cell culture and animal models 
have shown that altered expression of c-myc clearly plays an important role in tumourigenesis 
(McEwan el a/. 1996).
Constitutive high-level c-myc expression is known to lead to changes in growth rate, 
increased sensitivity to growth factors, and inhibition of differentiation in numerous cell types 
(DeVita et al. 1993). Constitutive c-myc expression induced by gene amplification is observed 
frequently in cancers of the breast, lung, prostate, colon carcinomas, leukemias, and lymphomas 
(Dang 1999; Catapano et al. 2000). Elevated c-myc expression is seen in 1/3 of all breast and 
colon carcinomas (Dang 1999; Wang et al. 2005), while altered c-myc expression has been 
observed in human breast, colon, and cervical carcinomas, as well as small cell lung carcinomas.
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osteosarcomas, glioblastomas, and myeloid leukemias (Facchini and Penn 1998; Dang 1999; 
Wang et al. 2005).
Burkitt's lymphoma provides a well-studied example of c-myc chromosomal 
translocation. This cancer disease involves the reciprocal chromosomal translocation of c-myc 
and one of the immunoglobulin genes (McKinnell et al. 1998; Dang 1999). The c-myc oncogene 
breakpoint is located in human chromosome 8q24 (DeVita et al. 1993; McKinnell et al. 1998), 
while the immunoglobulin genes are located at the breakpoints 14q23, 2pl2, and 22q ll 
(McKinnell et al. 1998; Dang 1999). Burkitt’s lymphomas are believed to have abnormal 
expression of the c-myc oncogene after this translocation, and it is believed that this abnormal 
expression is a result of the proximity of the c-myc oncogene to the transcriptional control 
elements of immunoglobulin (Brugge et al. 1991; DeVita et al. 1993; Dang 1999). The result of 
the reciprocal translocation is an amplification of ten- to twenty-fold in c-myc gene expression 
(Dodson and Shapiro 2002). Gene amplification is due to an increase in the number of c-myc 
copies in the cell, which results in subsequent over expression of the c-myc gene (Dodson and 
Shapiro 2002). The reciprocal translocation seen in Burkitt’s lymphomas leads to the 
development of a malignant clone, and to the appearance of a tumour mass (Brugge et al. 1991; 
DeVita et a/. 1993).
Cooperation of c-myc with other activated oncogenes also plays a role in the 
tumourigenic conversion of normal cells (DeVita et al. 1993) This cooperative activation 
phenomenon holds true for all cancer pathways, in that no single genetic event can directly lead 
to neoplasia. This also partially explains how it is possible that c-myc expression can very often 
be quite contradicting. Protein expression very much depends on the identity of both of the 
cofactors and/or cooperative oncogenes involved. Several oncogenic studies suggest that
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targeting c-myc is a valid approach to inhibit proliferation and survival of a variety of different 
cancers (Catapano et al. 2000; Hermeking 2003) Developing c-myc inhibitors is of obvious 
significance, as they could potentially offer new therapeutic applications to numerous types of 
cancers.
According to the Canadian Cancer Society, an estimated 69,500 Canadians succumbed to 
cancer in 2005. They state that based on current incident rates, 38% of Canadian women and 
44% of Canadian men will develop cancer during their lifetimes. Just under 10,000 (-14% ) 
(Dang 1999; Dang et al. 1999) of the estimated 69,500 deaths in 2005 will directly involve 
altered expression of c-myc; a fact that underlines the significance of finding ways to control and 
regulate c-myc expression in cancerous cells.
1.1.4 c-myc Messenger RNA Stability and Degradation
It is well documented that c-myc mRNA can be degraded in vivo via deadenylation 
followed by 3’->5’ decay governed by adenosine and uridine (AU)-rich elements (AREs) at its 
3’ untranslated region (UTR) (Brewer 1999; Doyle et al. 2000; Bremer et al. 2003). In addition, 
another c-myc mRNA instability sequence, called the coding region determinant (CRD), has 
been identified in vitro, and can be found in the last 180-250 nucleotides of the carboxyl terminal 
end of the coding region (Figure 2) (Lee et al. 1998; Lemm and Ross 2002).
Sequences spanning the CRD have been found to regulate c-myc mRNA levels/stability 
in vivo. For example, it was determined that stable globin mRNA rapidly became unstable when 
the CRD of c-myc was inserted into the coding region of the globin mRNA (Ross and Herrick 
1994). Several other studies concluded that the CRD was required to post-transcriptionally 
down-regulate c-myc mRNA during differentiation of C2 myoblasts into differentiated myotubes 
(Kren et al. 1996; Yielding et al. 1998). In addition, it was determined that the removal of either
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the 3'- or 5'-UTR had no effect on the stability of the c-myc mRNA in vivo, further supporting the 
hypothesis that the CRD plays a key role in c-myc mRNA stability (Bonnieu et al. 1988; Laird- 
Offringa et a/. 1991).
c-myc mRNA is also susceptible to endonucleolytic attack, and has been demonstrated to 
be cleaved endonucleolytically in vivo (Hanson and Schoenberg 2001) as well as in vitro by four 
enzymes: an RNase E-like enzyme (Wennborg et al. 1995), the RasGTP-ase activating protein 
G3BP (Tourriere et al. 2001; Tourriere et al. 2003), a partially characterized -39  kDa 
mammalian protein (Lee et al. 1998), and a novel mammalian endoribonuclease (Bergstrom et 
al. 2006), which is the focal point of this thesis.
The full length coding region determinant (FL-CRD) nucleotide sequence is believed to 
be a binding site for a protein that is thought to shield the mRNA from endoribonuclease attack 
(Figure 2) (Lee et al. 1998; Rodgers et al. 2002). This shielding protein, or CRD-binding protein 
(CRD-BP), binds with high specificity to the FL-CRD mRNA (Prokipcak et al. 1994; Lemm and 
Ross 2002), effectively prolonging its half-life (Lee et al. 1998; Doyle et al. 2000). Under 
normal cellular conditions the c-myc mRNA instability sequence is thought to be protected from 
decay by the CRD-binding protein (CRD-BP) (Lee et al. 1998). It has been proposed that when 
the CRD-BP binds to the polysome-associated c-myc mRNA, the CRD-BP may act to shield the 
mRNA from endonucleolytic attack (Bernstein et al. 1992; Prokipcak et al. 1994; Lemm and 
Ross 2002). When an excess of FL-CRD competitor mRNA was added, it was found that the 
CRD-BP dissoeiated from the c-myc mRNA leaving the CRD unshielded and vulnerable to 
endonuclease attack (Bernstein et al. 1992; Lemm and Ross 2002).
Coding Region
5’-UTR 3 ’-UTR
CRDc-myc mRNA
FL-CRD o f c-myc mRNA (nts 1705-1886)
Figure 2. Human c-myc mRNA with CRD, 5’-, and 3’-untranslated regions (UTR) 
indicated. The FL-CRD of c-myc mRNA is also illustrated (Lee et al. 1998).
1.2 Endoribonucleases Capable of Degrading mRNA
The main goal of this thesis is to characterize and, if possible, identify the -35  kDa 
protein that co-purified with the native endoribonuclease capable of endonucleolytically cleaving 
the CRD of c-myc mRNA in vitro. In order to adequately compare the characteristics and 
properties of this novel enzyme to those of other endoribonucleases, it is necessary to first review 
the literature of known endoribonucleases capable of degrading mRNA in species where mRNA 
degradation has been vigorously studied.
1.2.1 Prokaryotic (Bacteria) Endoribonucleases:
To date, there are 6 endoribonucleases that have been shown to degrade mRNA in 
prokaryotes; RNase E, RNase G, RNase III, MazF, PemK, and RNase P. The major 
characteristics of each of these 6 prokaryotic endoribonucleases are summarized in Table 1 (Pg.
3oy
i) RNase E:
The endoribonuclease RNase E, which is encoded by the m e  gene (mapped at 24 minutes 
(Nicholson 1999)), was first discovered in E. coli as a rRNA processing protein that converts the 
precursor 9S to immature 5S rRNA (Grunberg-Manago 1999; Nicholson 1999).
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RNase E is found in many organisms, including eubacterial genomes and plant plastids 
(Redko et al. 2003), and functional homologues have now been identified in mammals 
(Nicholson 1999). It has been discovered that RNase E plays roles in the decay of bacteriophage 
T4 and specific bacterial mRNAs (Kennel! 2002; Ueno and Yonesaki 2004), and is capable of 
cleaving RNA I, the antisense regulator of replication of ColEl. (Grunberg-Manago 1999; 
Kushner 2002). RNase E has also been reported to cleave the mRNAs encoding OmpA and 
TrxA, ribosomal proteins S20 and S15 {rpsT and rpsO) (Rauhut and Klug 1999; Kennell 2002), 
as well a being involved in processing the 5' end of 16S rRNA, tRNAs, and maturing the RNA 
subunit of RNase P (Rauhut and Klug 1999; Kushner 2002; Redko et al. 2003). RNase E is also 
implicated in the cleavage of lOSa RNA, which is the tmRNA responsible for rescuing stalled 
ribosomes from aberrant termination (Callaghan et al. 2003), and is capable of removing the 
poly(A) tails from the 3'-ends of various RNAs (Lee et al. 2002). RNase E has been shown to be 
a key player in the degradation of mRNA in E. coli, and is believed to be the endoribonuclease 
responsible for the initial cleavage reaction (Kushner 2002; Callaghan et al. 2003; Redko et al.
2003).
RNase E, which is one of the largest polypeptides in E. coli (Callaghan et al. 2003), 
appears to be a Mg^'^-dependent (Nicholson 1999) homodimer consisting of 1061 AA subunits 
(Condon and Putzer 2002), with a SDS-PAGE estimated molecular weight of 180 kDa and a 
calculated mass of 118 kDa (Grunberg-Manago 1999; Nicholson 1999; Rauhut and Klug 1999). 
This apparent differenee in molecular masses, which suggests an atypieal structure (Nicholson 
1999), is thought to be due to a central region that is rich in proline residues (Grunberg-Manago 
1999X
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There are three domains in the RNase E protein sequence: the amino terminal domain 
(AA 1-528), central domain (AA 597-684), and carboxyl terminal domain (AA 734-1061) 
(Grunberg-Manago 1999; Kushner 2002). The arginine-rich RNA-binding domain, which is 
found mostly in the central region (AA 267-390) (Callaghan et al. 2003), is not believed to be 
necessary for the RNases enzymatic activity (Grunberg-Manago 1999; Rauhut and Klug 1999). 
The catalytic domain of RNase E has been mapped to the N-terminal domain from amino acid 
residues 1-498 (Grunberg-Manago 1999), and can confer activity independently of the remaining 
amino acid sequence (Jiang and Belasco 2004). While the N-terminal domain of E. coli RNase E 
is highly conserved in prokaryotes, the C-terminal domain is not (Kushner 2002). The N- 
terminal region, which is responsible for the protein's preferential partitioning which is seen 
close to the cell membrane (Lee et al. 2003), has also been found to form a catalytically active 
tetramer (Callaghan et al. 2003). The C-terminal of RNase E, while having many regions of 
little secondary structure (Callaghan et al. 2003), does, however, provide a scaffold for the 
assembly of the degradosome, of which RNase E is an integral component (Condon and Putzer 
2002; Kushner 2002; Callaghan et al. 2003; Lee et al. 2003; Redko et al. 2003; Schubert et al. 
2004). The exact role that the degradosome plays in E. coli mRNA degradation is still in 
question as RNase E mutants lacking the C-terminal region necessary for degradosome activity 
were not found to exhibit abnormal mRNA decay properties (Kushner 2002).
While it was originally believed that RNase E cleavage sites in E. coli require a single­
stranded consensus sequence of (A/G)AUU(A/U) and additional stem loop anchors (Rauhut and 
Klug 1999), recent data has suggested that the stem loop anchors are not an essential component 
for activity, and that RNase E preferentially cleaves single-stranded AU-rich regions (Feng et al. 
2002; Lee et al. 2003) without strong sequence specificity (Steege 2000) to generate cleavage
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fragments which usually have 5' phosphates (~ 60%) and 3' hydroxyls (~ 40%) (Nicholson 1999; 
Rauhut and Klug 1999; Kennell 2002; Kushner 2002; Redko et al. 2003).
RNase E has been shown to be have a homologue in E. coli called RNase G (Grunberg- 
Manago 1999; Rauhut and Klug 1999; Lee et al. 2003). This would suggest that perhaps RNase 
E, similar to the proposed action of RNase G, plays a role in intracellular transport (Rauhut and 
Klug 1999). RNase E and RNase G are suspected to work together in a cooperative fashion to 
sequentially mature the 5' end of 16S rRNA (Grunberg-Manago 1999; Condon and Putzer 2002).
Studies have also shown that RNase E activity is highly dependent on the state of the free 
5' terminus of the mRNA substrate (Grunberg-Manago 1999; Nicholson 1999; Kennell 2002; 
Kushner 2002; Redko et al. 2003). It is now believed that 5'-triphosphates are much less 
efficiently cleaved by RNase E than transcripts that have 5 '-monophosphates (Mackie 1998; 
Rauhut and Klug 1999; Feng et al. 2002; Kennell 2002; Kushner 2002; Callaghan et al. 2003; 
Condon 2003; Lee et al. 2003; Redko et al. 2003).
It is important to note that mutants lacking the catalytic domain of RNase E have been 
shown to have no effect on the functional decay rate of mRNA in E. coli (Kennell 2002). In fact, 
several studies have shown that even in the complete absence of RNase E, rapid mRNA 
degradation still occurs (Kennell 2002). This information would appear to conflict the 
hypothesis that RNase E is the key player in initiating mRNA decay in E. coli, but supports the 
theory that RNase G or RNase III can functionally take the place of RNase E.
ii) RNase G:
CafA, a 50 kDa protein which possibly acts on cytoskeletal elements (Rauhut and Klug 
1999) with known roles in chromosome segregation and cell division (Lee et al. 2002), has been 
shown to be a homolog of RNase E in E. coli (Grunberg-Manago 1999; Rauhut and Klug 1999;
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Steege 2000). The CafA protein, which is known to have very similar enzymatic activity and 
sequence specificity to RNase E, has since been renamed RNase G (Li et al. 1999; Steege 2000; 
Condon and Putzer 2002).
RNase G, which is encoded by the rng gene (Li et al. 1999) and is 489 amino acids long 
(Jiang and Belasco 2004), has been found to share extensive sequence similarity with RNase E 
amino acids 1-498 (Kaberdin and Bizebard 2005), with 49.5% sequence similarity and 34.1% 
sequence identity (Kushner 2002). The RNase G amino acid sequence, unlike RNase E, lacks an 
arginine-rich region and the degradosome scaffold domain (Condon and Putzer 2002; Jiang and 
Belasco 2004).
The ancestral protein from RNase E and G has tentatively been identified as a -500 kDa 
protein, which can be found on more than half of the eubacteria species investigated (Condon 
and Putzer 2002). The protein has been found to have equal homology to RNase G and the N- 
terminal region of RNase E (Condon and Putzer 2002).
Functional overlap between RNase E and RNase G has been demonstrated (Callaghan et 
al. 2003), and it has now been determined that not only is RNase G dependent on the state of the 
5'-end (Kaberdin and Bizebard 2005), but it is also involved in the decay of the adhE transcript 
(Kushner 2002). Early studies indicated that neither RNase E or RNase G had the capabilities to 
mature the 5'-end of 16S rRNA independently, but needed to work in association with each other 
in a two step process (Li et al. 1999). The proposed functional overlap of these two RNases has 
since been further supported by a more recent study which showed that RNase G can provide 
independent viability to a rne deficient mutant strain, which indicates that the rng gene, which 
encodes RNase G, can carry out the same essential activities of RNase E (Lee et al. 2002).
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Similar to RNase E, RNase G cleaves single-stranded RNAs in a site-specific manner, 
and as discussed, shows a preference for 5'-monophosphates (Kaberdin and Bizebard 2005). 
RNase G, like RNase E, must first assemble into its multimeric state to have activity, which 
supports the theory that 5'-end binding by one RNase subunit can cause conformational changes 
that could potentially enhance the binding of a second RNase unit (Baker and Condon 2004). 
Despite the relatively large number of known targets for RNase E in E. coli, only a small handful 
of targets have been identified for RNase G, with the most prominent being the precursor of 16S 
rRNA (Kaberdin and Bizebard 2005). Sequence comparisons of RNase G has found that almost 
all bacteria contain RNase G-like enzymes (Callaghan et al. 2003).
iii) RNase III:
RNase III from E. coli is a dimeric endoribonuclease that is specific for double-stranded 
RNA (Nicholson 1999; Steege 2000; Condon and Putzer 2002). RNase III, encoded by the 55 
minute mapping rnc gene (Nicholson 1999), has also been found to specifically degrade stem- 
loop structures in vivo (Conrad and Rauhut 2002), especially in intercistronic regions (Kushner 
2002). The homodimer RNase III, whose catalytic domain is located within the amino-terminal 
region, has a signature box of eleven amino acids, seven of which are highly conserved (Conrad 
and Rauhut 2002). RNase III is also capable of autoregulating itself by recognizing and cleaving 
its own stem-loop structure (Conrad and Rauhut 2002). The Mg^'^-dependent (Nicholson 1999) 
-26  kDa endoribonuclease RNase III plays a role in the processing of 16S and 23S rRNA from 
the 30S precursor transcript (Condon and Putzer 2002; Kushner 2002), and is also known to be 
involved in the degradation of several mRNA transcripts, usually through the elimination of 
various stem-loops found upstream of the translation start site (Kushner 2002). It is also
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believed that untranslated 5' regions of mRNAs can be cleaved by RNase III, which would then 
initiate RNA degradation by RNase E (Conrad and Rauhut 2002).
RNase III is also believed by some to be implicated in the initial endoribonucleolytic 
cleavage event (Condon and Putzer 2002). Others, however, believe that RNase III is not a 
major player in mRNA degradation in E. coli because deletion of the RNase III structural gene 
(me) did not lead to a significant change in the mRNA stability or turnover rate (Grunberg- 
Manago 1999; Steege 2000; Kennell 2002; Kushner 2002). The endoribonuclease RNase III, 
which is active as a 52 kDa homodimer (Nicholson 1999) that is 226 amino acids long (Conrad 
and Rauhut 2002), acts to cleave phosphodiesters to generate 3'-hydroxyls and 5'-phosphates 
(Nicholson 1999; Conrad and Rauhut 2002).
RNase III has been found ubiquitously throughout the eubacteria, with the exception of 
Deinococcus radiodurans (Condon and Putzer 2002). RNase III homologues in bacteria have 
been shown to share approximately 35% amino acid sequence similarity (Conrad and Rauhut 
2002), while sequence homology between the rnc gene of E. coli and the rnc gene of B. subtilis 
show -60%  similarity (Condon 2003).
Various orthologues to RNase III have also been identified in eukaryotic species, some 
with additional domains, with the best known being the enzyme Dicer of the RNA interference 
pathway (Condon and Putzer 2002). E. coli RNase III orthologues are also known to exist in the 
eukaryotic species S. cerevisiae (nuelease Rut Ip - 20% homology), Schizosaccharomyces pombe 
(P ad  nuclease - 25% homology), and Caenorhabditis elegans (RNase III sequence and DExH- 
box RNA helicase sequence) (Nicholson 1999; Fortin et al. 2002). A virus that infects the 
unicellular alga Chlorella, also has an RNase III orthologue in its genome (Nicholson 1999).
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iv) M azF:
MazF, located on the E. coli relA operon (Loris et al. 2003), is a highly conserved toxin 
that is believed to be a sequence-specific (ACA) endoribonuclease capable of degrading mRNA 
independently of ribosomes (Zhang et al. 2003).
MazF, which is encoded by the mazEF addiction module (consisting of two overlapping 
genes - mazE and MazF), was found to preferentially cleave single-stranded mRNA in between 
the A and C of the ACA sequence (Zhang et al. 2003). MazF is known to be a long-lived toxic 
protein that is antagonized by MazE, and is easily cleaved by protease ClpPA (Loris et al. 2003). 
MazF, which is a 111 amino acids long with a molecular weight of 12.1 kDa (Engelberg-Kulka 
and Glaser 1999), is unable to cleave ACA sequences found in double-stranded duplex structures 
such as RNA/RNA and RNA/DNA duplexes (Zhang et al. 2003). MazF exists as a dimer in 
solution by itself, but is normally integrated in a 1:2 ratio with mazE in a stable MazE-MazF 
complex (Zhang et al. 2003). The mazE-MazF complex is responsible for programmed cell 
death in bacteria and is believed to autoregulate its own synthesis (Loris et al. 2003).
While amino acid sequences of MazF are highly conserved in numerous prokaryotes, it is 
hypothesized that the sequence-specificity of the cleavage of MazF homologues would vary from 
organism to organism (Zhang et al. 2003). Recent work supports the notion that MazF is an 
ACA sequence-specific endoribonuclease by showing that the 2'-hydroxyl of the X  residue in 
XACA is essential for MazF cleavage (Zhang et al. 2005). While no structural similarity exists 
between the two, it is hypothesized that MazF acts in a similar fashion to that of RNase A, and 
that mRNA interferases are, in fact, novel restriction enzymes (Zhang et al. 2005).
Other studies provide somewhat contradictory results, maintaining that MazF only exerts 
its endoribonuclease activity when associated with a ribosome and that its activity is dependent
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on sequence-specific cleavage sites analogous to those of the RelE toxin (Christensen 2003). 
Leading to further confusion of the mechanistic activity of MazF is the findings from another 
study that states that MazF recognizes a slightly different sequence for its specificity, and that 
NAG (where N is preferentially an A or U) is the mRNA sequence targeted for degradation 
(Zhang et al. 2005).
v) PemK:
PemK is also an E. coli toxin, and is encoded by the peml-pemK addiction model 
(homologous to the kis-kid addiction model) (Loris et al. 2003; Zhang et al. 2003; Zhang et al. 
2004b). PemK bas been shown to inhibit the replication of ColFl by acting at the initiation of 
DNA synthesis, but appears incapable of inhibiting P4 DNA replication in vitro (Zhang et al. 
2004b). PemK, which is a 123 amino acids long with a molecular weight of -12  kDa (Hols et al. 
1997), is believed to be an endoribonuclease that can cleave cellular mRNA in a sequence- 
specific manner, effectively blocking protein synthesis (Zhang et al. 2004b). PemK, which can 
only cleave single-stranded RNA substrates, preferentially cleaves the A residue at its 5' or 3' 
side in the sequence UAN, where N can be C, A, or U (Zhang et al. 2004b). It has also been 
shown that the mazEF and peml-pemK  systems interact with each other for functionality (Loris 
et al. 2003). When temperature-sensitive mutants of PemI can no longer prevent cell growth 
inhibition in the presence of PemK they are complemented by MazE (Loris et al. 2003).
It is yet to be shown whether PemK is capable of inhibiting chromosomal DNA 
replication (Zhang et al. 2004b). PemK is not unique to bacteria, but also exists in various 
eukaryotes as well, suggesting that PemK has a common target sequence in both prokaryotes and 
eukaryotes (Zhang et al. 2004b). It has recently been proposed that PemK and its homologues
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represent a new, relatively unexplored family of mRNA interfering endoribonucleases (Zhang et 
al. 2004b).
vi) RNase P:
The ribonucleoprotein enzyme ribonuclease P (RNase P) functions to remove the 5' 
leader sequences of precursor tRNAs to generate mature 5' termini (Altman et al. 1989; Guerrier- 
Takada et al. 2002; Li and Altman 2003; Xiao et al. 2005) in all three kingdoms of life (Archaea, 
Bacteria, and Eukarya), as well as in mitochondria and chloroplasts (Hartmann and Hartmann 
2003; Kouzuma et al. 2003; Marquez et al. 2005). RNase P has an RNA component that has 
been found to be a catalytic subunit (Hartmann and Hartmann 2003) capable of independently 
catalyzing the pre-tRNA cleavage event in vitro (Xiao et al. 2005). In bacteria, RNase P consists 
of a catalytic RNA subunit (Ml Ribozyme in E.coli) that is typically between 350-400 
nucleotides in length, and a single, small, basic 120 amino acid protein (C5 protein in E. coli) 
(Higgins et al. 1993; Hartmann and Hartmann 2003; Raj and Liu 2003). RNase P in most 
archaea and all eukaryotes is also composed of a single RNA subunit, but requires many protein 
subunits for activity (Jarrous 2002; Hartmann and Hartmann 2003; Hopper and Phizicky 2003; 
Marquez et al. 2005; Xiao et al. 2005). Unlike RNase P in bacteria and several archaea, the 
RNA subunit in higher organisms does not independently possess enzyme activity in vitro (Xiao 
et al. 2002; Hartmann and Hartmann 2003; Marquez et al. 2005).
It has also been determined that the mitochondrial RNA processing endoribonuelease 
(RNase MRP) found in eukaryotes is related to RNase P; the RNA subunits of both share the 
same architecture in the domain surrounding helix P4, which has been found to be a critical 
component of RNase P's catalytic activity (Jarrous 2002; Hartmann and Hartmann 2003). This 
notion is supported by the fact that eight of the nine known associated protein subunits are the
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same in RNase P and RNase MRP (Ziehler et al. 2001). RNase MRP is discussed in greater 
detail later in Section 1.3.3.
RNase P has also been discovered to endonucleolytically cleave several polycistronic 
operon mRNAs in vitro in E. coli (Li and Altman 2003). It was determined that tryptophanase 
(tna) operon mRNA, which encodes a low affinity, high capacity tryptophan permease (Gong et 
al. 2001), was cleaved by RNase P between U47 and G48, generating 3' and 5' cleavage products 
with 5' phosphates and hydroxyls, respectively (Li and Altman 2003). It is believed that the 
cleavage products generated by RNase P are then rapidly degraded by degradosome RNase E, 
which preferentially degrades 5' monophosphates; a hypothesis that was verified by experiments 
which showed that RNase E degrades RNase P cleavage products (Li and Altman 2003). These 
findings suggest that RNase P is most likely involved in the degradation of a more diverse 
variety of RNAs then was originally thought.
Table 1 on the next page summarizes the 6 known prokaryotic endoribonucleases capable 
of degrading mRNA, and identifies their size, cleavage specificity, and whether they are part of 
an enzyme complex.
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Table 1. Prokaryotic (bacteria) endoribonucleases capable of degrading mRNA
Name of 
Endoribonuclease
Cleavage
Specificity Size of Protein
Part of 
complex References
RNase E 5' to ss AREs 1061 AA, 118 
kDa
degradosome Feng et at. 2002; Lee at al. 2003
RNase G 5' to ss AREs 489 AA, 50 kDa degradosome Kaberdin and Bizebard 2005
RNase III ds-stem loops, 5'- UTR
226 AA, 26 kDa degradosome
Nicholson 1999; Steege 
2000; Condon and Putzer 
2002; Conrad and Rauhut 
2002
MazF
ss 3' to N of 
NAG, where N = 
A or U
111 AA, 12.1 
kDa
MazE/MazF
complex
Engelberg-Kulka and 
Classer 1999; Zhang etal. 
2005
PemK
ss 5' or S' to A of 
AUN, where N = 
0 , A, or U
123 AA, -12  
kDa
Peml/PemK
complex
Hols etal. 1997; Zhang et 
ai. 2004
RNase P
ss tna operon 
mRNA between 
U47 and G48
RNA subunit; 
350-400 nt, 100 
130 kDa; 
protein = 120 
AA, -12.5 kDa
1 catalytically 
active RNA 
subunit and 1 
protein subunit
Li and Altman 2003; 
Hartmann and Hartmann 
2003, Kazantsev et ai. 2003
1.2.2 Lower Eukaryote (Yeast) Endoribonucleases:
To date, the RNase III orthologue R ntlp and mitochondrial RNA processing 
endoribonuclease (RNase MRP) are the only two endoribonucleases that have been shown to 
degrade mRNA in yeast. The major characteristics of these 2 yeast endoribonucleases are 
summarized in Table 2 (pg. 32).
i) Rntlp:
R ntlp is the only known RNase III orthologue in the yeast Saccharomyces cerevisiae, 
and is capable of processing pre-rRNAs, small nuclear RNAs (snRNAs), and small nucleolar 
RNAs (snoRNAs) such as unspliced pre-mRNAs and lariat introns (Chanfreau 2003; Danin- 
Krieselman et al. 2003; Lee et al. 2005). Rntlp, which is composed of 471 amino acids (Fortin
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et al. 2002) and has a molecular weight of -55 kDa, is unique in that it acts to 
endonucleolytically cleave specific double-stranded RNA hairpins that are capped by tetraloop 
sequences that carry the weak consensus sequence AGNN (N is any nucleotide) (Nagel and Ares 
2000; Danin-Krieselman et al. 2003; Lee et al. 2005). The tetraloop structures, which have been 
found to be essential for cleavage, are positioned 14 to 16 bp away from the AGNN recognition 
sequence (Chanfreau 2003), which suggests that R ntlp  is acting as an RNA helical ruler (Danin- 
Krieselman el al. 2003). R ntlp  acts to cleave the short (12-15 bp) stem-loops which contain 
bulges and internal loops (Leulliot et al. 2004). Once R ntlp has made the initial endonucleolytic 
cleavage, the remaining RNA is rapidly degraded in the 5'-^3' direction by the exonucleases 
X rnlp and Rat Ip, or by 3 '^ 5 ' exonucleases contained within the exosome (Nagel and Ares 
2000; Lee et al. 2005). Further studies have since discovered that many genes coding for iron 
uptake are expressed at higher levels in the absence of R ntlp, which suggests that Rntlp- 
mediated RNA surveillance is required to prevent iron toxicity (Lee et al. 2005).
ii) RNase MRP:
Mitochondrial RNA processing endoribonuclease (RNase MRP) is a ribonucleoprotein 
protein which is involved in the processing of ribosomal RNA (rRNA) (van Eenennaam et al. 
2001a; Li et al. 2004). RNase MRP functions to cleave pre-rRNA at the A3 site to generate 
5.8Sshort rRNA (van Eenennaam et al. 2001b; Li et al. 2004; Salinas et al. 2005). RNase MRP is 
also known to function in primer formation for mitochondrial DNA replication and cell cycle 
control (van Eenennaam et al. 2001b; Li et al. 2004). In S. cerevisiae, RNase MRP consists of a 
single 340 nt long RNA molecule (Cai et al. 1999), encoded by the Nuclear Mitochondrial 
Endonuclease 1 (NMEl) gene, and at least nine protein sub-units (van Eenennaam et al. 2001a; 
Li et al. 2004). As mentioned earlier, RNase MRP is believed to be an evolutionary ancestor to
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RNase P, as the two share eight of the nine protein sub-units, have a similar 'cage-shaped' 
secondary structure, and are localized in the nucleolus (van Eenennaam et al. 2001 a; Li et al. 
2004). Despite their similarities, both endoribonucleases have distinct sequence cleavage 
specificity (Li et al. 2004).
RNase MRP has been found to cleave CLB2 (cyclin B gene) mRNA in its 5 -UTR region 
in vitro (Gill et al. 2004). While the site specificity of this endonucleolytic cleavage event is still 
unknown, the remaining CLB2 mRNA transcript is believed to be rapidly degraded 5 '^ 3 ' by the 
exonuclease X rnl (Gill et al. 2004). Degradation of the CLB2 mRNA transcript by RNase MRP 
provides the cell a means of regulating the cell cycle in a fashion that complements the protein 
degradation machinery (Gill et al. 2004). In addition, RNase MRP has also been found to be the 
cause of cartilage hair hypoplasia, a genetic disease that causes short, brittle, sparse hair, and 
immunodeficiency (Ridanpaa et al. 2001; Gill et al. 2004).
Table 2 below summarizes the major characteristics of the 2 known yeast 
endoribonucleases capable of degrading mRNA.
Table 2. Lower eukaryote (yeast) endoribonucleases capable of degrading mRNA
Name of 
Endoribonuclease Cleavage Specificity Size of Protein
Part of 
complex References
Rntlp
ds RNA hairpins, capped 
by tetraloops of sequence 
AGNN, N = any nt
471 aa, -55 kDa unknown
Nagel and Ares 2000; 
Fortin etal.  2002; Lee et  
ai. 2005
RNase MRP 5'-UTR of CLB2 mRNA
RNA sub-unit: 
340 nt; protein 
subunits: 1 at 
100.5 kDa, rest < 
32.8 kDa
1 RNA 
subunit with 
at least nine 
protein 
subunits
Cai etal.  1999; Gill etal.  
2004
32
1.2.3 Higher Eukaryote (Vertebrate) Endoribonucleases:
To date, there are 20 different vertebrate endoribonucleases that have been demonstrated 
to cleave mRNA. Some of these endoribonucleases have been well characterized, while the 
identity of others remains unknown. This section reviews the properties and characteristics of 
these 20 vertebrate endoribonucleases. The main characteristics of these vertebrate
endoribonucleases are summarized in Table 3 (pg. 56).
i) PMR-1:
Polysomal ribonuclease 1 (PMR-1) is a polysome-associated mRNA endonuclease that is 
capable of initiating the destabilization of albumin mRNA (Bremer et al. 2003; Yang et al. 2004; 
Yang and Schoenberg 2004), and providing vigilin is not bound, Xenopus vitellogenin mRNA 
(Cunningham et al. 2001a; Stevens et al. 2002). PMR-1 is one of the most highly characterized 
vertebrate endoribonucleases and is activated following the estrogen stimulation of Xenopus 
hepatocytes to degrade serum protein mRNAs (Cunningham et al. 2001a; Stevens et al. 2002; 
Yang and Schoenberg 2004). PMR-1, which is a novel member of the peroxidase gene family 
(Chernokalskaya et al. 1998; Cunningham et al. 2001a), has shown no similar sequence-motifs 
with other known endonucleases, including RNA binding domains (Bremer et al. 2003; Yang 
and Schoenberg 2004). PMR-1 has been found to share 57% sequence homology to 
myeloperoxidase (Chernokalskaya et al. 1998), and has been determined to lack both heme and 
N-linked carbohydrates (Cunningham et al. 2001a).
It has been proposed that estrogen activates a pathway in which PMR-1 is the principal 
latent mRNA endonuclease responsible for global mRNA decay (Cunningham et al. 2001a). 
PMR-1 can be found ubiquitously throughout Xenopus tissues, and is found to have a 22-fold 
increase in activity in the presence of estrogen, which results in the degradation of polysomal-
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bound substrate mRNAs (Cunningham et al. 2001a; Yang et al. 2004). A recent study found that 
PMR-1 is uniformly distributed on polysomes throughout the cytoplasm, and that it does not 
colocalize in the cytoplasmic foci with Dcpl (Yang et al. 2004). This study also concluded that 
the PMR-1 mediated endonuclease mRNA decay selectively occurred on a polysome-bound 
complex, ~680 kDa in size, that contained both PMR-1 and the substrate mRNA (Yang et al. 
2004). The catalytically active form of PMR-1 was found to be a -60  kDa protein 
(Chernokalskaya et al. 1998; Cunningham et al. 2001b).
There are two domains on PMR-1 that are believed to be involved in endoribonuclease 
targeting (Cunningham et al. 2001a), one lies within the N-terminal domain, residues 200 to 250, 
and the other is in the C-terminal domain within the last 100 residues (Yang et al. 2004). Loss of 
either of these proposed catalytic domains inactivated PMR-1, and stabilized the albumin mRNA 
(Yang et al. 2004). The N-terminal domain of PMR-1 is believed to contain a region that acts to 
control the efficiency of the substrate targeting process (Yang et al. 2004). Further investigation 
also revealed that one or more tyrosine kinases functions as regulators to the endonucleolytic 
decay pathway of albumin mRNA (Yang et al. 2004).
PMR-1 was determined to preferentially cleave single-stranded RNA at UG dinucleotides 
within the 5 -coding region of albumin mRNA as well as other AYUGA elements (Hanson and 
Schoenberg 2001; Bremer et al. 2003), where Y can be either a C or U residue (Stevens et al. 
2002). In the absence of vigilin, PMR-1 cleaves vitellogenin mRNA in its 3 -UTR region in 
vitro and in vivo (Cunningham et al. 2000). It has been noted that vitellogenin mRNA is 
selectively stabilized over albumin mRNA (Cunningham et al. 2001a), and it is believed this 
occurs because vigilin has been found to bind the vitellogenin mRNA 3 -UTR with a -30  fold 
higher affinity than for albumin mRNA containing PMR-1 recognition sequences (Cunningham
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et al. 2000). Once vigilin binds to the vitellogenin mRNA 3 -UTR, it effectively blocks the 
vitellogenin mRNA transcript from endonucleolytic cleavage from PMR-1 (Cunningham et a l  
2000; Goolsby and Shapiro 2003). It has been determined that vigilin is an essential protein in 
human cells, and is proposed that vigilin plays critical roles in the control of cytoplasmic mRNA 
metabolism (Goolsby and Shapiro 2003).
ii) Argonaute2:
RNA interference (RNAi) involves the conversion of dsRNA into much smaller RNA 
fragments, which are usually in the ~21 to 26 nucleotide size range, and termed small interfering 
RNAs (siRNAs) (Provost et a l  2002; Liu et a l  2004; Zhang et a l  2004a). The siRNAs have 
been proposed to act as guide sequences for instructing the RNA-induced silencing complex, 
referred to as RISC, to destroy specific mRNAs (Provost et a l  2002). Argonaute proteins, which 
were first discovered as a component of the purified -500 kDa RISC complex in Drosophila, are 
now believed to play key roles in the activity of RISCs in fungi, plants, worms, protozoans, and 
mammals (Hammond et a l  2001; Liu et a l  2004).
The Argonaute family of proteins can be identified by the presence of two characteristic 
domains, referred to as PAZ and PIWI (Liu et a l  2004; Parker et a l  2004). The -20  kDa PAZ 
domain is found on the N-terminal of Argonaute proteins, and based on it's crystal structure, is 
believed to act in RNA binding (Parker et a l  2004). The PIWI domain is found on the C- 
terminal, is -  20 kDa in size, and believed to be the catalytically active site of Argonaute 
proteins; a hypothesis based on the discovered structural similarity of this region with RNase H 
(Parker et a l  2004). Argonaute proteins are generally classified into two subfamilies, and the 
placement into these subfamilies depends on whether the protein most closely resembles
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Arabidopsis Argonaute] or Drosophila Piwi (Liu et al. 2004). Drosophila Argonaute! is 694 
amino acids long and has a molecular weight of ~ 130 kDa (Hammond et al. 2001).
There are currently four Argonaute proteins known to exist in mammals, and all are 
Argonaute] subfamily members named Agol through Ago4 (Liu et al. 2004). Recent studies, 
however, suggest that only Ago2 in mammals is capable of cleaving the RNA substrate, 
regardless of the siRNA used (Liu et al. 2004; Meister et al. 2004). It was found that disruption 
of Ago2 produced an embryonic-lethal phenotype, suggesting that Ago2 is essential for 
embryonic development (Liu et al. 2004). Small changes to the Ago2 sequence were found to 
disrupt its ability to form cleavage-competent RISC (Liu et al. 2004). The PIWI domain of 
Ago2 was tested to determine if it contained the catalytic activity of RISC, and it was found that 
mutant Ago2 proteins were incapable of forming cleavage-competent RISC (Liu et al. 2004).
Argonaute!, along with Dicer, has recently been determined to be required for the rapid 
degradation of the 3'-UTR of mRNA containing AREs of tumor necrosis factor-alpha, which 
would suggest that the Argonaute! ARE-targeting is an essential step in ARE-mediated mRNA 
degradation (Jing et al. 2005).
It is believed that Argonaute! provides the catalytic mechanism of RISCs, and therefore 
the driving force of RNAi (Liu et al. 2004). It has been suggested that in eukaryotic Argonaute 
proteins, it is the RNase H-like domain that has the catalytic activity (Parker et al. 2004).
iii) Dicer:
The two enzymes that are responsible for catalyzing the process of RNAi are believed to 
belong to the RNase Ill-family of endoribonucleases (Fortin et al. 2002), and are referred to as 
Dicer and Drosha (Liu et al. 2004; Parker et al. 2004). Dicer is a relatively large, multi-domain 
endoribonuclease that processes, without specificity, dsRNAs to -21 nucleotide long siRNAs
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that then act as effectors during RNAi and in excision of microRNAs (miRNAs) from hairpin 
precursors (Fortin et al. 2002; Nicholson and Nicholson 2002; Doi et al. 2003; Zhang et al. 
2004a). Dicer, which was found to be a 1906 amino acid protein in mice (Nicholson and 
Nicholson 2002), and a 1912 amino acid protein in humans (Provost et al. 2002), has been found 
ubiquitously in eukaryotes with the exception of baker's yeast (Zhang et al. 2004a). Only one 
gene that codes Dicer-like proteins has been found to exist in vertebrates; the Dicer-encoding 
gene was found to be essential for viability in mammals (Zhang et al. 2004a).
The Mg^'^-dependent (Provost et al. 2002) Dicer, which is a ~200 kDa multidomain 
protein (218 kDa in humans) (Provost et al. 2002), includes a DExH RNA helicase/ATPase 
domain, DUF283 and PAZ signatures, a dsRNA binding domain (dsRBD), and two RNase III- 
like neighboring domains called R llla and Rlllb (Fortin et al. 2002; Nicholson and Nicholson 
2002; Provost et al. 2002; Zhang et al. 2004a). Recent studies, which generated mutants of 
human Dicer and E. coli RNase III residues implicated in catalysis, found that both enzymes 
have only one catalytic center containing two RNA cleavage sites that produce products with 2 
nt 3' overhangs (Parker et al. 2004; Zhang et al. 2004a), which contradicts earlier reports of 
Dicer containing two catalytic centers (Fortin et al. 2002). Based on their findings, Zhang et al. 
hypothesize that Dicer functions through an mtramolecular dimerization of its two RNase III 
domains, which is assisted by the flanking of the RNA binding domains PAZ and dsRBD (Zhang 
et al. 2004a).
Human dicer has also been found to have a strong preference for cleaving siRNAs from 
the ends of dsRNA substrates (Parker et al. 2004; Zhang et al. 2004a). It is hypothesized that 
this process evolved as a cellular defense mechanism to activity of transposable DNA elements 
and viral infections (Fortin et al. 2002; Nicholson and Nicholson 2002; Parker et al. 2004). As
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mentioned earlier, Dicer has also been found to be required for the rapid degradation of the 3'- 
UTR of mRNA containing AREs of tumor necrosis factor-alpba (Jing et al. 2005).
iv) ErEN:
Globin mRNAs are among the most stable mRNA transcripts, and as a result, have been 
studied in detail (Rodgers et at. 2002). a-globin mRNA contains a C-ricb region in it's 3'-UTR 
which provides stability to the transcript as well as serving as a binding site for the 
ribonucleoprotein complex called the a-complex (Wang and Kiledjian 2000a; Rodgers et al. 
2002). The a-complex is known to further stabilize the 3'-UTR by interacting with the poly(A) 
binding protein (PABP) which is bound to the poly(A) tail at the 3' end of the transcript (Rodgers 
et al. 2002). The a-complex has been demonstrated to protect the 3 -UTR from the 
endoribonucleolytic activity of ErEN, an erythroid enriched endoribonuclease (Wang and 
Kiledjian 2000a; Rodgers et al. 2002).
The ATP-independent (Wang and Kiledjian 2000a) ErEN endoribonuclease is unusual in 
that it is dependent on the poly(A) tail, as it requires deadenylation of the RNA transcript prior to 
cleavage of the 3 -UTR (Wang and Kiledjian 2000b; Rodgers et al. 2002). It was discovered that 
the PABP plays a specific role in protecting the mRNA body from cleavage, as well as it’s 
originally documented role of stabilizing the poly(A) tail (Wang and Kiledjian 2000b). The 
cleavage event of ErEN appears to be a sequence-specific cleavage that has been mapped to 
nucleotide -63, between dinucleotide CU, within the 3 -UTR (Wang and Kiledjian 2000a; 
Rodgers et al. 2002). A 6-nucleotide mutation around this site was found to completely block 
the action of ErEN (Rodgers et al. 2002). ErEN has been found to require a 26 nt region of the 
a-globin 3 -UTR for endoribonuclease cleavage; mutations within this region have been found to 
completely abolish ErEN activity, which suggests that the entire region is necessary for activity
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(Wang and Kiledjian 2000b; Rodgers et al. 2002). ErEN has been found to work independently 
of divalent cations, and has been found to cleave most effectively at biological temperatures and 
salt concentrations (Rodgers et al. 2002). ErEN was found to be ~ 40 kDa on a denaturing gel 
filtration, but was determined to be ~ 160 kDa on a non-denaturing gel filtration, which suggests 
that ErEN is part of an enzyme complex and is associated with other proteins for its sequence- 
specific cleavage (Rodgers et al. 2002). The true identity of this endoribonuclease is still 
unknown.
v) An endoribonuclease capable of degrading p-globin mRNA:
It has been determined that human P-globin mRNAs that contain nonsense codons are 
preferentially endonucleolytically degraded at UG dinucleotides (UC dinucleotide cleavages 
were also observed), in the cytoplasm of erythroid cells (Bremer et al. 2003). Studies have 
illustrated that polysomes of murine erythroleukemia (MEL) cells were shown to cleave P-globin 
and albumin mRNA in vitro in many of the same sites as PMR-1 (Bremer et al. 2003). A more 
recent study confirmed that human p-globin mRNA is endonucleolytically cleaved with the same 
biochemical properties and sequences as that of PMR-1 (Bremer et al. 2003). Based on these 
findings, researchers came to the conclusion that the surveillance of erythroid eells with 
nonsense-containing p-globin mRNAs is a cytoplasmic process that is capable of functioning on 
translating mRNAs, and that an endonucleolytic cleavage step is involved in P-globin mRNA 
decay (Stevens et al. 2002; Bremer et al. 2003). Furthermore, it was determined that both 
nonsense-containing and nonsense-free human P-globin mRNA in erythroid cells is degraded by 
a UG-site-selective endoribonuclease (Stevens et al. 2002). The size and identity of this 
endoribonuclease is not currently known.
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vi) An endoribonuclease capable of degrading transferrin receptor mRNA:
Transferrin receptor (TfR) mRNA expression is highly iron-dependent, and represents 
one of the most highly studied eukaryotic systems for investigating mRNA turnover (Binder et 
al. 1994; Posch et al. 1999). TfR mRNA has been found to contain specific stability elements, 
such as iron-responsive elements (IREs) and AU-rich instability elements (AREs) (Erlitzki et al.
2002). Iron-regulatory proteins (IRPs) act to stabilize TfR mRNA when iron is scarce, by 
binding to specific sites in the 3 -UTR (Posch et al. 1999). High levels of iron promotes 
degradation of TrF mRNA, a process that can be prevented by the presence of the translational 
inhibitor eycloheximide (Binder et al. 1994). These specific protein factors, possibly Tfr-IRE 
interactions with IRPs (Erlitzki et al. 2002), appear to bind to transferrin receptor mRNA to 
prevent endonucleolytic activity (Rodgers et al. 2002).
In the absence of IRPs and in high iron concentrations, the TfR mRNA is rapidly 
degraded (Binder et al. 1994). It has been found that when TfR mRNA is treated with an iron 
source a 3 -UTR endonucleolytic cleavage event occurs resulting in a truncated TfR mRNA 
transcript (Binder et al. 1994). This cleavage of human TrF mRNA was mapped to a single­
stranded region in the 3' UTR between the GA dinucleotide within the 5 -GAACAAG-3' 
sequence (Binder et al. 1994). It was also determined that poly(A) tail shortening does not occur 
prior to the cleavage event, and that the 3' cleavage product is polyadenylated in the same 
fashion as full-length mRNA (Binder et al. 1994). At this time, the identity, size, and amino acid 
sequence of the endoribonuclease capable of degrading TfR mRNA are unknown.
vii) An endoribonuclease capable of degrading IGF-II mRNA:
Human insulin-like growth factor II (IGF-II), which plays important roles in cell growth 
and development, is a 67 amino acid-long mitogenic polypeptide (van Dijk et al. 2001) that
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shows structure and function homology to insulin (van Dijk et al. 1998). The IGF-II gene, 
whose expression encodes a family of mRNAs which all include prepro IGF-II, contains nine 
exons and four promoters (P1-P4) constituting a complex transcriptional unit (Meinsma et al. 
1992). The transcribed RNAs from the various promoters can range from 2.2 to 6.0 kb in size 
(van Dijk et al. 2001). IGF-II gene expression is known to be regulated at the post- 
transcriptional, translational, and post-translational levels (van Dijk et al. 1998).
Full length IGF-II mRNA can be cleaved in a site-specific endonucleolytic fashion along 
it's 4 kb long 3 -UTR (Meinsma et al. 1992; van Dijk et al. 1998; van Dijk et al. 2001). This 
cleavage event produces a very stable, poly(A) tail-containing (van Dijk et al. 1998) 1.8 kb RNA 
fragment that is generated from the 3 -UTR of exon 9 (Meinsma et al. 1992), as well as an 
unstable 5' product that contains the IGF-II coding region (van Dijk et al. 2001). Similar 
endonucleolytic cleavage and products were observed in the IGF-II mRNAs of both rat and 
mouse (van Dijk et al. 2001). The 5' cleavage-generated mRNA product lacks a poly(A) tail, so 
it is highly unstable and does not get translated. This suggests that the endonucleolytic cleavage 
of IGF-II mRNAs provides IGF-II with a mechanism to regulate it's own protein expression, 
acting on the level of mRNA stability (van Dijk et al. 2001).
It was originally determined that two widely separated sequence elements within the 3'- 
UTR, referred to as element I and II, are necessary for the IGF-II endonucleolytic cleavage event 
(Meinsma et al. 1992). Further investigation revealed that the sequence-specific cleavage site 
must be single-stranded, and the presence of an accessory protein that interacts with a stem-1 oop 
structure located 133 to 77 nts upstream of the cleavage site was detected (van Dijk et al. 1998). 
It has now been determined that two extensive IGF-II RNA secondary structures act in a 
cooperative fashion to maintain the sequence- and structure-specificity of the RNA internal loop
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cleavage site (van Dijk et al. 2001). A study that investigated the effects of the 5' leader 
sequence of IGF-II found that cleavage efficiency was enhanced in highly ordered leader 
sequences, but was determined to be a slow process in standard cell culture conditions (van Dijk 
et al. 2001). This study also determined that in high cell densities of IGF-II endogenously- 
expressed human cell lines Hep3B and CaCo2, the endonucleolytic cleavage event was up- 
regulated 3-5-fold (van Dijk et al. 2001). The identity, size, and amino acid sequence of the 
endoribonuclease capable of cleaving IGF-II mRNA remains unknown,
viii) ARD-l/NIPP-1:
The activator of RNA decay, ARD-1, is a human cDNA sequence that was identified as 
being able to reverse the pleiotropic effects of temperature-sensitive and deletion mutations in 
the E. colt gene rne (Claverie-Martin et al. 1997; Chang et al. 1999). The human ARD-1 protein 
sequence was also found to share sequence homology with the Rne protein, which included 
domains of eukaryotic proteins involved in RNA binding, macromolecular transport, and 
endocytosis (Claverie-Martin et al. 1997). Further investigation revealed that the 13.3 kDa 
ARD-1 is a single-strand- and site-specific Mg^^-dependent endoribonuclease that cleaves RNA 
in the same fashion as RNase E (with similar cleavage sites and products with 5'-phosphate 
ends), as well as functioning as a domain of NIPP-1 (Claverie-Martin et al. 1997).
Bovine NIPP-1, a specific 38.5 kDa nuclear inhibitor of protein phosphatase 1 (PP-1) 
(Chang et al. 1999), was found to contain a peptide sequence at its carboxyl terminal region that 
is almost identical to that of the human ARD-1 cDNA (Claverie-Martin et al. 1997; Chang et al. 
1999). It has since been determined that ARD-1 has been found to exist in human cells as a 
discrete protein, and that ARD-1 and NIPP-1 are isoforms that are encoded by a single gene and 
the same alternatively spliced precursor mRNA (Chang et al. 1999). It was also found through
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cDNA analyses that ARD-1 and NIPP-1 mRNAs diverge at the 3'-end of exon 1, where a 474 nt 
sequence remains in ARD-1 but is excised in NlPP-1 (Chang et al. 1999).
More recent studies indicate that NIPP-1 contains a ARD-1 identical carboxyl terminal 
region (Parker et al. 2002) which, in addition to containing a lysine-rich RNA binding domain 
that preferentially associates with AU rich sequences, has endoribonuelease activity (Chang et al. 
1999). It has now believed that ARD-1 is a rare splice variant of NIPP-1 (Parker et al. 2002).
ix) An endoribonuclease capable of degrading Xenopus XIbbox2B mRNA:
Over a deeade ago, an mRNA sequence from a Xenopus homeo box-eontaining gene, 
referred to as Xlhbox2B, was found in vivo to be endonucleolytieally degraded in a site-specifie 
manner when injected with Xenopus oocytes (Brown and Harland 1990). It was found that the 
cleavage sequence is located in between the protein-coding region and the 600 nt region in the 3'- 
UTR (Brown and Harland 1990; Brown et al. 1993). These results were further supported when 
similar observations were made in vitro, along with the diseovery that oocytes also contained a 
sequenee-speeific RNA binding factor capable of inhibiting the endoribonuclease activity 
(Brown et al. 1993). The endoribonuelease responsible for the cleavage event was found to 
cleave independently of translation and ribosomes (Brown et al. 1993). In addition, Harland et 
al. also found another Xenopus eDNA, called X ool, which contains a similar long destabilizing 
element to that found in Xlhbox2B (Brown et al. 1993). They determined that the destabilization 
was due to a single, 19 nt-long sequence (5'-CACCCUACCUACCCAACUA-3'), and further 
hypothesized that the endoribonuelease and protective factor recognition sites were overlapping 
in this region (Brown et al. 1993). The -120 kDa protein that cleaves Xenopus Xlhbox2B 
mRNA has been shown to be sequence-specific when multiple binding sites were reiterated into 
heterologous RNA (Rodgers et al. 2002). It is also known that specific protein factors bind to
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Xenopus Xlhbox2B mRNA to prevent endonucleolytic activity (Rodgers et al. 2002). The 
identity of this endoribonuclease remains unknown.
x) An endoribonuclease capable of degrading HuR-associated mRNA:
HuR is a specific mRNA binding protein that is a widely expressed member of the human 
embryonic lethal abnormal vision (ELAV) protein family that was originally discovered because 
of their role as tumour antigens (Zhao et al. 2000; Brennan and Steitz 2001). As a ubiquitously 
expressed nuclear protein, HuR rapidly shuttles between the nucleus and the cytoplasm, 
providing a mechanism where HuR could protect mRNAs from cytoplasmic degradation 
(Brennan and Steitz 2001). HuR contains three highly conserved recognition domains; while the 
first and second domains recognize U-rich regions, the third domain has been found to bind to 
the poly(A) tail (Zhao et al. 2000). While the mechanism of HuR activity is not yet clear, it has 
been proposed that an endoribonuclease cleaves the mRNA within the U-rich element (Zhao et 
al. 2000). This hypothesis was supported by the findings that a novel endoribonuclease was 
found to specifically cleave within the sequence 5'-GUUUUG-3' located in the 5 -UTR HuR 
binding site in p27*^ *^^ ' mRNA (Zhao et al. 2000). The authours of this study further propose that 
perhaps, contrary to the current belief that the p27'^^^’ gene is regulated at protein turnover, the 
P27KIP1 jg regulated by changes in mRNA stability (Zhao et al. 2000). The identity, size, 
and amino acid sequence of the endoribonuclease capable of cleaving p27*^ *’’' mRNA is 
unknown.
xi) V irion host shutoff (Vhs):
The herpes simplex virus (HSV) is a large enveloped DNA virus that can infect 
mammalian cells and then replicate within their nuclei (Elgadi et al. 1999; Everly et al. 2002).
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During the HSV lytic infection of host cells, viral and gene expression is regulated through a 
variety of transcriptional and post-transcriptional controls (Elgadi et al. 1999).
The most widely characterized post-transcriptional mechanism for regulating host and 
viral mRNAs is the 58 kDa (Elgadi et al. 1999) HSV virion host shutoff, abbreviated Vhs 
(Everly et al. 2002). The Vhs protein can trigger rapid termination of host protein synthesis, 
disrupt pre-existing polysomes, and accelerate the degradation of host mRNAs (Elgadi et al. 
1999; Everly et al. 2002). Simply put, Vhs acts to direct the cellular machinery to stop 
synthesizing host proteins and begin generating viral proteins. Vhs, which is a UL41 gene 
product, has been found to destabilize most viral and cellular mRNAs during infection, but is 
unable to degrade rRNAs or tRNAs (Elgadi et al. 1999; Everly et al. 2002).
It has been proposed that the Vhs protein is, in fact, an endoribonuclease that triggers 
shutoff by degrading mRNAs (Elgadi et al. 1999). This hypothesis is supported by the findings 
of significant amino acid sequence homology with the DNA replicating and repair fen-1 family 
of nucleases, and the observation of Vhs-dependent mRNA degradation in cytoplasmic HSV- 
infected cell extracts and purified HSV virions (Elgadi et al. 1999). It has also been shown that 
Vhs induced mRNA decay, which is a Mg^^-dependent process, was not affected by the absence 
of ribosomes or the presence of either a 3' poly(A) tail or a 5' cap structure (Elgadi et al. 1999).
The initial Vhs endonucleolytic cleavage site appears to be clustered over the 5' quadrant 
of the transcript, approximately 200 to 700 nts from the 5' terminal (Elgadi et al. 1999). More 
recent studies confirm that initial cleavage occurs in the 5' end, and show that in vitro transcribed 
Vhs was found to preferentially cleave downstream of a picornavirus internal ribosome entry site 
(Everly et al. 2002). In an experiment that generated Vhs-homologous mutants, it was found that 
the mutants that abolished nuclease activity in the homologues also completely inactivated Vhs
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activity (Everly et al. 2002). Furthermore, this study investigated a reported association of Vhs 
with the mammalian translation initiation factor eIF4H by generating a multi-protein complex of 
these two proteins and glutathione 5-transferase (GST) and expressing the fusion protein in 
bacteria cells (Everly et al. 2002). Results indicated that the isolated wild-type fusion protein 
contained endoribonuclease activity, while the mutated Vhs/GST-eIF4H complex (with 
mutations in only the amino acids believed to be critical for Vhs activity) had no activity (Everly 
et al. 2002). Whether Vhs itself acts as an endoribonuclease, or whether it activates another 
cellular RNase or associates with other cellular proteins, such as elF4H, for activity remains to 
be elucidated.
xii) An endoribonuclease capable of degrading H epatitis B virus mRNA:
The hepatitis B virus (HBV) is a small enveloped noncytopathic hepatotropic virus 
(Heise et al. 2001) that belongs to the hepadnavirus family (Zheng et al. 2004). HBV has a 3.2 
kb circular and partially double-stranded DNA genome (Zheng et al. 2004) that encodes four 
overlapping unspliced messages that terminate at a common polyadenylation site (Heise et al. 
2001). La autoantigen (p45), an HBV RNA binding protein, can be cleaved by cytokine-induced 
proteolytic cleavage leading to the rapid disappearance of HBV RNA (Heise et al. 2001). While 
it was originally reported that La binds to 5'-end predicted stem-loop structures located in the 
post-transcriptional regulatory elements between nucleotides 1243 and 1333 of HBV RNA 
(Heise et al. 2001), recent studies have narrowed this down to the region between nucleotides 
1275 and 1291 (Ehlers et al. 2004). It was determined that an endoribonuclease cleaved the 
HBV RNA immediately 5' of the stem-loop structure bound by the La binding protein at 
nucleotides 1269 to 1270 and 1271 to 1272 (Heise et al. 2001). It was also observed that the 
endoribonuclease activities were upgraded concomitantly with HBV RNA decay and the
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appearance of a La protein fragment (Heise et al. 2001). This is concurrent with the fact that 
numerous RNA-binding proteins are known to be able to protect susceptible cleavage sites from 
endonucleolytic cleavage.
The endoribonuclease discussed here was found to be a 26 kDa protein that acted 
independently of Mg "^ ,^ showed reduced activity at high salt concentrations, and generated 
cleavage products with 3' phosphates (Heise et al. 2001). While the cleavage site recognized by 
the endoribonuclease to intact viral RNA prepared from the livers of HBV transgenic mice was 
mapped to the sequence 5'-CCAUACU-3', it is currently not known what role the surrounding 
nucleotides or the structural aspects of the RNA play in the recognition of the cleavage site 
(Heise et al. 2001). Heise et al. propose that the enzyme responsible for the cleavage of HBV 
RNA is a novel endoribonuclease, as it does not share common characteristics of other known 
RNases (Heise et al. 2001). This hypothesis was supported by the findings that HBV RNA 
coprecipitated with human La protein antibodies (Ehlers et al. 2004). It is has also been 
suggested that both the La protein and HBV RNA form a complex whose endoribonucleolytic 
cleavage is influenced by the composition of the complex, structural features of the RNA, and 
interacting cellular factors (Ehlers et al. 2004). The identity of this endoribonuclease remains 
unknown,
xiii) RNase L:
Ribonuclease L (RNase L) is an interferon-inducible, unique ankyrin-repeat 
endoribonuclease that is activated by 5'-triphosphorylated, 2',5'-linked oligoadenylate (2-5A) 
synthetases (Silverman 2003; Pandey and Rath 2004). RNase L is known to function in the 
pathways of interferon action against viral infections (Silverman 2003) by degrading single­
stranded RNA (including mRNA, rRNA, and viral RNA), usually at the UA and UU
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dinucleotides (Mishra 2002), and leading to apoptosis in mammalian cells (Pandey and Rath
2004). Activation of RNase L appears to be the only function for 2-5A (Silverman 2003). In 
humans, RNase L activity requires at least one 5'-phosphoryl group and a minimum of three 
adenyl residues joined in a 2'-5' linkage (Li et al. 2000). RNase L is inactive as a monomer, but 
active as a homodimer (Dong et al. 2001; Pandey and Rath 2004). It has recently been 
determined that mammalian RNase L is biochemically active in a prokaryotic environment (in E. 
coll) without the presence of its cofactor, 2-5A, which suggests that RNase L is not only an 
antiviral gene, but a prokaryotic antibacterial gene as well (Pandey and Rath 2004).
RNase L is a 741 kDa protein in humans, whose RNase catalytic center can be found in 
the C-terminal region (Silverman 2003). In the presence of 2-5A the endoribonuclease activity 
can be repressed by a common protein/protein interaction domain that, in RNase L, is made up of 
nine ankyrin repeats and found in the N-terminal half (Zhou et al. 2000; Silverman 2003). It has 
been hypothesized that the ankyrin repeat homology may be due to regulation by interacting 
proteins, such as the ATP-binding cassette (ABC) homology protein RLI(HP68) (Silverman
2003). RLI(HP68) is capable of inhibiting RNase L when levels are high, and can stimulate 
activity when levels are low (Silverman 2003). The N-terminal region also contains two P-loop 
motifs and a cysteine-rich region (Mishra 2002). It is also believed that RNase L has kinase-like 
domains in it's central region (C-terminal half), although there is little evidence to support the 
notion of RNase L kinase activity aside from sequence comparison studies (Mishra 2002; 
Silverman 2003). Both the kinase-like and ribonuclease domains found in the C-terminal half of 
RNase L are related to the Ire I kinases/ribonucleases that are known to function in the unfolded 
protein response pathway (Zhou et al. 2000; Silverman 2003). It has been proposed that RNase 
L plays a role in the post-transcriptional attenuation of the interferon response (Li et al. 2000).
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While believed to be present in all eukaryotes, RNase L has only been identified in reptiles, 
birds, and mammals (Silverman 2003).
xiv) IRE-1:
IRE-1 is an endoplasmic reticulum (ER) transmembrane glycoprotein with both kinase 
and endoribonuclease activity (Urano el al. 2000; Yin-Liu and Kaufman 2003). Stress in the ER 
leads to the autophosphorylation of IRE-1, and the resulting activation of it's endonucleolytic 
activity (Yin-Liu and Kaufman 2003). IRE-1 is involved in the intracellular signaling pathway 
known as the unfolded protein response (UPR), which is responsible for transmitting information 
about the status of protein folding in the ER lumen to the cytoplasm and nucleus (Dong el al. 
2001; Yin-Liu and Kaufman 2003).
The majority of information regarding IRE-1 has been obtained through studies focused 
on yeast species, such as Saccharomyces cerevisiae (Urano et al. 2000). In this species, IRE-1 
activates the gene expression responsible for splicing the transcription factor H a d  p's 
nonfunctional mRNA transcript to one that is active (Urano et al. 2000). The now active H aclp 
mRNA binds to the promoters of genes that are known to code for chaperones, thus activating 
them, and facilitating the UPR pathway (Urano et al. 2000).
While the true mechanism of IRE-I s involvement in the UPS pathway in mammalian 
systems remains to be elucidated, it is believed to be much more complex than that observed in 
yeast (Tirasophon et al. 2000; Urano et al. 2000). XBPl mRNA is the substrate RNA of IR E -la  
and IRE-1 P (human IREl homologues) in mammals, and codes a transcription factor containing 
a basic leucine-zipper domain (Tirasophon et al. 2000; Yin-Liu and Kaufman 2003). The 
endonucleolytic activity of IRE-1 initiates the splicing of XBPl mRNA to generate the mature 
mRNA (Yin-Liu and Kaufman 2003). IRE-1, which is then responsible for activating the
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transcription of XBPl in the nucleus, is negatively regulated by BiP, the ER chaperone (Yin-Liu 
and Kaufman 2003).
The carboxyl terminal of Ire Ip, the yeast protein, was determined to be composed of a 
Ser/Thr protein kinase domain, and a site-specific endoribonuclease domain that continued into 
the cytoplasm (Tirasophon et al. 2000). Both IR E -la  and IRE-1(3 share the same domain 
structure of yeast Ire Ip and both enzymes were found to cleave the 5' and 3' splice site of HACl 
mRNA (Tirasophon et al. 2000). Overexpression of either IR E -la  or IR E l-(3 in mammalian 
cells resulted in the activation of the UPR pathway (Tirasophon et al. 2000). It was also 
determined that the endoribonuclease domain of human IRE-1 a , which is 977 amino acids in 
length with a molecular weight of 110 kDa, shares structural and sequence homology with 
RNase L, an endoribonuclease that mediates the interferon antiviral response (Tirasophon et al.
2000). Studies involving the generation of human IRE-1 a  mutants found that 
endoribonucleolytic activity was mapped to nucleotides 196, 644, 672, and 673, corresponding to 
the dinucleotides GC, UG, AC, and CU, respectively (Tirasophon et al. 2000). 
Endoribonuclease cleavage of yeast HACl mRNA appeared to occur between the dinucleotides 
GC and GA (Tirasophon et al. 2000). Furthermore, it was discovered that trans- 
autophosphorylation occurs between human IR E -la  molecules, suggesting that functional 
endoribonuclease activity depends on a homodimer of functional domains of two RNases 
(Tirasophon et al. 2000).
xv) An endoribonuclease capable of degrading apolipoprotein II mRNA:
Estrogen-regulated chicken apolipoprotein II mRNA has been determined to be 
endonucleolytically cleaved in its 3' non-coding region, independently of deadenylation (Binder 
et al. 1989). The cleavage events occurred predominately at 5'-AAU-3' or 5'-UAA-3' sequences
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found in two single-stranded domains within the 3'-UTR (Binder et al. 1989; Ratnasabapathy et 
al. 1990). Degradation target sites within the apolipoprotein II mRNA were found in two 
separate domains of secondary structures; the upstream domain, nucleotides (nts) 400-547, 
extends from the translation stop codon to the stem-loop D structure while the downstream 
domain, nts 568-643, terminates within the universal polyadenylation signal (Ratnasabapathy et 
al. 1990). Initial UV cross-linking experiments labelled the upstream domain as predominately 
recognizing a ~ 34 kDa protein, while the downstream domain predominately recognized a ~ 60 
kDa protein (Ratnasabapathy et al. 1990).
More recent work has found that eight estrogen-induced proteins cross-linked to the 3’- 
UTR but not to the coding region or the 5 -UTR (Margot and Williams 1996). These included 
two barely detectable proteins, at 132 and 50 kDa, and six strongly detected proteins, at 83, 74, 
65, 58, and 45 kDa (Margot and Williams 1996). This study also found that a 150 nt domain, 
from nt 510 to polyadenylation sequence, provided the minimal RNA sequence required for 
maximal cross-linking (Margot and Williams 1996). These findings suggest that estrogen is 
capable of inducing the assembly of a multi-protein complex whose eight proteins are capable of 
either binding independently, or as a complex, to apolipoprotein II mRNA, and in doing so, 
catalyze endonucleolytic cleavage within the 3 -UTR of the mRNA (Margot and Williams 1996).
An estrogen-regulated mRNA stabilization factor (E-RmRNASF) has now also been 
identified and characterized, and is believed to act as a binding protein to protect apolipoprotein 
II mRNA from endonucleolytic degradation (Ratna and Oyeamalu 2002). This study was able to 
narrow the binding domain of E-RmRNASF to be between nts 402-548, within the 3 -UTR of 
apolipoprotein mRNA (Ratna and Oyeamalu 2002).
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The exact size and identity of the endoribonuclease(s) responsible for the 
endoribonucleolytic cleavage of apolipoprotein II mRNA remains unclear.
xvi) An endoribonuclease capable of degrading Interleukin-2 mRNA
Interleukin-2 (IL-2) mRNA, which encodes a key regulatory cytokine and the principal 
mitogen of the immune system, has been found to be endonucleolytically degraded in vitro by an 
enzyme purified from the cytoplasm of human T lymphocytes (Hua et al. 1993; Seko et al.
2004). Although the 3 -UTR of IL-2 contains an ARE (Seko et al. 2004), the RNasin-resistant 
endoribonuclease was found to selectively cleave IL-2 mRNA within the coding region, 
predominately within nts 400-430, and to a lesser extent in the 3'-noneoding region (Hua et al. 
1993). Maximum activity of the -65 kDa endoribonuclease was detected in the presence of 
Mg "^ ,^ regardless of prior deadenylation or decapping (Hua et al. 1993). The exact cleavage 
speeificity and identity of this endoribonuelease remains unknown.
xvii) RasGAP-Associated G3BP:
The G3BP (ras-GTPase-activating protein SH3-domain-binding protein) family of 
proteins are known to act in both signal transduction and RNA metabolism (Kennedy et al.
2001). The evolutionarily conserved endoribonuclease G3BP is a 52 kDa (Tourriere et al. 2001) 
RNA-binding protein that was initially characterized through it's SH3 domain interaction with a 
Ras-GTPase-activating protein ealled RasGAP p i 20 (Guitard et al. 2001; Tourriere et al. 2001; 
Tourriere et al. 2003).
G3BP is a ubiquitously expressed protein that contains several unusual motifs (Barnes et 
al. 2002). The C-terminal region of G3BP contains two characteristic RNA-binding protein 
domains, termed RN Pl and RNP2, as well as a RGG-box rich domain (arginine-glycine- 
arginine) (Guitard et al. 2001), which lends support to the notion that G3BP is involved in RNA
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processing (Barnes et al. 2002). The N-terminal domain, residues I to 120, has been shown to 
be homologous to the nuclear transporter factor 2 (NTF2), while the central region, residues 140 
to 240, has been determined to be rich in acidic residues (Tourriere et al. 2001).
G3BP, which has been found to require site-specific phosphorylation for RNase activity, 
cleaves the 3 -UTR of c-myc mRNA in vitro (Guitard et al. 2001 ; Tourriere et al. 2001 ; Barnes et 
al. 2002). G3BP's domain structure suggests that G3BP's are scaffolding proteins that can link 
signal transduction to RNA metabolism (Irvine et al. 2004). Furthermore, it has been proposed 
that G3BP works in association with an array of other proteins in a phosphorylation-dependent 
mechanism to post-transcriptionally regulate other mRNAs (Irvine et al. 2004). Some of these 
transcripts code for proteins that are important in transcription and cytoskeletal arrangement, 
such as c-myc and Tau, respectively (Irvine et al. 2004). It has been determined that G3BP is a 
highly active endoribonuclease that specifically cleaves single-stranded transcripts between CA 
dinucleotides (Tourriere et al. 2001).
G3BP RNase activity is positively regulated by phosphorylation at several sites; serine 
149 is one of these sites, and is dependent on RasGAP and regulated negatively by Ras signaling 
(Tourriere et al. 2003). G3BP1 and G3BP2 protein subunits have now been shown to be 
encoded by two separate genes, which reside on human chromosomes 5 and 4, respectively 
(Freneh et al. 2002). These two proteins are known to be involved in Ras signaling, NFkappaB 
signaling, the ubiquitin proteasome pathway, and RNA processing (French et al. 2002). G3BP2 
expression has been found to be specific to human breast cancer tissue and was determined to be 
over-expressed in 88% of the tumours examined (French et al. 2002). G3BP has also been 
shown to be identical to DNA helicase VII, an enzyme that plays critical roles in DNA 
replication, repair, and recombination in humans (Barnes et al. 2002).
53
xviii) A -  65 kDa RNase E-like endoribonuclease capable of degrading c-myc mRNA:
A ~65 kDa endoribonuclease has been purified from human cell extraets that is eapable 
of cleaving c-myc mRNA within its 3 -UTR (Wennborg et al. 1995). This endoribonuclease is 
similar to the bacteria endoribonuclease, RNase E, in that it also processes E. coli 9S RNA and 
the outer membrane protein A (ompA) mRNA, and was found to eross-react with RNase E 
antibodies (Wennborg et al. 1995). The Mg^'^-dependent endoribonuelease also cleaves mRNA 
with the same speeifieity as RNase E, eleaving within the 5'-AUUUA-3' motif found in the 3'- 
UTR of c-myc mRNA (Wennborg et al. 1995). The identity of this endoribonuclease remains 
unknown.
xix) A ~39 kDa endoribonuclease capable of degrading c-myc mRNA:
A mammalian liver cytoplasmic endoribonuclease capable of degrading the CRD of c- 
myc mRNA in vitro has been tentatively identified as a -39  kDa protein, with properties similar 
to those of other known mRNA RNases (Lee et al. 1998). This soluble enzyme, whieh was 
isolated from a high salt extraet of rat liver polysomes, is a Mg^^-dependant protein which is not 
a member of the RNaseA family as it is resistant to RNasin, a RNase A class inhibitor (Lee et al. 
1998).
This novel endoribonuclease cleaves the deproteinized c-myc CRD mRNA with high 
specificity and preferentially attacks a RNA segment that is rich in A residues (Lee et al. 1998). 
It was found that the endoribonuclease cleaved the 88 nt CRD mRNA substrate at two major 
cleavage sites (Lee et al. 1998). The 5'-labelled substrate was found to specifically cleave at -  
30 nts 3' from the 5' terminus, while the 3 '-labelled substrate was cleaved -  60 nts from its 3'- 
terminus (Lee et al. 1998). Furthermore, it was found that the these degradation produets 
eorresponded to the original 88 nt full-length mRNA substrate (Lee et al. 1998). The main
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cleavage site was mapped to a 10 nt segment between nts 1727 and 1736, which corresponds to 
5'-CAUGAAAAG-3'. A more precise cleavage site was mapped to nts 1731 and 1735, but could 
not be elucidated further because of the ambiguity of nt 1731 being followed by four A residues 
(Lee et al. 1998). The amino acid sequence and identity of this endoribonuclease is currently 
unknown.
Table 3, on the next page, summarizes the known vertebrate endoribonucleases capable 
of degrading mRNA, and identifies their individual cleavage specificity, size, and whether or not 
they exist in a complex.
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Table 3. Higher eukaryote (vertebrate) endoribonucleases capable of degrading mRNA.
OS
mRNA Endoribonuclease Cleavage Specificity Size P art of Complex References
Albumin PMR-1 ss UG dinucleotides in 5' coding region; ss 5 ’- 
AYUGA-3' (Y = C or U) in 3'-UTR
protein -6 0  kDa; 
complex: -680  kDa
unidentified RNP 
complex
Hanson and Schoenberg 2001; Bremer et al. 
2003; Stevens et al. 2002
ViteUogenin PMR-1 ss 5'-AYUGA-3' (Y = C or U) in 3-UTR
protein -6 0  kDa; 
complex; -680  kDa
unidentified RNP 
complex
Cunningham et al. 2000; Cunningham et al. 
2001; Goolsby and Shapiro 2003
siRNA comlimentary 
mRNA Argonaute! ds RNAs in RNAi; 3'-UTR AREs
Ago2: 694 aa, -130  
kDa; RISC: -500  kDa
RISC Hammond el a/. 2001; Liu, el n/. 2004
viial RNAs involved 
inRNAi Dicer ds RNAs in RNAi; miRNAs from precursors
Dicer: 218 kDa; RISC; 
-500  kDa
RISC
Fortin et al. 2002; Nicholson and Nicholson 
2002; Doi el ii/. 2003; Zhang el ii/. 2004a
or-Globin ErEN dinucleotides 63-64 - CU, in CU rich region in 3'- 
UTR
-4 0  kDa denatured
unknown
complex
Wang and Kiledjian 2000a; Wang and Kiledjian 
2000b
P-Globin unknown ss UG and UC dinucleotides in 3 -UTR unknown unknown Bremer el al. 2003;
Transferrin receptor unknown ss 5'-GAACAAG-3' in 3'-UTR unknown unknown Binder el a/. 1994
IGF-11 unknown ss in 3 -UTR unknown unknown
Meinsma el al. 1992; van Dijk e l al. 1998; 
van Dijk el ii/. 2001
unknown ARD-1/NIPP-1 ss AREs ARD-1: 13.3 kDa; 
NIPP-1; 38.5 kDa
unknown Claverie-Martin el al. 1997; Chang el al. 1999
XUibox2B unknown 5'-CACCCUACCUACCCAACUA-3' in 3-UTR -120  kDa unknown Brown and Harland 1990; Brown et al. 1993; 
Rodgers et al. 2002
p27"''' unknown 5'-GUUUUG-3' in 5'-UTR unknown unknown Zhao et al. 2000
viral RNAs involved 
with HSV vhs
5' region, -400  nts from 5' terminal; downstream 
of picornavims internal ribosome entry site
58 kDa
vhs/eIF4H
complex
Elgadi el al. 1999; Everly 2002
Hepatitis B virus unknown ss 5'-CCAUACU-3' (nts 1269 and 1271) 26 kDa
La protem/HBV 
RNA complex Heise et al. 2001
viral RNA RNase L single-stranded UA and UU dinucleotides 741 kDa unknown Mishra 2002
XBPl and H AC l lRE-1 ss GC, GA, UG, AC, and CU dinucleotides 977 aa, 110 kDa unknown Tirasophon el al. 2000; Lee el al. 2002
Apolipoprotein 11 unknown ss 5'-AAU-3' or 5'-UAA-3' in 3'-UTR unknown
multiple protein 
complex
Binder el al. 1989; Ratnasabapathy el al. 
1990
lnterleukin-2 unknown between nts 400-430 o f coding region -65 kDa unknown Hua el al. 1993
c-myc RasGAp-associated
G3BP ss CA dinucleotides in 3 -UTR 52 kDa unknown Tourriere e l ol. 2001
c-myc RNase E-like ss 5'-AUUUA-3' in 3 -UTR -65 kDa unknown Wennborg el a/. 1995
c-mvc unknown 5'-CAUGAAAAG-3’ in coding region -39  kDa unknown Lee el al. 1998
c-myc, p-globin. 
MDRl unknown ss CA, UA, and UG dinucleotides in coding region
-35  kDa, four others at 
-10-25 kDa
suspected 5 
protein complex Bergstrom el al. 2005; Tafech 2005
1.3 A novel mammalian endoribonuclease capable of degrading the CRD of c-mvc mRNA 
in vitro'.
A second novel mammalian endoribonuclease has been found that can also 
endonucleolytically degrade the CRD of c-myc mRNA (nts 1705-1792) in vitro (Bergstrom et al. 
2006). This second novel endoribonuclease was accidentally discovered while purifying the 
original -39  kDa endoribonuclease (Lee et al. 1998).
This second native mammalian endoribonuclease was isolated from a high salt extract of 
rat liver polysomes and purified using an initial pH-precipitation step, followed by five column 
chromatography steps: phosphocellulose, reactive blue-4, reactive green-19, Affi-gel, heparin- 
Sepharose (Lee et al. 1998; Bergstrom et al. 2006). The endoribonucleolytic activity against the 
CRD c-myc mRNA was found to co-purify with five major proteins, one at -  35 kDa, and four at 
-10-25 kDa (Bergstrom et al. 2006). It is proposed that the smaller proteins are possibly 
degradation products or modified forms of the larger -35  kDa protein (Bergstrom et al. 2006). It 
is also possible that the -35  kDa protein is a dimer of the two smaller peptides, or perhaps 
completely different peptides altogether (Bergstrom et al. 2006). The other possibility is that 
these proteins are normally tightly bound together in a complex, and need to associate with each 
other for endoribonucleolytic enzyme activity.
The novel mammalian endoribonuclease was found to not require an RNA co-factor for 
activity, was found to generate cleavage products with 3' hydroxyl groups, and is capable of 
degrading single- and double-stranded RNAs, but incapable of degrading DNAs (Bergstrom et 
al. 2006). The native mammalian endoribonuclease was also found to not cleave DNA-RNA 
duplexes (Bergstrom et al. 2006). In addition, this enzyme was also found to cleave mRNAs 
other then CRD c-myc, including /3-globin RNA (nts 50-169), multi-drug resistance 1 {MDRl)
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RNA (nts 745-922), and the 5'-UTR of c-myc RNA (nts 1-217), which suggests that the 
endoribonuclease is sequence-specific, and not substrate-specific (Bergstrom et al. 2006). The 
novel mammalian endoribonuclease, which was found to be Mg^'^-independent, was determined 
to be active up to 60 °C but completely inactivated at 70 °C (Bergstrom et al. 2006).
Furthermore, the native mammalian endoribonuclease was also determined to 
preferentially cleave CA (nts 1742 and 1768), and to a lesser extent, UA (nts 1747 and 1751) and 
UG (1720) dinucleotides (Lee et al. 1998; Bergstrom et al. 2006; Tafech 2006). It was also 
determined that the native mammalian endoribonuclease cleaved at nts 1727-1732 within the 
sequence 5'-CAUGAA-3' (Bergstrom et al. 2006). The amino acid sequence and identity of this 
endoribonuclease is currently unknown.
1.4 Thesis Objectives
The main goal of this thesis was to characterize the human recombinant protein p35 
(Rpp35) in an effort to identify the -35 kDa protein that co-purified with the native mammalian 
endoribonuclease capable of degrading the CRD of c-myc mRNA in vitro.
Prior to the candidates arrival in the Lee Lab, heparin-sepharose purified fractions that 
corresponded to the native mammalian endoribonucleolytic activity were subjected to 12% SDS- 
PAGE and stained with silver-stain. The -35  kDa protein was then gel-purified and the gel 
slices sent to Keck Laboratories at Yale University for protein identification. This process 
involved the digestion of the -35 kDa peptide with trypsin, which exclusively cleaves C-terminal 
to lysine and arginine residues (Olsen et al. 2004), and then subjecting the trypsin-digested 
peptides to matrix assisted laser desorption ionization (MALDI) mass spectrometry (MS) 
analysis. The resulting peptide masses were checked against the NCBI databases to determine 
whether the enzyme had previously been sequenced. Only 4 tryptic peptides, out of the 22 major
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peptide masses, were matched in the database to a Mus musculus protein with 100% sequence 
homology. This protein has been identified as a member of a family of proteins referred to as 
target-soluble iV-ethylmaleimide-sensitive factor-attachment receptor proteins (SNAREs), and 
since that time, our lab has obtained the human-equivalent protein in full-length complimentary 
DNA (cDNA) from Origene Technologies, as well as the cDNA without the transmembrane 
domain (ATMD), from collaborators in Japan, referred to here as recombinant protein p35 
(Rpp35) and Rpp35 ATMD, respectively.
AIM I:
In an effort to definitively identify the ~35 kDa protein that co-purified with the native 
mammalian endoribonuclease, the tentative human orthologue Rpp35 protein needed to be 
expressed and tested for endoribonuclease activity. The first aim of this thesis, therefore, was to 
generate, purify, re-fold, and then test recombinant p35 for endoribonuclease activity.
This aim was accomplished using Rpp35 ATMD cDNA that was previously incorporated 
into a Qiagen pQE31 plasmid as well as the full-length Rpp35 cDNA incorporated into a 
pHTTVK plasmid. Both the Rpp35 ATMD and the Rpp35 were tagged with six consecutive 
histidine residues at their amino terminal. The plasmids were transformed into BL21 expression 
cells, where gene expression was restored via induction using Isopropyl-P-D-thiogalactosidase 
(IPTG). The BL21-plasmid containing cells were proliferated, and then lysed to release the 
Rpp35. Purification was performed using a nickel-nitrilotriacetic aeid-agarose column (Qiagen), 
which, according to Qiagen's QIAexpressionist™, is based on the high selectivity of nickel- 
nitrilotriacetic acid (Ni-NTA) resin for proteins eontaining an affinity tag of six consecutive 
histidine residues. Once the recombinant p35 had been purified, it was tested against the y ^^P-
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5'-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792) (Figure 3) for enzymatic activity 
using an in vitro endoribonuclease assay.
Coding Region CRD
5 ’-UTR 3 ’-UTR
c-myc mRNA
FL-CRD o f c-myc mRNA (nts 1705-1886)
32p-5’-labeled-CRD of c-myc mRNA (nts 1705-1792)
Figure 3. Human c-myc mRNA with CRD, 5’-, and 3’-untranslated regions (UTR) 
indicated. The FL-CRD of human c-myc mRNA and the '-laheled-CRD of c-myc
mRNA (nts 1705-1792) substrate used to test for endorihonuclease activity are indicated 
(Lee et al. 1998).
Some of the questions that Aim I sought answers to were: i) can the Rpp35 be purified 
under native conditions? ii) if purified under denatured conditions, can Rpp35 be renatured? iii) 
does the native or renatured Rpp35 exhibit identical endoribonuclease activity?
AIM II:
The second aim of this thesis was to perform five main characterization experiments in an 
attempt to elucidate the identity of the -35  kDa protein that co-purified with the native 
mammalian endoribonuclease. This was accomplished by a variety of characterization 
experiments that were conducted on the native mammalian endoribonuclease and/or Rpp35. 
These characterization experiments included: i) the size-exclusion separation of the two large 
proteins that co-eluted with Rpp35, and subsequent testing of these proteins for endoribonuclease 
activity; ii) comparing the endoribonucleolytic activity of Rpp35 to that of the novel mammalian
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endoribonuclease and other recombinant proteins; iii) mapping the cleavage sites and specificity 
of Rpp35 as compared to the native mammalian endoribonuclease against CRD c-myc mRNA; 
iv) investigating the specificity of Rpp35 and phosphocellulose-purified native mammalian 
endoribonuclease through Western blot experiments using Rpp35-oligopeptide generated 
polyclonal antibodies; v) performing immunoprécipitation experiments on Rpp35 and 
phosphocellulose-purified native mammalian endoribonuclease, as visualized by Western blot, 
and then testing these immunoprecipitated fractions for depleted endoribonuclease activity.
Aim II sought answers to the following questions: i) does Rpp35 generate the same 
cleavage fragments and/or possess the same cleavage specificity as the native mammalian 
endoribonuclease?; ii) does the Rpp35-oligopeptide generated polyclonal antibody source bind 
and detect Rpp35, and does it also cross-react with the phosphocellulose-purified native 
mammalian endoribonuclease?; iii) can Rpp35 and/or the phosphocellulose-purified native 
mammalian endoribonuclease be immunoprecipitated, and if so, is their respective 
endoribonuclease activity depleted?
Finding answers to these questions will help to characterize the native mammalian 
endoribonuclease capable of degrading CRD c-myc mRNA, and allow for the comparison of the 
properties of this novel enzyme to the properties of Rpp35 and other known endoribonucleases.
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CHAPTER 2 - GENERATION AND CHARACTERIZATION OF THE HUMAN
RECOMBINANT PROTEIN p35
The first aim of this thesis was to express and eharacterize human recombinant protein 
p35 (Rpp35). This chapter describes the steps involved in generating RNase-free 5'-y^^F- 
radiolabelled CRD c-myc mRNA substrate (nts 1705-1792), as well as the generation, induction, 
purification, and testing of Rpp35 for endoribonuclease activity against the 5'-y^^P-radiolabelled 
CRD c-myc mRNA substrate.
2.0 Methods:
All experiments and reactions were carried out on ice unless otherwise indicated.
2.0.1 Proteinase K treatment of pUC19 plasmid construct containing the CRD c-myc DNA 
sequence (nts 1705-1792).
First, a stock solution of 20 mg/mL Proteinase K (EM Sciences, Darmstadt, Germany), 
and a 10 X Proteinase K buffer (100 mM Tris-Cl [pH 8.0], 50 mM ethylenediamine tetra-acetic 
acid [pH 8.0] [EDTA] [Sigma-Aldrich, St. Louis, MO], 500 mM sodium chloride (NaCl) 
[Sigma-Aldrich, St. Louis, MO]) were prepared. Two hundred and fifty pL of 1.6 pg/pL of 
previously purified pUC19 plasmid containing the CRD c-myc DNA sequence (nts 1705-1792) 
was treated with 1.41 pL of 20 pg/pL stock Proteinase K in 25 pL of 10 X Proteinase K buffer, 
and 6.25 pL of 20% sodium dodecyl sulfate (SDS) (EM Sciences, NJ) for one hour at 37°C.
After the one-hour incubation step, standard phenol/chloroform extraction was performed 
twice, followed by standard ethanol precipitation. Standard phenol/chloroform extraction 
involved the addition of 1/2 volume DNA phenol solution (Sigma-Aldrich, St. Louis, MO) and 
1/2 volume chloroformdsoamyl alcohol (CHCLiIAA) 49:1 (Fluka, Germany), mixing 
thoroughly, and spinning at 12,000 rpm for 5 minutes. The top layer was carefully removed and 
placed in a new eppendorf tube where 1 volume of CHCLiIAA was added, mixed thoroughly,
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and spun at 12,000 rpm for 5 minutes. Once again, the top layer was carefully transferred into a 
new eppendorf tube and the entire phenol/chloroform extraction procedure was repeated (for a 
total of two times). The final top layer was transferred into a new eppendorf tube where standard 
ethanol precipitation was carried out. This step involved the addition of 2 volumes of chilled 
100% ethanol (EtOH) (Commercial Alcohols Inc., Vancouver, BC) and 1/10 volume 3 M 
sodium acetate (NaOAc) (EM Sciences, Darmstadt, Germany) pH 5.2, mixing thoroughly, and 
storing at -20“C for >30 minutes prior to spinning at 13,200 rpm (Centrifuge 5415 R, Eppendorf, 
Hamburg, Germany) for 10 minutes. The supernatant was then either poured off or aspirated, 
and 200 pL of cold 70% EtOH was gently added and then spun at 13,200 rpm for 5 minutes. 
Once again the supernatant was removed, and the pellet allowed to air dry for ~ 15 minutes 
before being re-suspended in 100 pL of ddH%0. The purified proteinase K treated pUC19 
plasmid containing the CRD c-myc DNA sequence (nts 1705-1792) was then quantified by 
measuring the absorbance of the plasmid at 280 nm on an UV/Vis spectrophotometer. 
Quantification was accomplished by first blanking the spectrophotometer with 1 mL of ddHiO, 
and then measuring the absorbance of 5 pi of the plasmid in 995 pL of ddHiO.
2.0.2 Digestion and in vitro transcription of pUC19 plasmid construct containing the CRD 
c-myc DNA sequence (nts 1705-1792)
The RNase-free pUC19 plasmid containing the CRD c-myc DNA sequence (nts 1705- 
1792) was digested and then in vitro transcribed in preparation for 5'-dephosphorylation and 5'- 
y^^P-radiolabelling (Figure 4).
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CRD 1705-1792 
DNA plasmid Digestion
CRD 1705-1792 DNA In vitro transcription
CRD 1705-1792 RNA 5' Dephosphorylation
5 ’-Dephosphorylated CRD 1705-1792
y32p.
^  radiolabelling
5'-y ^^P-radiolabelled CRD 1705-
Figure 4. Preparation steps in the generation of the 5 ' radiolabelled CRD c-myc 
mRNA substrate (nts 1705-1792)
Digestion was accomplished by subjecting ~5 pg of the pUC19 plasmid to the restriction 
enzyme JS’coRl (Invitrogen Life Technologies, Carlsbad, CA) in a total reaction volume of 10 
pL, consisting of final concentrations of 1 U/pL EcoR l, and 1 X reaction buffer (lOX React3 
buffer) (Invitrogen Life Technologies, Carlsbad, CA), and then made up to volume using ddHzO. 
The mixture was first mixed by finger-flicking, and then quickly pulsed prior to incubating at 37 
°C for 3 hours. After incubation, the linearization was checked by running 1 pL of the digested 
plasmid, along with 1 pL of the uncut plasmid (as a control) on an ethidium bromide-stained 1% 
agarose gel at 45 mA for -90  minutes. Digestion was visualized using the Chemilmager^'^ 
System (Alpha Innotech Corporation, San Leandro, CA).
Upon confirming adequate plasmid digestion, the remaining reaction mixture containing 
the digested plasmid was brought up to a volume of 200 pL with ddHiO, and standard 
phenol/chloroform extraction and ethanol precipitation was performed as described earlier 
(Section 2.0.1). The air-dried DNA pellet was then re-suspended in ddHzO to give a final 
concentration of -  0.2-0.3 ug/uL.
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In vitro transcription was accomplished using an Ambion MEGAscript® SP6 Kit 
(Ambion, Inc., Austin, Texas). Transcription was typically carried out in a total reaction volume 
of 20 pL, which consisted of: 4 pL of digested DNA, 2 pL of lOX reaction buffer, 2 pi of each 
of the 50 mM ribonucleotide triphosphates (rNTPs) (ATP, UTP, CTP, and OTP), 1 pL of 100 
mM DTT, 1 pL of RNasin (40 U/pL) (Promega, Madison, WI), and 4 pL of the SP6 RNA 
polymerase enzyme mix. The in vitro transcription reaction was carried out at 37 °C for 2 hours. 
The plasmid template was then degraded by incubating at 37 °C for an additional 15 minutes in 
the presence of 1 pL of DNase I (Ambion, Inc., Austin, Texas). Diethylpyrocarbonate (DEPC) 
(Sigma-Aldrich, St. Louis, MO) HgO was added to bring the reaction volume to 200 pL, at 
which time standard phenol/chloroform extraction and ethanol precipitation were carried out, but 
now using RNA phenol (Sigma-Aldrich, St. Louis, MO) instead of DNA phenol. The air-dried 
pellet was re-suspended in 50 pL of DEPC H2O and transferred to a ProbeQuant^'^ G-50 Micro 
Column (Amersham Biosciences, Montreal), where it was spun at 3000 rpm for 2 minutes to 
remove any unincorporated rNTPs. The RNA was quantified by measuring the absorbanee of 
the sample at 260 nm on an UV/Vis spectrophotometer, and the quality of the RNA determined 
by loading 1.5 pL of the sample (-500 ng) with 3 pL of RNA gel cocktail mix [10 X N- 
morpholino propanesulfonic acid (MOPS) (Sigma-Aldrich, St. Louis, MO), EDTA, NaOAc, 
ddH^O, DEPC H2O), formaldehyde (Sigma-Aldrich, St. Louis, MO), formamide (EM Sciences, 
Darmstadt, Germany), ethidium bromide, and DEPC H2O] and 3 pL of loading dye on a 2% 
agarose/1.8% formaldehyde gel and running at 50 mA for -  90 minutes. The CRD c-myc mRNA 
substrate (nts 1705-1792) was visualized using the Chemilmager™ System.
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2.0.3 Déphosphorylation, 5 -end radiolabelling with ATP, and gel-purification of CRD 
c-myc mRNA sequence (nts 1705-1792).
Dephosphorylation of the 5' terminal was typically carried out in a 100 pL reaction 
volume containing ~7 pg of RNA, 2 pL of RNasin (40 U/pL), 5 pL of DTT (100 mM), 5 pL of 
10 X reaction buffer, 10 pL of calf intestinal alkaline phosphatase (CIAP) (1 U/pL), (Roche 
Diagnostic Inc, Montreal), and made up to volume with DEPC H2O. The reaction took place at 
37 °C for 30 minutes, at which time the total volume was adjusted to 200 pL with DEPC H2O. 
To inactivate the CIAP and quench the dephosphorylation reaction, 1 pL of 0.5M EDTA (pH 
8.0) was added, as well as 4 pL of 5M NaCl, and 10 pL of 20% SDS. The solution was mixed 
thoroughly, and then standard phenol/chloroform extraction was performed twice, followed by 
standard ethanol precipitation. The air-dried pellet was re-suspended in 20 pL of DEPC H2O to 
give a concentration of -0.25-0.5 pg/pL, and then stored at -20 °C.
Five'-terminal y^^P-radiolabelling of the RNA transcript was accomplished in a total 
reaction volume of 25 pL, which contained 10 pL of dephosphorylated RNA ( -  5 pg), 3 pL of 
DTT (100 mM), 1.5 pL of RNasin (40 U/pL), 2.5 pL of 10 X T4 Polynucleotide Kinase (PNK) 
reaction buffer (New England Biolabs, Beverly, MA), 4 pL of PNK (10 U/pL) (New England 
Biolabs, Beverly, MA), and 4 pL (40 pCi) of y^^P-ATP (GE Healthcare, Montreal). The y^^P- 
ATP and PNK were added last, and to the side of the reaction tube. The mixture was pulsed, 
mixed, pulsed again, and then incubated at 37 ”C for one hour. After incubating, the reaction 
volume was brought up to 50 pL by the addition of DEPC H2O, and then transferred into a G-50 
spin column to remove any unincorporated y^^P-ATP. Total volume was adjusted to 200 pL
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with DEPC H%0 and standard phenol/chloroform extraction was performed twice, followed by 
standard ethanol precipitation (as described earlier in section 2.0.1 ).
The air-dried 5'-radiolabelled RNA pellet was typically re-suspended in 20 pL of 9M 
urea/phenol loading dye, loaded into two lanes on a 6% polyacrylamide/7M urea gel, and ran in 
0.5 X TBE (Tris-Cl, Boric acid [Sigma-Aldrich, St. Louis, MO], EDTA) running buffer at a 
constant 30 mA for -45 minutes, or until the bromophenol blue (Sigma-Aldrich, St. Louis, MO), 
dye front was -1cm  from the bottom edge of the gel. The gel glass sheets were separated, the 
gel land-marked with ^^P-ATP, and quickly exposed to a Cyclone storage phosphor screen 
(Packard Instrument/Canberra Company, Meriden, Connecticut) for about 15 seconds. The 
image was scanned using the Cyclone Phospholmager (Packard Instrument/Canberra Company, 
Meriden, Connecticut) and visualized using OptiQuant software. A full-size image was printed 
off, and based on the land mark technique, the radioactively labelled 1705-1792 RNA transcript 
was excised from the gel using EtOH-sterilized scalpel and forceps. Each lane containing the 
RNA was cut lengthwise into three slices, and all three were placed into 400 pL of probe elution 
buffer (PEB). The PEB consisted of 670 pL of 7 M NH4OAC, 20 pL of 0.5 M EDTA (pH 8.0), 
100 pL of 20% SDS, and was made up to 10 mL with DEPC H2O before 7 mL of RNA phenol 
was added. The PEB was mixed thoroughly before use, and was aliquoted as a homogenous 
mixture. The gel slices were vortexed extensively every hour of the 6-hour 37 “C incubation 
period. Standard phenol/chloroform extraction was then performed twice, followed by ethanol 
precipitation. The air-dried radioactive RNA pellet was typically re-suspended in 30 pL of 
DEPC H2O, and 2 pL of this was used for scintillation counting on a Tri-Carb 1600 TR liquid 
scintillation counter (Packard Instrument/Canberra Company, Meriden, Connecticut). The 5'- 
y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792) was diluted further with DEPC
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H2O to get a working concentration of -30,000 counts per minute (cpm)/p,L and stored at -20 °C. 
The gel-purified 5'-y^^P-radiolabelled CRD c-myc mRNA substrate was typically viable for about 
one week.
2.0.4 Preparation of DH5a competent cells
D H 5a competent cells from Escherichia coli were used to proliferate the pQ E31 -Rpp35 
ATMD. The competent cells were prepared by first taking a small pipette stab of the -80 °C 
stored stock D H 5a cells and incubating them overnight in 3 mL of fresh Luria-Bertani (LB) 
broth (Invitrogen Canada Inc., Burlington, ON) at 37 °C with agitation in a VWR 
Scientific/Sheldon model 1575 incubator.
Five hundered pL of the overnight culture was incubated in 50 mL of LB broth in a 250 
mL beaker until the cell density reached an UV/Vis spectrophotometer 600 nm absorbance 
(Abseoo) reading between 0.4 - 0.6. For the D H 5a cells, this typically took 3 hours. The 50 mL 
of freshly cultured cells were transferred to a 50 mL Nalgene spin tube and centrifuged at 2500 
rpm for 5 minutes. The supernatant was decanted and discarded, and the pellet resuspended in
2.5 mL of cold 50 mM calcium chloride (CaClz) (Sigma-Aldrich, St. Louis, MO). Once 
thoroughly re-suspended, the solution was made up to 25 mL with cold 50 mM CaCl2, stored on 
ice for 30 minutes, and centrifuged at 2500 rpm for 5 minutes. The supernatant was removed, 
and the pellet resuspended in 3.5 mL of the cold 50 mM CaCli. The DH5a competent cells were 
stored at 4 °C, and had a shelf life of about three to four weeks.
2.0.5 Transform ation and plating o f pQ E31-Rpp35 ATMD into D H 5a ceils.
The pQF31-Rpp35 ATMD, obtained from collaborators in Japan was supplied at a 
concentration of 0.15 mg/mL. Fifteen ng of the pQF31-Rpp35 ATMD was added to 100 pL of 
D H 5a competent cells in a chilled 14 mL Nalgene test tube and incubated on ice for 30 minutes,
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before heat-shocking at 42 °C for 2 minutes. The transformation mix was then cooled on ice 
before 1 mL of fresh LB broth was added; this solution was allowed to incubate in the shaker at 
37 °C for 30 minutes. At this time, previously prepared ampicillin (50 mg/mL) (Sigma-Aldrich, 
St. Louis, MO) LB agar (Invitrogen Canada Inc., Burlington, ON) plates (1/1000 dilution of 
ampicillin) were warmed up for 20 minutes in the incubator prior to plating. Three dilutions 
( 1/ 1000, 1/ 100, and 1/ 10) of the plasmid were prepared and plated, along with the remaining 
concentrate. The plates were allowed to incubate at 37 °C for 30 minutes with their lids slightly 
off before being inverted and incubated upside down overnight. Individual colonies were 
selected and transferred, via pipette, to 14 mL Nalgene test tubes containing 3 mL of LB broth 
and 1.5 pL of 50 mg/mL ampicillin. The cultures were incubated overnight with agitation at 37 
°C.
2.0.6 Small-scale plasmid purification and digestion of pQE31-Rpp35 ATMD.
One and a half mL of the freshly cultured D H 5a cells containing the pQE31-Rpp35 
ATMD was transferred to a 1.5 mL eppendorf tube and spun at 13,000 rpm for 1 minute. The 
supernatant was discarded, and the pellet re-suspended in 500 mL of STET Buffer (8% sucrose, 
5% Triton X-100 [BDH Inc., Toronto, ON], 50 mM EDTA [pH = 8.0], 50 mM TRIS [pH = 8.0], 
made up to volume with ddH^O). Ten pL of freshly prepared 50 mg/mL lysozyme (Invitrogen 
Canada Inc., Burlington, ON) was added and the mix vortexed to lyse open the cells. The lysed 
cells were then boiled for 1 minute before being centrifuged at 13,000 rpm for 10 minutes. The 
bacterial cells genomic DNA, which was present as a fluffy white pellet, was removed with a 
sterile toothpick leaving only the plasmid DNA solution behind.
An equal volume of isopropanol was added to the solution, mixed well, and then stored at 
-20 °C for 20 minutes. The precipitated plasmid DNA was pelleted by eentrifuging at 13,200
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rpm for 10 minutes at 4 °C. The supernatant was discarded, and the pellet was gently washed 
with 200 mL of cold 70% EtOH before being centrifuged again at 13,200 rpm for 5 minutes. 
The supernatant was removed, and the pellet allowed to air dry for -15 minutes before being re­
suspended in 20 pL of ddHiO.
A small scale, 10 pL total volume plasmid digestion (mini-digest) was carried out with 
the four restriction enzymes Psti, BamHl, Kpnl, and Hindlll, to confirm the DNA sequence and 
restriction sites of the pQE31-Rpp35 ATMD. All four of these restriction enzymes were 
provided at a concentration of 10 U/pL (Invitrogen Canada Inc., Burlington, ON). Pstl and 
Hindlll both used React2 lOX buffer, Bam lll used React3 lOX buffer, and Kpnl used React4 
lOX buffer (Invitrogen Canada Inc., Burlington, ON). Two pL of plasmid was added to 1 pL of 
restriction enzyme, 1 pL of 10 X buffer, and 6 pL of ddH^O, mixed, pulsed, and then allowed to 
incubate at 37 °C for 30 minutes. After the 30-minute incubation, 1 pL of RNase A (1 mg/mL) 
(Sigma-Aldrich, St. Louis, MO) and 2 pL of loading dye were added. The solution was then 
mixed, pulsed, and loaded onto an ethidium bromide-stained 1% agarose gel and ran at 45 mA 
for -9 0  minutes. The digestion was visualized using the Chemilmager™ System.
2.0.7 Clone propagation and large-scale (200 mL) plasmid purification (midi-prep) of 
pQE31-Rpp35 ATMD.
One of the successfully mini-digested clones was proliferated in preparation for the 
plasmid purification step, which is based on established protocols (Sambrook et al. 2002). In the 
first step, 20 pL of the positive clone culture was added to 200 mL of LB broth and 200 pL of 
ampicillin (50 mg/mL) in a 500 mL Erlenmeyer and propagated overnight in the 37 °C shaker.
The fresh culture was centrifuged at 5000 rpm for 10 minutes, the supernatant removed 
by decanting and then aspiration, and the pellet loosened by vortexing. Half of a mL of a 25 mM
70
Tris-Cl, 50 mM EDTA (pH 8.0) buffer solution was added and the mixture vortexed, before 4.5 
mL more of the Tris-Cl, EDTA (TE) solution was added, and the pellet completely re-suspended. 
10 mL of a freshly prepared 0.2 M NaOH, 1% SDS solution was then added, and the mixture 
gently swirled before incubating on ice for 10 minutes. Seven and a half mL of ice-cold 5 M 
KOAc was added next, the mixture swirled, and then placed on ice for another 5 minutes. The 
mixture was centrifuged at 5000 rpm for 20 minutes, and the supernatant decanted through Mira 
cloth (CalbioChem, Darmstadt, Germany) into a 50 mL Falcon tube. Fourteen mL of room 
temperature isopropanol was added, mixed well, and incubated at room temperature for 15 
minutes before being centrifuged a 4000 rpm for 10 minutes at 4 °C. The supernatant was 
removed by aspiration and the pellet air-dried for 15 minutes. The pellet was next dissolved by 
vortexing in 2.25 mL of TE Buffer (pH=7.4). Once completely re-suspended, 0.75 mL of 10 M 
NH4OAC (BDH Inc., Toronto, ON) was added and the solution incubated on ice for 20 minutes. 
The mixture was centrifuged at 4000 rpm for 10 minutes at 4 “C.
The supernatant, containing the plasmid DNA, was carefully pipetted into a new 15 mL 
falcon tube prior to the addition of 2 volumes, typically ~6 mL, of cold 100% EtOH, which was 
followed by gentle mixing. The DNA was precipitated out of solution by incubating at -20 °C 
for 20 minutes, before being pelleted by centrifuging at 4000 rpm for 10 minutes at 4 °C. The 
supernatant was poured off and the pellet was gently washed twice with 200 pL of chilled 75% 
EtOH, before being allowed to air-dry for 15 minutes. The pellet was loosened by vortexing in 
150 pL of TE buffer (pH 8.0), and then transferred to a new eppendorf tube. The original tube 
was rinsed out with an additional 100 pL of TE buffer (pH 8.0), which was added to the first 150 
pL. At this time, 5 pL of RNase A (1 mg/mL) was added, the solution mixed, pulsed, and then 
incubated at 37 °C for 40 minutes. One hundered and ten pL of 5 M NaCl and 95 pL of a 30%
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Polyethylene Glycol 6000 (PEG-6000) (VWR, Canada), 1.5 M NaCl solution were added, the 
mixture vortexed, and incubated on ice for 30 minutes.
The gel-like precipitate was completely dissolved in -180 pL of TE buffer (pH 8.0). The 
standard phenol/chloroform extraction step was then carried out, followed by standard EtOH 
precipitation, as described earlier (section 2.0.1). The air-dried pellet was typically re-suspended 
in 100 pL of TE buffer.
2.0.8 Preparation of BL21 (DE3) competent cells, and transformation and plating of 
pQE31-Rpp35 ATMD.
The procedures used to generate competent BL21 (DE3) cells were identical to those 
outlined for the DH 5a cells (section 2.0.4), with the exception that the BL21 cells took an 
average of 2 hours and 30 minutes in the 37 °C shaker to reach the appropriate cell density as 
determined by absorbance at 600 nm on a UV/Vis spectrophotometer. The methods utilized to 
transform and plate the pQE31-Rpp35 ATMD into the BL21 cells were identical to those used to 
transform and plate the pQE31-Rpp35 ATMD into the D H 5a cells (section 2.0.5).
2.0.9 Colony propagation and induction optimization of pQE31-Rpp35 ATMD.
For the induction experiments performed on the pQE31-Rpp35 ATMD, the media used 
was always LB broth, and the only additive (aside from Isopropyl-P-D-thiogalactosidase (IPTG)) 
was the addition of ampicillin in the colony proliferation step.
An ampicillin-resistant colony was transferred to a 14 mL Nalgene round-bottom test- 
tube and proliferated overnight in 3 mL of LB broth containing 1.5 pL of 50 mg/mL ampicillin 
in the 37 “C shaker overnight. Five hundred pL of the inoculated overnight culture was then 
added to 50 mL of LB broth containing 25 pL of 50 mg/mL ampicillin and allowed to proliferate
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in the 37 °C shaker until the Absgoo ~ 0.4-0.6. Obtaining this optimum cell density typically took 
2 hours and 30 minutes.
In the first induction experiments, time was the tested variable, and the 37 ‘’C-incubated 
samples were collected at 0, 0.5, 1, 3, 6, and 10 hours. Two experiments were conducted 
concurrently, for both IPTG final concentrations of 0.5 mM and 2 mM. This was accomplished 
by first making a fresh 1 M IPTG (Invitrogen Canada Inc., Burlington, ON) solution, and then 
adding 25 pL and 100 pL to each 50 mL aliquot of fresh Absgoo ~ 0.4-0.6 culture, to generate 
induction cultures with final IPTG concentrations of 0.5 mM and 2 mM, respectively. Prior to 
IPTG addition, a ImL un-induced sample was transferred to a 1.5 mL eppendorf tube, 
centrifuged at 12,000 rpm for 2 minutes, the supernatant removed, and the pellet frozen at -20 °C 
for later SDS-PAGE analysis. Immediately after IPTG addition, a I mL time zero sample was 
also collected, pelleted, and stored in the same fashion as the un-induced control. At each of the 
respective time points, 1 mL samples were transferred to 1.5 mL eppendorf tubes, centrifuged at
12,000 rpm for 2 minutes, and the pellets frozen at -20 °C.
Once all samples had been collected and pelleted, a freshly prepared 2X SDS loading dye 
(2% SDS, 20% glycerol [Sigma-Aldrich, St. Louis, MO], 20 mM Tris-Cl, pH 8.0, 2 mM EDTA), 
with 10% P-mercaptoethanol (VWR, Canada) was made. Each pellet was then re-suspended in 
50 pL of the 2X SDS, 10% P-mercaptoethanol loading dye, pulsed, boiled for 5 minutes, allowed 
to cool to room temperature, and then 10 pL of the mix was loaded onto a 12% SDS- 
polyacrylamide gel (30 mL 6% polyacrylamide/Bis, 150 pL fresh 10% ammonium persulfate, 25 
pL TEMED). Ten pL of protein marker (molecular weight [MW] range 6500-205,000 Da) (GE 
Healthcare, Montreal) was added to 10 pL of the 2X SDS, 10% P-Mercaptoethanol loading dye, 
and this mixture was also boiled for five minutes prior to being loaded onto the gel. The 12%
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SDS-polyacrylamide gel was then ran at 240 volts (EC 105-120V, EC Apparatus Inc., VWR, 
Canada) until the bromophenol blue dye front had reached the bottom of the gel.
The glass plates holding the gel were separated, and the gel stained in -100 mL of 
Coomassie blue dye (50% MeOH, 10% acetic acid, 0.1% Coomassie blue [Sigma-Aldrich, St. 
Louis, MO]) for >3 hours at room temperature on a shaker platform. The gel was then de­
stained at room temperature for -3  hours in Coomassie blue de-staining solution (50% MeOH, 
10% acetic acid), until the resolution of the protein bands was adequate for interpretation. It was 
found that the de-staining solution had to be changed periodically, and that immersing the gel in 
deionized water quenched the de-staining reaction. The results were visualized using the 
Chemilmager^'^ System.
The next three induction experiments were conducted concurrently at temperatures of 17, 
22, and 37 °C, with all three using varying final IPTG concentrations of 0, 0.1, 0.5, 1, 2, 3, and 5 
mM, with a five-hour constant incubation time. These experiments were accomplished by first 
making a fresh stock 1 M IPTG solution, and then adding the appropriate amount to each 50 mL 
aliquot of fresh Abseoo ~ 0.4-0.6 culture. Prior to IPTG addition, a ImL un-induced sample was 
transferred to a 1.5 mL eppendorf tube, centrifuged at 12,000 rpm for 2 minutes, the supernatant 
removed, and the pellet frozen at -20 °C for later SDS-PAGE analysis. After the 5-hour 
incubation time, 1 mL samples of each of the varying IPTG concentrations were transferred to
1.5 mL eppendorf tubes, centrifuged at 12,000 rpm for 2 minutes, and the pellets frozen at -20 
°C. As described earlier, these pellets were then re-suspended in 50 pL of 2X SDS, 10% P- 
Mercaptoethanol loading dye, boiled, subjected to 12% SDS-PAGE, stained, de-stained, and then 
visualized using the Chemilmager™ System.
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2.0.10 Transformation and plating of pHTT7K-Rpp35 into BL21 (DE3) cells.
The pHTT7K-Rpp35 plasmid was constructed as described later (Chapter 2, Section 
2.1.7). The first step was to make fresh BL21 (DE3) competent cells, as described earlier in 
sections 2.0.4 and 2.0.8. Fifty pL of 200 ng/pL pHTT7K-Rpp35 was transformed into 200 pL 
BL21 competent cells and then plated onto fresh kanamycin agar plates using the same 
procedures utilized for the transformation and plating of pQE31-Rpp35 ATMD (sections 2.0.5 
and 2.0.8).
2.0.11 Colony propagation and induction optimization of pHTT7K-Rpp35.
Individual colonies were selected and transferred via sterile pipette to 14 mL Nalgene test 
tubes containing 3 mL of LB broth and 1.5 pL of 50 mg/mL kanamycin and incubated overnight 
with agitation at 37 °C.
Induction involving the pHTT7K-Rpp35 was performed on a smaller scale, so as not to 
use excess reagents. 120 pL of the fresh overnight-culture of pHTT7K-Rpp35 containing BL21 
cells was added to a 25 mL Erlenmeyer flask containing 12 mL of LB broth and 12 pL of 25 
mg/mL kanamycin, and the cells allowed to proliferate in the 37 °C shaker until the Abseoo ~ 0.4- 
0.6. This was performed in duplicate, with one of the 12 mL cultures being used as a negative 
control. The control cell culture was treated identically to the induced sample except that no 
isopropyl-P-D-thiogalactosidase (IPTG) was added.
Prior to the addition of the IPTG to the positive-control culture, an un-induced 1 mL 
sample was collected and centrifuged in a 1.5 mL Eppendorf tube at 12,000 rpm for 2 minutes, 
the supernatant removed, and the pellet stored at -20 °C. One M IPTG was added to the 
remaining 11 mL of cell culture to give a final IPTG concentration of 1 mM. Both of the cell 
cultures (induced and un-induced) were incubated at 37 °C with agitation for a period of 10
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hours, with 1 mL samples being collected at 0, 1, 2, 3, 5, 7, and 10-hour time intervals. Each 
sample was centrifuged at 12,000 rpm for 2 minutes, the supernatant removed, and the pellet 
stored at -20 °C. The pellets were then re-suspended in 50 pL of 2X SDS, 10% p- 
Mercaptoethanol loading dye, boiled, subjected to 12% SDS-PAGE, the gels stained with 
Coomassie blue, de-stained, and then visualized using the Chemilmager^'^ System as described 
earlier (section 2.0.9).
2.0.12 Optimizing the cell-lysis procedure and determining the solubility of Rpp35.
Cell lysis optimization was accomplished by first repeating the induction experiment, but 
on a larger scale. 2 mL of freshly proliferated BL21 containing pHTT7K-Rpp35 was transferred 
to a 1 L Erlenmeyer flask containing 400 mL of LB broth and 400 pL of kanamycin (25 mg/mL), 
and shaken in the 37 °C incubator/shaker until the Abseoo ~ 0.4-0.6. At that time, a 2 mL sample, 
representing the negative, un-induced control, was removed and placed in a 14 mL round-bottom 
test tube. A I M  stock IPTG solution was then added to the remaining 398 mL of BL21 
pHTT7K-Rpp35 cell culture to give a final IPTG concentration of 1 mM. Another 2 mL sample, 
the positive, induced control, was immediately collected and placed in another 14 mL round- 
bottom test tube. Both of the two 2 mL control samples, as well as the remaining 396 mL 
culture, were then placed back in the shaker and incubated for another 5 hours at 37 °C. The two 
2 mL controls were spun at 12,000 rpm for 2 minutes, their supernatants removed, and the pellets 
stored at -20 °C. Two 15 mL aliquots, taken from the 396 mL culture, were centrifuged at 6000 
rpm for 15 minutes at 4 °C, their supernatants removed, and the pellets stored at -20 °C. 
Centrifuging at 6000 rpm for 15 minutes in polypropylene spin tubes pelleted the remaining 381 
mL culture, which, once the supernatant was removed, was stored at -80 °C.
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One of the 15 mL induced pellets was re-suspended in 2 mL of bacterial protein 
extraction reagent (B-PER), (Pierce Biotechnology Inc., Rockford, IL) while the other 15 mL 
pellet was re-suspended in 2 mL of B-PER containing 3% N-lauroyl sarcosine (Sigma-Aldrich, 
St. Louis, MO). Each of these two samples were then split into two 1 mL fractions and placed in
1.5 mL eppendorf tubes. Each sample, whether re-suspended in B-PER or re-suspended in B- 
PER with 3% N-Lauroyl sarcosine, was then tested to see the effects of sonication. Sonication 
was accomplished using a Eisher Scientific ultrasonic dismembrator, model 100, outfitted with a 
microtip. The sonication procedure, which was based on recommendations of the Qiagen 
QIAexpressionist™ book, involved six 10-second bursts at medium power (250 Watts), with 10- 
second intervals, with the entire process being conducted on ice.
Once all the samples had been thoroughly re-suspended and sonicated, they were re­
pelleted by centrifuging at 12,000 rpm for 15 minutes at 4 °C. Ten pL of each of the 
supernatants was mixed with 10 pL of 2X SDS, 10% (3-Mercaptoethanol loading dye, while the 
pellets were re-suspended in 50 pL of 2X SDS, 10% P-Mercaptoethanol loading dye. All of the 
2X SDS, 10% P-Mercaptoethanol loading dye-suspended samples were then boiled, 10 pL of the 
sample subjected to 12% SDS-PAGE, the gels stained with Coomassie blue, de-stained, and then 
visualized using the Chemilmager™ System as described earlier in section 2.0.9.
2.0.13 Large-scale induction of Rpp35 and protein purification using nickel-nitrilotriacetic 
acid matrix.
A large-scale 1.5 L induction of Rpp35 was conducted. This involved first proliferating 
fresh overnight-grown BL21-containing pHTT7K-Rpp35 in 12 mL of LB broth containing 12 
pL of 25 mg/mL kanamycin as described earlier. Because the 1.5 L total induction volume 
exceeded our Erlenmeyer flask capacity, the experiment was split into three 1 L Erlenmeyer
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flasks that each contained 500 mL of LB broth and 500 p,L of 25 mg/mL kanamycin. Four mL 
of the overnight cell culture was then transferred to each of the three flasks, which were shaken 
in the incubator at 37 °C until the Abseoo ~ 0.4-0.6 (~3 hours and 30 minutes).
As described earlier (section 2.0.12), a 2 mL sample representing the negative, un- 
induced control, was removed and placed in a 14 mL round-bottom test tube. A 1 M stock IPTG 
solution was then added to the remaining cell culture to give a final IPTG concentration of 1 
mM. Another 2 mL sample representing the positive, induced control, was immediately 
collected and placed in another 14 mL round-bottom test tube. Both of the two 2 mL control 
samples, as well as the remaining culture, were then paced back in the shaker and incubated for 
another 5 hours at 37 “C. The two 2 mL controls were then centrifuged and pelleted as describer 
earlier (section 2.0.12). The remaining induced culture was centrifuged at 5000 rpm for 15 
minutes at 4 °C, the supernatant was removed, and the bulk pellet stored at -80 °C.
The bulk pellet was thawed on ice for 15 minutes and then completely re-suspended in 
140 mL of B-PER containing 7 dissolved mini-EDTA-free protease inhibitor tablets (Roche 
Diagnostics, Montreal, Quebec). Once the mixture had been thoroughly re-suspended it was re­
pelleted by centrifuging at 12,000 rpm for 10 minutes at 4 °C. The supernatant was aspirated off, 
and the pellet re-suspended in 75 mL of IX  phosphate buffered saline (PBS) (0.8% NaCl, 0.02% 
KCl, 0.144% sodium phosphate, dibasic (Na2HPÜ4), 0.024% potassium phosphate, monobasic 
(KH2PO4), pH 7.4). Once again the mixture was centrifuged at 12,000 rpm for 10 minutes at 4 
°C. The supernatant was removed and stored at 4 °C, while the pellet was completely re­
suspended in 50 mL of 100 mM NaH2P04, 10 mM Tris-Cl, 8 M urea (Fisher Scientific, Canada), 
pH 8.0, protein denaturing solution, referred to here as simply Buffer B, pH 8.0. The solution 
was transferred to a 15 mL Teflon hand-homogenizer (Kontes Glass Co., Vineland, NJ) and
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homogenized for twenty strokes. The mixture was then centrifuged at 12,000 rpm for 1 minute 
at 4 °C, and the supernatant saved and stored at 4 °C.
The protein content in this fraction was quantified by performing a Bradford assay, which 
measures the absorbance of the sample at 595 nanometers (nm). A blank (reference) was 
prepared using 200 pL of Bio-Rad dye (Bio-Rad Industries, Hercules, CA) and 800 pL of Milli- 
Q purified (Milli-Q Synthesis A 10, Millipore, Molsheim, France), double distilled, and 
autoclaved water (ddH20). Samples were prepared using 200 pL Bio-Rad dye, 795 pL ddHzO, 
and 5 pL of sample, mixed thoroughly, and allowed to react for 15 minutes. Absorbanee was 
determined on an UV/Vis spectrophotometer (UltraSpee 1000, GE Healthcare, Montreal) at a 
wavelength of 595 nm.
All of the buffers used for the Rpp35 purification process consisted of 100 mM 
NaH2P04 , 10 mM Tris-Cl, 8 M urea solutions, and the only difference was that the pH was either
8.0, 6.3, 5.9, or 4.5, corresponding simply to Buffers B, C, D, and E, respectively.
A small-scale Ni-NTA mini-column was used to test the effectiveness of the purification 
procedure as well as to confirm that the Rpp35 had, in fact, been induced. This was 
accomplished by placing 2 mL of the Ni-NTA slurry into a 10 mL Qiagen mini-column and 
equilibrating with 3 volumes of Buffer B. Immediately upon loading the 1 mL of Buffer B re­
suspended Rpp35 sample (1.6 mg total protein), two flow-through fractions were collected in 0.5 
mL aliquots. This was followed by washing the mini column with 3 volumes of Buffer B, 
corresponding to six 0.5 mL fractions, and then with 3 volumes of Buffer C, also corresponding 
to six 0.5 mL fractions. Three volumes of Buffer D were added, and six more 0.5 mL fractions 
collected. Finally, 3 volumes of Buffer E were loaded, and six additional 0.5 mL fractions were 
collected. All of the 0.5 mL fractions were stored at -20 °C.
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Ten |aL of each of the 0.5 mL fractions was mixed with 10 |aL of 2X SDS, 10% p- 
Mercaptoethanol loading dye, the samples boiled, subjected to 12% SDS-PAGE, the gels stained 
with Coomassie blue, de-stained, and then visualized using the Chemilmager™ System as 
described earlier in section 2.0.9.
Large-scale (22 mL) Rpp35 purification was accomplished using an Amersham C -10/20 
chromatography column (GE Healthcare, Montreal) powered by a model 1610 ISCO Tris pump 
(ISCO Inc., Lincoln, NE) at a constant flow-rate of 0.52 mL/minute, with fractions collected by 
an ISCO Eoxy Jr. fraction collector (ISCO Inc., Lincoln, NE). Twenty mL of the Ni-NTA resin, 
30% EtOH solution was gently mixed to homogeneity and then carefully transferred to two 50 
mL Falcon tubes and centrifuged at 500 rpm for 2 minutes. The EtOH was decanted off, and the 
Ni-NTA resin was transferred to a 250 mL beaker eontaining 50 mL of Buffer B. The two were 
allowed to gently mix for 5 minutes using a magnetic stirrer. The Ni-NTA was then loaded into 
the column and allowed to gradually settle before being packed to remove air bubbles.
Once the Ni-NTA resin had been packed, it was equilibrated with 1 volume of Buffer B. 
The 22 mL Rpp35 sample (35 mg total protein) was completely loaded onto the column before 
being washed with 2 volumes of Buffer B (pH 8.0). Ten 10 mL flow-through fractions were 
collected immediately following the loading of the Rpp35 sample. Once all of the flow-through 
fractions had been collected, the column was washed with 3 volumes of Buffer C (pH 6.3), 
whose elution fractions were collected in eighty 0.5 mL aliquots. Because the mini column 
SDS-PAGE indicated that the majority of the Rpp35 protein eluted at a pH of 6.3 (Buffer C), it 
was decided that the elution step involving Buffer D, at a pH of 5.9, would not be included. 
Therefore, 3 volumes of Buffer E, pH 4.5 was loaded onto the column and collected in thirty 2
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mL fractions. The column was then washed thoroughly with 2 volumes more of Buffer E, and 
re-equilibrated with 5 volumes of Buffer B. Collected fractions were stored at 4 °C.
Ten |uL of each of the 2 mL fractions was mixed with 10 qL of 2X SDS, 10% P- 
Mereaptoethanol loading dye, the samples boiled, subjected to 12% SDS-PAGE, the gels stained 
with Coomassie blue, de-stained, and then visualized using the Chemilmager™ System as 
described earlier in section 2.0.9.
2.0.14 Dialyzing and refolding of purifîed denatured Rpp35
A concentrated sample of the purified Rpp35 was generated, so that the sample would be 
concentrated enough to display enzymatic activity against the y^^P-radiolabelled CRD 1705-1792 
RNA substrate. This was accomplished by pooling and concentrating previously purified 
Rpp35-rich pH 6.3 elution fractions. The 0.5 mL Buffer C, pH 6.3 elution fractions that were 
confirmed, via 12% SDS-PAGE, to contain the Rpp35 were pooled together and concentrated 
using size-exclusion 10,000 Da cut-off Pall Macrosep® and Nanosep® devices (Pall 
Corporation, East Hills, NY). The 44 mL of combined Buffer C, pH 6.3 elution fractions were 
pooled in a 50 mL volume Macrosep®, and centrifuged at 4000g for -50  minutes at 4 °C. The 
now -1 .7  mL concentrated Rpp35 sample was collected by attaching a concentrate collection 
cup to the Macrosep® device and spinning at 4000g for 2 minutes. This pooling and 
concentrating procedure was repeated on other previously purified Rpp35-containing pH 6.3 
elution fractions to give a total volume of -3 .5  mL of concentrated Rpp35, resulting in an overall 
-  22X decrease in volume.
The pooled and Macrosep®-concentrated Rpp35 sample (0.833 mg/mL) was quantified 
using the Bradford assay as well as by comparing the sample to various concentrations of Bovine 
Serum Albumin (BSA) using 12% SDS-PAGE. The Bradford assay was performed as described
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in section 2.0.13. For the SDS-PAGE quantification, four BSA standards were prepared in 1, 
2.5, 5, and 10 pg final concentrations using stock 10 mg/mL BSA (New England Biolabs, 
Beverly, MO). Seven pL of ddH%0 was added to 3 pL of the concentrated Rpp35 sample, and 
then 10 pL of 2X SDS, 10% P-Mercaptoethanol loading dye was added to both this sample as 
well as to the BSA standards. All of the samples were then boiled, subjected to 12% SDS- 
PAGE, the gels stained with Coomassie blue, de-stained, and then visualized using the 
Chemilmager™ System as described earlier in section 2.0.9.
The pooling and concentration of subsequent Rpp35 purifications generated samples with 
slightly higher concentrations (1.246 mg/mL, 1.6802 mg/mL, 1.811 mg/mL, and 2.921 mg/mL), 
which varied depending on the amount of purified Rpp35 pooled, the optimization of Macro- and 
Nanosep™ spin time, and the final volume of the sample.
A combination of buffer replacement and dialysis were used in an attempt to re-fold the 
denatured Rpp35. Four hundred pL of the Macrosep® concentrated Rpp35 sample (0.833 
mg/mL), still suspended in the 8M urea-denaturing. Buffer C (pH 6.3), was transferred into a 500 
pL capacity 10,000 Da cut-off Nanosep® device and centrifuged at 14,000g for 2 minutes at 4 
°C. 200 pL of Buffer B without urea (pH 8.0) was then added into the Nanosep® device, which 
was once again centrifuged at 14,000g for 2 minutes at 4 °C. All -150 pL of the remaining 
sample (2.921 mg/mL) was then transferred to a 500 pL-capacity Pierce Slide-A-Lyzer MINI 
Dialysis Unit, and dialyzed in 500 mL of Buffer B without urea (pH 8.0) at 4 °C for five hours. 
The Buffer B without urea (pH 8.0) was exchanged for 500 mL of fresh Buffer B without urea at 
the 2.5-hour mark. The dialyzed sample (-150 pL) was then quantified using the Bradford assay 
as described earlier in section 2.0.13. The dialyzed Rpp35 (2.265 mg/mL) was then stored at 4 
°C.
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For protein re-folding, the procedures were performed as per the suggested protocol 
included with the Takara refolding kit. Five hundred pL (416 pg) of the Macrosep®- 
concentrated Rpp35 sample was placed in a Nanosep® device and centrifuged at 14,000g for 10 
minutes at 4 °C. Forty-eight pL (140 pg) of this sample was then placed in a 1.5 mL Eppendorf 
tube and 150 pL of 8 M guanidine hydrochloride and 2 pL of 4 M dithiothreitol (DTT) were 
added. The mixture was then incubated at room temperature (22 °C) for one hour to allow for 
complete protein unfolding. Twenty pL of the unfolded protein solution was then placed in eight 
1.5 mL Eppendorf tubes containing 1.33 mL of Buffer B without urea (pH 8.0), and 70 pL of 
either 1% Tween 40, 1% Tween 60, 1% Cetyltrimethylammoniumbromide (CTAB), or 1% 
Myristylsulfobetaine (SB3-14). This was done in duplicate, so that there were 2 tubes containing 
each of the four surfactants. One of the duplicates received 14 pL of 200 mM DL-Cystine, while 
the other did not. Once all the reagents had been added, the solutions were incubated at room 
temperature (22 “C) for one hour. After the one our incubation step, 3% cycloamylase (CA) was 
added to the reactions at a ratio of 1:4 of 3% CA:total reaction volume. For example, the 
reaction tube that contained 20 pL of the unfolded protein solution, 1330 pL of Buffer B without 
urea (pH 8.0), 70 pL of 1% Tween 40, and 14 pL of 200 mM DL-Cystine had a total reaction 
volume of 1434 pL, and therefore received 358.5 pL of 3% CA. Once the 3% CA had been 
added to all of the reaction tubes, the samples were incubated at room temperature (22 °C) 
overnight. The next day, all of the samples were centrifuged at 12,000 rpm for 15 minutes. The 
supernatants were collected via pipette and transferred to individual Nanosep® devices before 
being centrifuged at 14,000g for 13 minutes. The -130 pL of sample remaining was transferred 
to new Eppendorf tubes and stored at -20 °C.
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2.0.15 Performing endoribonuclease assay and visualizing degradation products on a 6% 
denaturing polyacylamide/7 M urea gel.
To test for and visualize endoribonuclease activity, an in vitro endoribonuclease assay 
was conducted. The endoribonuclease assay involved first making a reaction cocktail consisting 
of final concentrations of 10 mM Tris-Cl (pH 7.4), 2 mM MgOAc, 50 mM KOAc, 0.1 mM 
spermidine (Sigma-Aldrich, St. Louis, MO), 2 mM DTT, and 0.57 U RNasin (40 U/pL). The 
reaction mixture was brought up to volume by adding the appropriate amount of DEPC H2O 
prior to the addition of the other reagents. 18 pL of the mixed and homogenous reaction cocktail 
was pipetted into each labelled 1.5 mL eppendorf reaction tube. This was the standard 
preparation for every endoribonuclease assay.
DEPC H2O was added in advance to equalize the final reaction volume, depending on 
how much of the enzyme sample was to be used. Typically this involved between 1-4 pL of 
sample. This meant that the controls, which received no enzyme, were supplemented with 
DEPC H2O instead of enzyme sample to ensure final reaction volumes were equal. Once the 
appropriate volume of DEPC H2O (if any) had been added, the tubes were mixed and pulsed. 
First, 1-4 pL of the sample fractions were added to one side of their respective reaction tubes. 
Next, 1 pL of the 30,000 cpm/pL y^^P-RNA transcript were immediately added to the other side 
of the reaction tube in the radioactive room. The tubes were then pulsed, quickly mixed, pulsed 
again, and incubated at 37 °C for five minutes.
The reaction was quenched by boiling the tubes for 3 minutes, followed by cooling on ice 
for 2 minutes. The reaction tubes were then pulsed, and 5 pL of the reaction sample was added 
to 5 pL of urea/phenol loading dye. The sample/dye mixture was first mixed and pulsed before
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loading the 10 pL/sample directly on to a 6% polyacrylamide/7 M urea denaturing gel. The gel 
was run in 0.5 X TBE running buffer at a constant 30 mA for -45 minutes, or until the 
bromophenol blue dye front was -1cm  from the bottom edge of the gel. The gel was then 
separated from the glass sheets, and fixed in 10% glacial acetic acid (Fisher Scientific Company, 
Nepean, Ontario), 10% Methanol (MeOH) (VWR International, Edmonton, Alberta) for -10  
minutes before being attached to filter paper and dried for -45 minutes in a gel dryer. The dried 
gel was typically exposed to a phosphor storage screen overnight. The image was then scanned 
using the Cyclone Phospholmager and visualized using the OptiQuant software.
To test the effectiveness of the dialysis procedure and the Takara re-folding kit, an 
endoribonuclease assay was performed. One pL of the dialyzed Rpp35 sample and 1 pL of the 
Takara re-folded Rpp35 samples were added to 18 pL of endoribonuclease reaction cocktail and 
tested for endoribonuclease activity. The endoribonuclease assay was performed and results 
visualized as described in earlier in this section.
2.0.16 Testing dialyzed Rpp35 fractions for endoribonuclease activity
The pH 8.0 flow-through and pH 6.3 elution fractions that were selected for visualization 
on SDS-PAGE were also the same fractions that were dialyzed to test for native 
endoribonuclease activity. Un-induced and induced control samples were also subjected to the 
same buffer replacement/dialysis procedure outlined below.
Three hundred pL of each selected fraction was placed in individual 10,000 Da cut-off 
Nanosep® devices and centrifuged at 14,000g for 10 minutes. One hundred pL of Buffer B 
without urea (pH 8.0) was then added to each of the Nanosep® devices, which were centrifuged 
at 14,000g for 10 minutes. Another 100 pL of the Buffer B without urea (pH 8.0) was then 
added, and the 10-minute centrifugation step repeated. Finally, 150 pL of Buffer B without urea
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(pH 8.0) was added, and the mixture pipetted up and down gently to release any Nanosep®- 
membrane-bound protein. The 150 pL from each fraction was then transferred into individual 
500 pL-capacity Pierce Slide-A-Lyzer MINI Dialysis Units, and dialyzed in 500 mL of Buffer B 
without urea (pH 8.0) at 4 °C for five hours, with the dialysis buffer being exchanged at the 2.5 
hour mark. The dialyzed protein fractions (-180 pL) were then transferred to 1.5 mL Eppendorf 
tubes and stored at 4 °C.
Four pL of each of these fractions were used to test for endoribonuclease activity using 
the standard endoribonuclease assay as described in Chapter 1, section 2.0.15.
2.1 Results and Discussion:
2.1.1 Proteinase K treatment of pUC19 plasmid construct containing the CRD c-myc DNA 
sequence (nts 1705-1792)
The first step in generating non-contaminated radiolabelled substrate RNA was to treat 
the previously purified (Qiagen midiprep kit) pUC19 plasmid containing the CRD c-myc DNA 
sequence (nts 1705-1792) with Proteinase K. This step was introduced when difficulty was 
encountered obtaining non-degraded RNA, as Proteinase K treatment is known to remove 
contaminating RNases from sensitive RNA (Sambrook et al. 2002).
While direct visualization of the effect of treating the pUC19 plasmid containing the 
CRD c-myc DNA sequence (nts 1705-1792) with Proteinase K was not possible, the treatment 
step did appear to be very effective at eliminating contaminating RNases based on the quality of 
the RNA transcript that it generated as compared to the RNA generated previously from a non- 
Proteinase K treated plasmid (data not shown).
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Figure 5. pUC19 DNA Plasmid restriction map, including MCS.
To test samples for endoribonuclease activity, a radiolabelled RNA probe was first 
generated from the CRD c-myc DNA sequence (nts 1705-1792) contained within a pUC19 
plasmid. pUC19 plasmids, which are isolated from E. coli, are 2686 base pairs in length, 
resistant to ampicillin, and include a multiple cloning site (MCS) (Figure 2) (Stellwagen 2003). 
These plasmids are double-stranded circular DNA molecules, of which >90% is in supercoiled 
form (Stellwagen 2003). The pUC19 plasmid that was provided already had the CRD c-myc 
DNA sequence (nts 1705-1792) incorporated into its MCS, just upstream of an EcoRl restriction 
site at nt 396. When these uncut circular DNA structures are run on a 1% agarose gel they 
normally appear as three bands. The lower bands usually represent various forms of double­
stranded super-coiled plasmid DNA, whereas the higher bands usually represents relaxed 
circular, or nicked single-stranded DNA (Stellwagen 2003).
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The p u e  19 plasmid containing the CRD c-tnyc DNA sequence (nts 1705-1792) was 
digested with the restriction enzyme EcoRl and visualized on a 1% agarose gel transcription 
(Figure 6), in preparation for in vitro transcription. This gel included a 1 Kb Plus DNA ladder, 1 
pL sample of the uncut pUC19 plasmid containing the CRD c-myc DNA sequence (nts 1705- 
1792) as a control, and a 1 pL sample of the EcoRI digested pUC19 plasmid containing the CRD 
c-myc DNA sequence (nts 1705-1792) (Figure 6, lanes 1, 2, and 3, respectively).
y y
y
^  cr
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Figure 6. Digestion of pUC19 plasmid containing CRD c-myc DNA sequence (nts 1705- 
1792) with restriction enzyme E coR l, as visualized on an ethidium bromide-stained 1% 
agarose gel. Lane 1 depicts 1 Kb Plus DNA Ladder, with respective bp markers indicated 
on the left with arrows. Lane 2 illustrates 2 pL (~5 pg) of undigested pUC19 plasmid 
containing the CRD c-myc DNA sequence (nts 1705-1792), while lane 3 depicts 2 pL (~5 pg) 
of the E coR l digested pUC19 plasmid containing the CRD c-myc DNA sequence (nts 1705- 
1792).
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The Proteinase K-treated plasmid was successfully digested using the restriction enzyme 
EcoR\, as compared to the uncut control (Figure 6, lane 2 compared to 3). It is unclear why the 
uncut plasmid generated four bands, as this is more than what was expected. The main band at 
~2200 bp was as expected, and represents the double-stranded super-coiled DNA (Figure 6, lane 
2). The bands that appear higher up on the gel, around -6000, -7000, and >12,000 bp are most 
likely relaxed circular or nicked single-stranded DNA (Figure 6, lane 2). The EcoRl digested 
pUC19 plasmid produced a major band at the expected -2700 bp as well as a minor band at 
-6000 bp, the latter of which is believed to be either incompletely digested plasmid or nicked 
single-stranded DNA as it corresponds to the -6000 bp band in the uncut plasmid. Nevertheless, 
plasmid digestion was deemed successful as the linearized plasmid containing the 88 nt sequence 
should migrate at 2688 bp, and the major band was observed at -2700 bp (Figure 6, lane 3).
2.1.2 In-vitro transcription of the digested pUC19 plasmid containing the 1705-1792 c-myc 
CRD sequence.
The in vitro transcribed CRD c-myc RNA (nts 1705-1792) was quantified by measuring 
the absorbance of the samples at 260 nm. The two transcribed RNA samples discussed here 
were determined to have concentrations of 0.130 pg/pL and 0.370 pg/pL. The transcribed RNA 
was also qualitatively analyzed by running -500ng of the RNA sample on a 2% 
agarose/formaldehyde gel. This gel included a 0.16-1.77 kb RNA Ladder (Invitrogen Canada 
Inc., Burlington, Ontario), and two samples of in vitro transcribed RNA (Figure 7, lanes 1, 2, and 
3, respectively).
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Figure 7. In vitro transcribed CRD c-myc mRNA (nts 1705-1792), as visualized on an 
ethidium bromide-stained 2% agarose/formaldehyde gel. Lane 1 is the 0.155 -1.6 Kb RNA 
marker, while lanes 2 and 3 represent ~500 ng of the transcribed CRD c-myc RNA (nts 
1705-1792) samples 1 and 2, respectively. The RNA ladder size markers are indicated to 
the left of lane 1 with black arrows.
In vitro transcription of two samples of the c-myc linearized 1705-1792 CRD DNA was 
found to generate high quality RNA as visualized on a 2% agarose/formaldehyde gel (Figure 7, 
lanes 2 and 3). The 88 nucleotide (nt) sequence (1705-1792) was successfully transcribed from 
the digested plasmid, as bright distinct bands were present in both transcribed samples, visible 
slightly below the 0.155 kb marker (Figure 7, lanes 2 and 3 compared to lane 1). As the RNA
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sequence is known to be 88 nts in length, it was expected that the RNA would appear below the 
0.155 kb RNA marker band, as was the case (Figure 7, lanes 2 and 3).
2.1.3 Gel-purification of 5'-^^P-radiolabelled CRD c-myc mRNA (nts 1705-1792)
As a measure to generate un-degraded 5'-^^P-radiolabelled RNA substrate, the RNA 
transcript was run on a 6% polyacrylamide/7 M urea denaturing gel and then quickly exposed to 
a phosphor storage screen to allow for gel band excision.
RNA sample 1 is depicted in lanes 1 and 2, while RNA sample 2 is seen in lanes 3 and 4 
(Figure 8A and 8B). This process involved three landmark positions, which are indicated with 
white arrows (Figure 8A and 8B).
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Figure 8. Gel-purification of 5'-^^P-radioIabelled CRD c-myc mRNA (nts 1705-1792). ^  
depicts tbe short before' exposure of the CRD c-myc RNA (nts 1705-1792) on a 6% 
polyacrylamide/7 M urea gel prior to excision with a scalpel. B: depicts tbe short after' 
exposure illustrating the successful excision of tbe CRD c-myc RNA. For both figures, 
RNA sample 1 is split in lanes 1 and 2, while RNA sample 2 is in lanes 3 and 4. Tbe black 
solid arrow indicates tbe CRD c-myc RNA (nts 1705-1792), while tbe non filled arrows 
represent the landmark positions 1-3.
The 'before' and 'after' exposures of the gel clearly show that the 1705-1792 RNA was 
successfully excised from the gel (Figure 8A and 8B). Both of those samples were successfully 
dephosphorylated, radiolabelled at the 5'-termini with ^^P-ATP, and gel-purified to generate
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clean, non-degraded radioactive substrates with -30,000 cpm/|aL, as visualized on a denaturing 
6% polyacrylamide/7M urea gel.
2.1.4 Small-scale digestion (mini-digest) of pQE31 Rpp35 ATMD and quantification of 
post-large-scale purified (midi-prep) pQE31 Rpp35 ATMD.
The cDNA for Rpp35 ATMD that was provided to us was already incorporated into a 
Qiagen pQE31 plasmid. In addition to an ampicillin-resistant gene, the low-copy pQE31 
plasmids also contain a T5 promoter//ac operator transcription-translation system (recognized by 
E. coli RNA Polymerase), a ribosome-binding site (RBS), an ATG start codon, a 6xHistidine tag 
sequence, a multiple cloning site (containing, among others, BamYil, Kpnl, Pstl, and HindUl 
restriction sites), and stop codons in all three reading frames (Figures 9 and 10)
(QIAexpressionist™).
Stop Codons
pQE-30 - -
pQE-31 AC 
pQE-32 — G
CgIE^
Figure 9. Main components of the pQE31 plasmid (QIAexpressionist^'^).
92
pQE-31/pQE-81 I
S m a I
Eco RI/RBS 6xH is Bom Sph I Sac K pnI X m o l S o il Pstl HitwJIK________
I AFgVkGAGGATCT — AC I  G G A TC C G C A T G C G A G C T C G G T A C C C C G G G T C G A C C TG C A G C C A A G C n| AATTaG CTGaG  1 1
R G S H is e p ito p e
Figure 10. Multiple cloning site of pQE31 plasmid (QIAexpressionist^'^).
According to the Qiagen product guide for the pQE31 plasmid vector, Pstl, BamRl, Kpnl 
and Hindlll restriction sites are all present in the plasmid's MCS (Figure 10) 
(QIAexpressionist™), so it was anticipated that all four restriction enzymes would effectively 
cleave the pQE31-Rpp35 ATMD, assuming that the restriction sites had not been altered during 
sub-cloning. The restriction map of full-length human Rpp35 (1580 bp), according to DNA 
Strider^“ , contains no restriction sites for Kpnl, Pstl, or Hindlll, but does contain the sequence 
targeted for cleavage by BamHl at nt 946. Unfortunately, our lab was not provided with the 
sequence of the pQE31-Rpp35 ATMD, so it was unclear exactly what sites Rpp35 ATMD had 
been sub-cloned into, or whether the Rpp35 ATMD did, in fact, contain the BamHl site at 
nucleotide 946. If the obtained pQE31-Rpp35 ATMD DNA sequence corresponds to what its 
name implies, cleavage using the BamHl restriction enzyme should only generate the linear form 
of the plasmid (one gel-band) and not two fragments because the TMD hydrophobic regions of 
Rpp35 start at nt 942.
The pQE31 Rpp35 ATMD colonies were subjected to small-scale, 10 pL total volume 
mini-digests using the restriction enzymes Pstl, BamHl, Kpnl and Hindlll, in an effort to confirm 
the DNA sequence and restriction sites of the pQE31-Rpp35 ATMD (Figure 11). This gel 
included a 1 Kb Plus DNA ladder, and 2 pL of the uncut pQE31-Rpp35 ATMD control (Figure 
11, lanes 1 and 3, respectively). This gel also included 2 pL samples of the Pstl, BamHl, Kpnl 
and Hindlll digested pQE31-Rpp35 ATMD (Figure 11, lanes 4, 5, 6, and 7, respectively).
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Figure 11. Ten (j,L total volume digestions using 2 |j,L of the pQE31 plasmid containing 
Rpp35 ATMD DNA sequence with 1 pL of restriction enzymes Pstl, B am ïll, Kpnl, and 
H indlU , as visualized on an ethidium bromide-stained 1% agarose gel. Lane 1 depicts 1 
Kb Plus DNA Ladder, with respective bp markers indicated on the left with arrows. Lane 
3 illustrates 2 pL of undigested pQE31-Rpp35 ATMD, while lanes 4, 5, 6, and 7 depicts the 
Pstl, BamH l, Kpnl, and digested pQE31-Rpp35 ATMD, respectively.
The uncut pQE31-Rpp35 ATMD control visualized as two bands very close together 
(both >12,000 bp); the lower, more intense band represents the super-coiled form of the plasmid, 
while the upper, less intense band represents nicked DNA in relaxed circular form (Figure 11, 
lane 3). BamHl, Kpnl, and Hindlll all successfully digested pQE31-Rpp35 ATMD, as evidenced 
by the single bands -5000-6000 bp, representing the linear DNA, as compared to the >12,000 bp 
bands generated by the uncut control (Figure 11, lanes 5, 6, and 7, and lane 3, respectively). The 
fact that PamFII successfully digested the pQE31 -Rpp35 ATMD and only generated one gel band
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provides support that the TMD of Rpp35 was effectively removed prior to sub-cloning into the 
pQE31 plasmid.
Unexpectedly, Pstl did not appear to digest the pQE31-Rpp35 ATMD, as compared to 
BamHl, Kpnl, and Hindlll digestions (Figure 11, lane 4, and lanes 5, 6, and 7, respectively). It is 
possible that the Pstl restriction sequences may have been altered or removed when the Rpp35 
ATMD was cloned into the pQE31 plasmid. While the exact cause of the Pstl restriction site 
problem remains enigmatic, the most plausible explanation is that the recognition site for the Pstl 
had inadvertently been mutated or deleted during ligation, which was conducted by our 
collaborators in Japan.
2.1.5 0.5 and 2 mM IPTG induction of pQE31-Rpp35 ATMD at 37 “C.
A decision was made to continue with the pQE31-Rpp35 ATMD, regardless of the Pstl 
quandary, and attempts were made to induce expression of the recombinant protein.
BL21 (DE3 strain) competent cells, which are isolated from E. coli, were used for 
induction because they are specifically designed for high-level protein expression (they lack 
ompT and Ion proteases) using the T7 RNA polymerase-based expression system. BL21 
competent cells express T7 polymerase after induction with IPTG, therefore promoting the 
transcription of genes under the T7 promoter (QIAexpressionist™). The DE3 refers to the fact 
that the host is a lysogen, and therefore carries a chromosomal copy of the T7 RNA polymerase 
gene, which is under the control of the lacUVS promoter, also inducible using IPTG 
(QIAexpressionist™).
It was anticipated that the protein expression induction experiments using the T7 
promoter system would need to be optimized, as there were numerous variables to consider. 
These variables included: induction temperature, induction time, the concentration of the IPTG,
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the media used, and the introduction of additives to the media (Baneyx 1999). The initial 
strategy was to induce expression at 37 °C using constant concentrations of IPTG, and to collect 
the samples at various time points. After several unsuccessful induction experiments, this 
strategy was altered, and time became the constant variable, with different induction 
temperatures and concentrations of IPTG being tested.
The first attempts to induce expression of the pQE3l-Rpp35 ATMD used final IPTG 
concentrations of 0.5 and 2 mM at an incubation temperature of 37 °C, with samples being 
collected at 0, 0.5, I, 3, 6, 10, and 17-hour intervals. Ten pL aliquots of each of the extracted 
samples, along with a protein marker and 10 pL of an un-induced cell lysate control were loaded 
and subjected to 12% SDS-PAGE (Figures 12 and 13).
Both of the two different IPTG eoncentrations produced very similar protein profiles as 
seen on 12% SDS-PAGE (Figures 12 and 13). It had been anticipated that the Rpp35 ATMD 
would migrate at -35-40 kDa, but neither gel indicated induction of a protein in this size range 
(Figures 12 and 13). It was observed, however, that in both of the gels two bands appeared after 
the 3-hour induction time point that had a calculated R f value, or an apparent molecular mass of 
-44  kDa (Figures 12 and 13, lanes 8, 9, and 10, and lanes 7, 8, and 9, respectively). This 44 kDa 
band, which is indicated on the right by the solid black arrow, could possibly represent induction 
of Rpp35 ATMD. Unfortunately, it is difficult to discern if the more intense protein bands seen 
in these samples are due to induced Rpp35 ATMD, or simply an artifact of increased BL2I 
bacteria proteins, as this experiment did not correlate amount of protein loaded to increasing cell 
density. Nevertheless, a significant increase in the intensity of the protein bands was observed 
after the three-hour incubation time period, while incubating beyond 6 hours did not appear to 
dramatically increase the protein band intensities (Figures 12 and 13). Based on these
96
observations, future induction attempts were limited to constant 5-hour incubation time. The 0.5 
mM and 2.0 mM IPTG-inductions of Rpp35 ATMD did not produce conclusive evidence that 
induction of Rpp35 ATMD had occurred.
66 kDa I 
55 kDa I 
45 kDa
30 kDa ' 
21 k D a '
3 4 5 6 7  8 9  10
Figure 12. 0.5 mM IPTG induction of pQE31-Rpp35 ATMD at 37 “C as visualized using 
12% SDS-PAGE. Lane 1 represents the 6.5-205 kDa protein marker, with respective 
markers indicated on the left with arrows. Lane 3 depicts 10 pL of the un-induced control 
sample (zero hours). 10 pL induced samples were collected at 0, 0.5, 1, 3, 6, 10, and 17- 
hour time intervals, as represented hy lanes 4,5,  6, 7, 8, 9, and 10, respectively. The arrow 
on the right indicates possible Rpp35 induction.
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Figure 13. 2 mM IPTG induction of pQE31-Rpp35 ATMD at 37 °C as visualized using 
12% SDS-PAGE. Lane 1 represents the 6.5-205 kDa protein marker, with respective 
markers indicated on the left with arrows. Lane 2 depicts 10 pL of the un-induced control 
sample (zero hours). 10 pL induced samples were collected at 0, 0.5, 1, 3, 6, 10, and 17- 
hour time intervals, as represented hy lanes 3, 4, 5, 6, 7, 8, and 9, respectively. The arrow 
on the right indicates possible Rpp35 induction.
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2.1.6 Five-hour pQE3I-Rpp35 ATMD induction attempts at 17, 22, and 37 ”C using 
varying final IPTG concentrations.
Based on the results from the previous induction experiments, it was decided to try three 
different induction temperatures, 17, 22, and 37 °C, for a constant induction time of 5 hours, 
using final IPTG concentrations of 0.1, 0.5, 1, 2, 3, and 5 mM. It was hoped that these 
concurrently carried-out experiments would provide both the optimum temperature of incubation 
as well as the optimum final IPTG concentration for induction of the pQ E31 -Rpp35 ATMD.
All three of the different temperature induction attempts (17, 22, and 37 °C corresponding 
to Figures 14, 15, and 16, respectively) included a 6.5-205 kDa protein marker and 10 pL of an 
un-induced cell lysate control in lanes 1 and 2, respectively. All three of different temperature 
experiments also included 10 pL samples of 0.1, 0.5, 1, 2, 3, and 5 mM final IPTG 
concentrations in lanes 3-8, respectively (Figures 14A, 14B, and 14C).
The 17 °C, 22 °C, and 37 °C attempts to induce Rpp35 ATMD was not successful using 
the above mentioned IPTG concentrations, as evidenced by the lack of a prominent, 
distinguishing protein band (-35-45 kDa) as compared to that of the un-indueed control (Figures 
14A, -B, and -C, lanes 3-8, and lane 2, respectively). It was observed that in the 17 °C induction 
attempt, the intensities of the protein bands noticeably diminished using final IPTG 
concentrations >1 mM (Figure 14A, lanes 6, 7, and 8). This observation correlates with the 
findings of others, who found that high concentrations of IPTG can actually be toxic to the cells, 
and using IPTG concentrations higher then the optimum for induction often results in the 
overwhelming of the transcriptional and translational machinery, thus reducing overall growth, 
and forcing the recombinant proteins to form insoluble inclusion bodies (Wen et al. 2004).
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Figure 14. 12% SDS-PAGE visualization of five-hour pQE31-Rpp35 ATMD induction at 
17 ( ^ ,  22 (B), and 37 “C (Ç) using various final IPTG concentrations. Lane 1 represents 
the protein marker, with respective markers indicated on the left with arrows. Lane 2 
depicts 10 pL of the un-induced control sample (time zero). Induction was attempted using 
final IPTG concentrations of 0.1, 0.5, 1, 2, 3, and 5 mM, as represented by the 10 pL 
samples in lanes 3, 4, 5, 6,7,  and 8, respectively. All samples were collected after a constant 
5-hour incubation period.
It was observed that in the 22 °C induction attempt, the 3 mM IPTG sample (Figure 14B, 
lane 7) produced protein bands that seemed slightly more intense then the other samples. This is 
most likely due to a sample preparation error; if the pellet was not thoroughly re-suspended, it 
would have been loaded onto the gel as a very viscous, globular, and more concentrated protein
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solution. This would result in the more intense protein bands observed in this sample, as 
compared to the other, more homogenous samples (Figure 14B).
Disappointingly, all three of these induction attempts failed to generate any 
distinguishing bands as compared to the un-induced controls that would suggest successful 
induction of Rpp35 ATMD (Figures 14A, -B, and -C). More discerning was the fact that the 2 
mM IPTG sample induced at 37 °C (Figure 14C) did not reproduce the earlier generated and 
discussed protein band (~ 44 kDa) (Figures 12 and 13).
2.1.7 1 mM IPTG induction of pHTT7K-Rpp35 at 37 °C
To avoid future potential insolubility issues, the ideal sequence to work with was the one 
without the hydrophobic transmembrane domain (pQE31-Rpp35 ATMD). However, based on 
the fact that there was uncertainty regarding the sequence of the pQE31 -Rpp35 ATMD provided 
by the Japanese group, and due to the inconclusive nature of the induction experiments 
performed, induction work on the pQE31-Rpp35 ATMD ceased, and efforts shifted to the 
induction of the full-length Rpp35, which had already been successfully incorporated into a 
pHTT7K plasmid by another Lee lab member.
The pHTT7K plasmid, which was obtained from Sidney Altman's lab, at Yale University, 
is another bacterial cloning vector that utilizes the T7 promoter system, contains a MCS, and 
includes a gene conferring resistance to the antibiotic kanamycin (Jarrous et al. 1998). The full- 
length human Rpp35 sequence was sub-cloned into the NdeVSacl sites of the 5107 bp pHTT7K 
plasmid using forward and reverse primers that incorporated the restriction cleavage sites 
recognized by Ndel and S ad, respectively. The purified pHTT7K-Rpp35 was provided at a 
concentration of 390 ng/pL.
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Induction of the pHTT7K-Rpp35 involved 1 mM IPTG induction at 37 °C, collecting 
samples at 0, 1, 2, 3, 5, 7, and 10-hour time intervals (Figure 15B). Un-induced and induced 
controls were concurrently generated, also using 1 mM IPTG and incubated for a constant 5 
hours at 37 “C (Figure 15A). Both of these gels included the 6.5-205 kDa protein marker in lane 
1, and a 10 pL un-induced sample in lane 2 (Figures 15A and 15B). Figure 15A also included a 
10 pL induced sample, while Figure 15B included 10 pL samples of 0, 1, 2, 3, 5, 7, and 10-hour 
time intervals as represented in lanes 3-9, respectively.
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Figure 15. ^  Controls. Five hour un-induced and 1 mM induced pHTT7K-Rpp35 at 37 
”C as visualized using 12% SDS-PAGE. Lane 1 represents the protein marker, with 
respective markers indicated on the left with arrows. Lane 2 depicts 10 pL of the un- 
induced control sample, which was collected at the 5-hour incubation time point. A 10 pL 
1 mM induced sample, lane 3, was also collected at the 5-hour incubation time point. The 
solid black arrow on the right indicates induced Rpp35. ^  12% SDS-PAGE visualization 
of pHTT7K-Rpp35 1 mM IPTG induction at 37 "C for various times. Lane 1 represents 
the protein marker, with respective markers indicated on the left with arrows. Lane 2 
depicts the time zero, 10 pL un-induced control sample. Induced samples were collected at 
0,1, 2, 3, 5, 7, and 10-hour time intervals, as represented hy 10 pL samples in lanes 3, 4, 5, 
6, 7, 8, and 9, respectively. The arrow on the right indicates Rpp35 induction.
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One mM IPTG induction of the pHTT7K-Rpp35 was successful as evidenced by the 
prominent protein band, ~44 kDa in size, that is visible in all of the greater than 1 hour 
incubation time samples and the induced sample (Figure 15B, lanes 4-9, and Figure 15A, lane 3, 
respectively), but absent in the zero hour time point and the un-induced samples (Figure 15B, 
lanes 2 and 3, and Figure 15A, lane 2, respectively). The presence of the -44  kDa protein band 
persisted in intensity up to the 10 hour time point (Figure 15B, lanes 4-9). The band representing 
the induced Rpp35 is indicated on the right of both figures with solid black arrows (Figures 15A 
and 15B).
Interestingly, the induced Rpp35 produced a protein band that was very similar in size to 
the bands seen in the attempts to induce Rpp35 ATMD, suggesting that those initial induction 
experiments on Rpp35 ATMD may have been successful after all.
It was also observed that the protein bands corresponding to the 1 and 2 hour time point 
samples were more intense then the other time point samples (Figure 15B, lanes 4 and 5). This is 
most likely due to the pellet not being thoroughly re-suspended in the loading dye, which would 
cause the sample to be very viscous and globular, which would result in a more concentrated 
protein sample. Induction of Rpp35 at 37 “C using a final IPTG concentration of 1 mM was a 
success. Once the Rpp35 had been successfully induced, as confirmed via SDS-PAGE, the 
BL21 cells were lysed to release the now prevalent Rpp35. In an effort to maximize the Rpp35 
yield, the cell lysis procedure was optimized. The main lysis reagent used was a bacterial protein 
extraction reagent (B-PER), but the use of sonication and N-Lauroyl Sarcosine, an anionic 
surfactant and commonly used cell lysis reagent, were also investigated. It is fairly common for 
recombinant proteins to become aggregated and form insoluble inclusion bodies when utilizing
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bacterial vectors, specifically when trying to use bacteria to over-express vertebrate proteins of 
interest (Harlow and Lane 1999). The cell lysis experiment, therefore, also provided an 
opportunity to investigate whether the Rpp35 was a soluble protein or, as anticipated, present in 
inclusion bodies.
The BL21 cells containing the Rpp35 were lysed with B-PER, with or without 3% N- 
Lauroyl Sarcosine, and with or without sonieation. The lysed cells were then centrifuged and 
pelleted, and both the pellet and the supernatant fractions were tested for the presence of the 
Rpp35 (Figures 16A and 16B). Both of these gels included a 6.5-205 kDa protein marker, and 
10 pL samples of both the un-induced and induced controls (Figures 16A and 16B, lanes 1, 2, 
and 3, respectively). For the gel representing B-PFR cell lysis without the addition of 3% N- 
Lauroyl Sarcosine, lanes 4 and 5 depict 10 pL of the pellet fractions with, and without 
sonication, respectively (Figure 16A). Lanes 6 and 7 represent 10 pL of the soluble, supernatant 
fraction, with and without sonication, respectively (Figure 16A). The gel that represents the B- 
PFR cell lysis with the addition of 3% N-Lauroyl Sarcosine also has 10 pL of the pellet fractions 
with and without sonication, as well as 10 pL samples of the soluble, supernatant fraction, with 
and without sonication (Figure 16B, lanes 4 and 5, and 6 and 7, respectively).
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Figure 16. 12% SDS-PAGE visualization of a 1 mM IPTG-induced Rpp35 pellet re­
suspended in B-PER with (B) and without (A) 3% N-Lauroyl Sarcosine, with and without 
sonication. Lane 1 represents the protein marker, with respective markers indicated on the 
left with arrows. Lane 2 depicts 10 pL of the un-induced control sample, while lane 3 
represents 10 pL of the induced control. Lanes 4 and 5 represents 10 pL of the pellet 
fraction, with and without sonication, respectively. Lanes 6 and 7 depict 10 pL of the 
soluble supernatant fraction, with and without sonication, respectively. The solid black 
arrow on the right indicates the normal migration position of the Rpp35.
The most obvious and immediate observation is that approximately 90% of the Rpp35 
(~44 kDa) is present in the pellet fraction, and <10% is in the supernatant (Figure 16A and 16B), 
lanes 4 and 5 compared to lanes 6 and 7, respectively). This clearly indicates that the majority of 
Rpp35 was insoluble, and tentatively confirmed suspicions that the Rpp35 aggregated to form 
inclusion bodies. When directly comparing the cell lysis results of B-PER without 3% N- 
Lauroyl sarcosine (Figure 16A), to B-PER with 3% N-Lauroyl sarcosine (Figure 16B), it is 
apparent that there are no significant differences in the yield of the Rpp35 in either the pellet or 
supernatant samples (Figures 16A and 16B, lanes 4 and 5, and lanes 6 and 7, respectively). This 
led to the conclusion that the addition of 3% N-Lauroyl sarcosine was not a necessary step in the 
cell lysis procedure. Similar observations were made when comparing the effects of sonication, 
in that the pellet samples that did not receive sonication (Figures 16A and 16B, lane 5) were
104
indistinguishable from the pellet samples that were sonicated (Figures 16A and 16B, lane 4). 
This led to the conclusion that sonication was also not a necessary step in the cell lysis protocol.
Overall, the addition of the 3% N-Lauroyl sarcosine and/or sonication to the cell lysis 
procedure did not appear to make a difference in the yield or solubility of Rpp35, and no 
significant differences can be seen between the samples (Figures 16A and 16B).
It was also observed that all four of the pellet samples showed slight smearing on the 
12% SDS-PAGE, some more apparent than others (Figures 16A and 16B, lanes 4 and 5). This 
was due to the fact that the pellet was re-suspended in the smallest possible volume (-50 pL) of 
2X SDS-loading dye, and when it was loaded onto the gel it was noticed that it was a very 
viscous, globular solution. The greater protein band intensity seen in the pellet fractions are, of 
course, due to the fact that almost all of the Rpp35 is present in these fractions. Increasing the 
re-suspension volume, and/or loading less of the sample onto the gel could have avoided this 
problem. A better solution would have been to quantify the samples and then load equal 
amounts of protein onto the SDS-PAGE.
2.1.9 Large-scale Rpp35 induction and small-scale Rpp35 purification
The recombinant p35 protein had been incorporated into the pHTT7K plasmid in such a 
fashion that a specific affinity tag, six histidine residues in a row (5'- 
CATCATCATCATCATCAC-3'), was incorporated into the Rpp35 sequence at the amino- 
terminal of the Rpp35 sequence. Rpp35 purification was accomplished using a nickel- 
nitrilotriacetic acid-agarose chromatography column (Qiagen) which is based on the high 
selectivity of nickel-nitrilotriacetic acid (Ni-NTA) resin for proteins containing an affinity tag of 
six consecutive histidine residues (6X Histidine tag) (QIAexpressionist™). The 6X histidine tag 
is poorly immunogenic, and because it is small and uncharged at a pH of 8.0 it usually does not
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affect secretion, compartmentalization, or more importantly in this case, re-folding of the fusion 
protein. (QIAexpressionist™). The 6X histidine tag has also been found to not interfere with the 
structure or function of the purified protein (QIAexpressionist™). Since it was established that 
Rpp35 was not a soluble recombinant protein, the Rpp35 was purified under denaturing 
conditions.
Once the Rpp35 induction and the cell lysis procedures had been optimized, a large-scale 
(1.5L) induced Rpp35 sample was generated. For the small-scale Ni-NTA mini-column 
purification experiment, only 1 mL of this Rpp35-rich induction sample was loaded onto the 
mini-column, representing 1.6802 mg of total protein. The denaturing purification procedure 
involved a sequentially-stepped decrease in the pH of the original 100 mM NaH2PÜ4, 10 mM 
Tris-Cl, 8 M urea, pH 8.0 denaturing Buffer B. The Rpp35, as outlined above, was originally 
denatured in Buffer B at a pH of 8.0. This was the same pH that the Ni-NTA column was 
equilibrated at and the pH of the sample that was loaded onto the column. Once the column had 
been equilibrated and the denatured Rpp35 sample loaded, the column was washed thoroughly 
with pH 8.0, 6.3, 5.9, and 4.5 denaturing solutions (corresponding to Buffers B, C, D, and E, 
respectively) to gradually elute the proteins, and separate the Rpp35 from other bacteria proteins.
The 12% SDS-PAGE depicting the mini-column purification included a 6.5-205 kDa 
protein marker (Figure 17, lane 1). This gel also depicts 10 pL samples of the Buffer B, pH 8.0 
flow-through fractions 1, 3, 5, 7, and 9 (Figure 17, lanes 2-6, respectively), as well as 10 pL 
samples of the Buffer C, pH 6.3 elution fractions 11, 13, and 15 (Figure 17, lanes 7, 8, and 9, 
respectively). The gel depicting the last Buffer C, pH 6.3 elution fraction, the Buffer D, pH 5.9 
elution fractions, and the Buffer E, pH 4.5 elution fractions was not included as the protein bands 
on this gel were not intense enough to allow for adequate visualization on a paper medium.
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Figure 17. Ni-NTA mini-column purification of 1 mM IPTG-induccd Rpp35 as visualized 
using 12% SDS-PAGE. Lane 1 represents the 6.5-205 kDa protein marker, vyith respective 
markers indicated on the left with arrows. Lanes 2-6 depict the 10 pL Buffer B, pH 8.0 
flow-thru fractions 1,3,5,7, and 9, respectively. Lanes 7-9 represent the 10 pL Buffer C, pH
6.3 elution fractions 11, 13, and 15, respectively. The solid black arrow on the right 
indicates Rpp35.
Despite the fact that it is difficult to discern all of the protein bands in the resulting gels, 
which is due to the small amount of initial protein loaded, Rpp35 was successfully partially 
purified using a sequentially stepped decrease in the pH values of a 8 M urea-based denaturing 
buffer (Figure 17).
Non-binding proteins can be seen eluting in the Buffer B, pH 8.0 flow-through fractions 
3 and 5 (Figure 17, lanes 3 and 4), while the majority of the Rpp35 (~44 kDa) can be seen 
eluting with the Buffer C, pH 6.3 fractions (Figure 17, lanes 7, 8, and 9), and to a lesser extent, in 
the Buffer E, pH 4.5 elution fraction (data not shown).
It is important to note that other proteins appeared to be co-eluting with the Rpp35, which 
can be seen in the Buffer C, pH 6.3 elution fractions (Figure 17, lanes 7, 8, and 9). Three co­
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eluting proteins are visible; two of the proteins appear to migrate at -85 and -98  kDa, while a 
much smaller protein can be seen migrating at -30  kDa (Figure 17, lanes 7, 8, and 9).
Nevertheless, the mini-column was successful in partially purifying the Rpp35, and 
appeared to elute the recombinant protein mostly (-80% ) with Buffer C, pH 6.3, and to a lesser 
extent with Buffer E, pH 4.5 (-20%).
2.1.10 Large-scale puriOcation of Rpp35 as visualized by 12% SDS-PAGE.
Once it had been established that the induced Rpp35 could be effectively purified using 
the Ni-NTA resin, the procedure was repeated, but on a much larger scale. Large-seale Rpp35 
purification (35 mg total protein) was accomplished using 20 mL of the Ni-NTA resin and a 
series of stepped pH changes in the 8 M urea denaturing buffer. Based on the results from the 
mini-column, which showed that the majority of Rpp35 eluted in Buffer C, pH 6.3, and Buffer E, 
pH 4.5, the procedure was modified so that the Buffer D, pH 5.9 was not used for the large-scale 
Rpp35 purification. Only certain fractions were chosen to depict the Rpp35 purification; these 
fractions were selected based on their UV/vis absorbance values measured during fraction 
collection.
Four 12% SDS-PAGE gels were used to visualize the large-scale purification of Rpp35. 
The first gel depicting large-scale purification of Rpp35 included a 10 pL un-induced sample, a 
10 pL induced sample, a 10 pL cell lysate (soluble fraction) sample, and a 10 pL sample of the 
pre-nickel column Rpp35 (Figure 18A, lanes 2, 3, 4 and 5, respectively). This gel also included 
10 pL samples of the Buffer B, pH 8.0 flow-through fractions 1, 2, 3, 9, and 10 (Figure 18A, 
lanes 6-10, respectively). The second gel represents 10 pL samples of the Buffer C, pH 6.3 
elution fractions 28, 31, 34, 37, 40, 43, 46, 49, and 52 (Figure 18B, lanes 2-10, respectively). 
The third 12% SDS-PAGE depicts 10 pL samples of the Buffer C, pH 6.3 elution fractions 55,
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58, 61, 64, 67, 70, 73, 76, and 79 (Figure 18C, lanes 2-10, respectively). The fourth gel 
represents 10 pL of the Buffer E, pH 4.5 elution fractions 82, 84, 86, 88, 90, 92, 94, 96, and 98 
(Figure 18D, lanes 2-10, respectively). An error was made when trying to convert the original 
image of the fourth gel into electronic form, so unfortunately the image presented here is not of 
the best quality as it has been reproduced from the original printed photo.
The 35 mg of the Rpp35-rich sample slightly overloaded the column, which is evidenced 
by the elution of Rpp35 in the Buffer B, pH 8.0 flow-through fractions 2 and 3 (Figure 18A, 
lanes 7 and 8, respectively). The Rpp35 eluting from the Ni-NTA column, indicated by solid 
black arrows on all four gels, is very prominent and obvious in the Buffer C, pH 6.3 elution 
fractions 31, 34, 37, 40, 43, 46, 49, and 52 (Figure 18B, lanes 3-10, respectively), and in Buffer 
C, pH 6.3 elution fractions 55, 58, 61, 64, 67, 70, 73, and 76 (Figure 18C, lanes 2-9, 
respectively). A small amount of Rpp35 can also be seen eluting in the Buffer E, pH 4.5 
fraetions 86, 88, 90, 92, and 94 (Figure 18D, lanes 4-8, respectively), but it is estimated that -85- 
90% of the Rpp35 eluted in the Buffer C, pH 6.3 fractions.
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Figure 18A. 12% SDS-PAGE visualization of large-scale purification of 1 mM IPTG- 
induced Rpp35. Lane 1 represents the protein marker, with respective markers indicated 
on the left with arrows. Lanes 2 and 3 represent the 10 pL samples of the un-induced and 
induced controls, respectively. Lane 4 depicts 10 pL of the cleared cell lysate, which 
represents the soluble fraction after cell lysis. Lane 5 depicts 5 pL (9 pg) of the column 
pre-load. Lanes 6-10 represent the Buffer B, pH 8.0 flow-through fractions 1, 2, 3, 9, and 
10, respectively. The solid black arrow on the right indicates the normal migration position 
of Rpp35 using 12% SDS-PAGE.
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Figure 18B. 12% SDS-PAGE visualization of large-scale purification of 1 mM IPTG- 
induced Rpp35. Lane 1 represents the protein marker, with respective markers indicated 
on the left with arrows. Lanes 2-10 represent the 10 pL Buffer C, pH 6.3 elution fractions 
28, 31, 34, 37, 40, 43, 46, 49, and 52, respectively. The solid black arrow on the right 
indicates the eluting Rpp35.
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Figure 18C. 12% SDS-PAGE visualization of large-scale purification of 1 mM IPTG- 
induced Rpp35. Lane 1 represents the protein marker, with respective markers indicated 
on the left with arrows. Lanes 2-10 represent the 10 pL Buffer C, pH 6.3 elution fractions 
55, 58, 61, 64, 67, 70, 73, 76, and 79, respectively. The solid hlack arrow on the right 
indicates the eluting Rpp35.
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Figure 18D. 12% SDS-PAGE visualization of Ni-NTA large-scale purification of 1 mM 
IPTG-induced Rpp35. Lane 1 represents the protein marker, with respective markers 
indicated on the left with arrows. Lanes 2-10 represents the 10 pL Bufl'er E, pH 4.5 elution 
fractions 82, 84, 86, 88, 90, 92, 94, 96, and 98, respectively. The solid hlack arrow on the 
right indicates the eluting Rpp35.
As was the case with the mini-column purification, it appears that other proteins are co­
eluting with the Rpp35. In the Buffer C, pH 6.3 elution fractions, it appears as if there are two 
higher molecular weight proteins (-85 and -98 kDa) eluting with Rpp35, as well as one other 
lower molecular weight protein (-30 kDa) (Figures 18B and 18C, lanes 2-10, respectively). 
Other co-eluting proteins can also be seen in the Buffer E, pH 4.5 fractions 88, 90, and 92 
(Figure 18D, lanes 5-7, respectively). Not only do these findings correlate with the proteins that 
co-eluted with Rpp35 using the mini-column purification procedure, but subsequent large-scale 
Rpp35 purifieations also found that these same proteins consistently co-eluted with Rpp35. 
These additional co-eluting proteins will be discussed in more detail in the charaeterization 
experiments section (Chapter 3, Section 3.0.2 and 3.1.3).
2.1.11 Dialysis and re-folding of Rpp35 to assess for endonucleolytic activity.
Elution fractions from the previous Rpp35 purifications that were found to be rich in 
Rpp35 were pooled and concentrated from -44  mL to -1.7 mL. This concentrated sample was 
then quantified using both the Bradford assay and by comparing it to four known BSA standards,
1.0, 2.5, 5.0, and 10.0 pg solutions, on a 12% SDS polyacrylamide gel (Figure 19, lanes 2, 3, 4, 
and 5, respectively). The BSA quantification of Rpp35 was necessary for polyclonal antibody 
development, as Invitrogen required known concentrations of the gel-purified Rpp35.
The BSA comparison concentration was determined by comparing the intensities of the 
BSA standards to the 3 pL sample of concentrated Rpp35. Visually, it was estimated that the 
intensity of the 2.5 pg BSA standard gel band was roughly equivalent to the intensity of the 3 pL 
Rpp35 gel band (Figure 19, lanes 3 and 5, respectively), which corresponds to an Rpp35 
concentration of -0 .8  mg/mL. The Bradford assay gave a concentration of 0.868 mg/mL.
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Figure 19. Quantification of pooled and concentrated Rpp35 sample using BSA standards 
for comparison, as visualized using 12% SDS-PAGE. Lane 1 represents the protein 
marker, vrith respective markers indicated on the left with arrows. Lanes 2-5 depicts the
1.0, 2.5, 5.0, and 10.0 pg BSA standards, respectively. Lane 6 represents 3 pL of the pooled 
and concentrated Rpp35 sample, indicated hy the solid hlack arrow on the right.
The pooling and concentration of subsequent Rpp35 purifications generated samples with 
slightly higher concentrations (1.246 mg/mL, 1.6802 mg/mL, 1.811 mg/mL, and 2.921 mg/mL), 
which varied depending on the amount of purified Rpp35 pooled, the optimization of Macro- and 
Nanosep™ spin time, and the final volume of the sample.
To test the Rpp35 to see if it has the same or similar endonucleolytic cleavage to that of 
the novel mammalian endoribonuclease, it was necessary to first attempt to re-nature the 
recombinant protein back to its native and functionally active 3-dimensional form. Two
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approaches were used to try to properly refold Rpp35. The first involved a combined buffer 
replacement with dialysis, while the second approach utilized a Takara re-folding kit.
The first approach involved buffer replacement in a Nanosep™ device, followed by 
simple dialysis of the recombinant protein by gradually removing the 8M urea-denaturing buffer, 
replacing it with a non-urea-containing, and therefore, non-denaturing equivalent buffer. The 
second approach was to use a Takara protein re-folding kit that utilizes various surfactants and 
molecular chaperones to refold denatured proteins. The Takara re-folding kit involved a two- 
step procedure that is designed to optimize the refolding conditions of proteins found in inclusion 
bodies. The first step involves the complete unfolding of the protein using Guanidine 
hydrochloride and DTT, while the second step involves the refolding of the protein using 4 
different surfactants to prevent molecular aggregation, and then removing the surfactants and 
restoring enzymatic activity using the synthetic chaperone, cycloamylase (CA) (Daugherty et al. 
1998; Sundari et al. 1999; Machida et al. 2000). The effects of the addition of DL-Cystine, 
which is important in the formation of protein stabilizing structures called disulfide bridges, was 
also investigated (Daugherty et al. 1998; Sundari et al. 1999; Machida et al. 2000). The 
procedure for this experiment was taken directly from the Takara re-folding kit instruction 
booklet (Daugherty et al. 1998; Sundari et al. 1999; Machida et al. 2000).
It was hoped that either of these methods would completely or partially re-nature Rpp35, 
and in doing so, allow Rpp35 to act as an endoribonuclease, generating identical or similar 
cleavage fragments to that of the novel mammalian endoribonuclease. As the only way to 
evaluate these two approaches was to actually test for endoribonuclease activity against the 5'- 
y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792), both experiments were
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conducted concurrently, and the results visualized on the same 6% polyacrylamide/7 M urea 
denaturing gel (Figure 20).
This endoribonuclease assay gel included the 30,000 cpm 5'-y^^P-radiolabelled CRD c- 
myc mRNA substrate (nts 1705-1792) substrate as a control, 2 pL (1-5 U) of post heparin- 
sepharose purified native enzyme (Bergstrom et al. 2006), 1.0 pL of soluble cell lysate, 1.0 pL 
of pre-dialyzed Rpp35, 1 pL of dialyzed Rpp35, and 1.0 pL of pre-refold Rpp35 (Figure 20, 
lanes 1 ,2 ,3 ,  4, 5, and 6, respectively). This gel also included 1 pL samples of all of the various 
Takara re folding surfactant combinations (1% Tween 40, 1% Tween 60, 1% CTAB, and 1% 
SB3-14, without and with 14 pL of 200 mM DL-Cystine) and their effects on Rpp35 (Figure 20, 
lanes 7-14, respectively).
The buffer replacement combined with dialysis appeared to restore enzyme activity, and 
the cleavage fragments generated by Rpp35 on a 6% polyacrylamide/7 M urea denaturing gel 
appeared to be similar to that of the native enzyme. (Figure 20, lanes 5 and 3, respectively). The 
Takara re-folding procedure performed on Rpp35 did not appear to result in the protein 
exhibiting any significant enzymatic activity (Figure 20, lanes 7-14).
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Figure 20. Endoribonuclease assay to determine the effectiveness of combined buffer 
replacement and dialysis vs. utilizing the Takara re folding kit to re-nature Rpp35 as 
visualized on a 6% polyacrylamide/7 M urea denaturing gel. Lane 1 represents the 30,000 
cpm 5'-y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792) control, while lane 
2 depicts 2 pL of post heparin-sepharose purified endoribonuclease (1-5 U). Lane 3 
represents 1 pL of the soluble cell lysate fraction, while lane 4 depicts 1 pL of the pre- 
dialyzed and still denatured Rpp35 sample. Lane 5 represents 1 pL of the dialyzed Rpp35 
sample. Lane 6 is a 1 pL sample of pre-refold Rpp35. Lanes 7 and 8 contain 1 pL samples 
depicting the effects of the Takara re folding procedure using 1% Tween 40, without and 
with 14 pL of 200 mM DL-Cystine added, respectively. Lanes 9 and 10 contain 1 pL 
samples representing the effects of using 1 % Tween 60, without and with 14 pL of 200 mM 
DL-Cystine added, respectively. Lanes 11 and 12 contain 1 pL samples depicting the 
effects of the Takara re folding procedure using 1% CTAB, without and with 14 pL of 200 
mM DL-Cystine added, respectively. Lanes 13 and 14 contain 1 pL samples representing 
the effects of using 1% SB3-14, without and with 14 pL of 200 mM DL-Cystine added, 
respectively. The black arrow on the right represents the 5 ' -y^^P-radiolabelled CRD c-myc 
mRNA substrate used to test for enzymatic activity, while the black arrow on the lower left 
indicates the typical cleavage fragments associated with novel endoribonuclease activity 
(Bergstrom et al. 2006).
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2.1.12 Testing dialyzed Rpp35 fractions for endoribonuclease activity
The individual Rpp35-rich Buffer C, pH 6.3 elution fractions were then dialyzed using 
the same buffer replacement and dialysis procedure, and selected fractions were used to test for 
activity against the 5'-y^^P-radiolabelled CRD c-myc mRNA substrate (Figure 21). The 6% 
polyacrylamide/7 m urea denaturing gel generated from this endoribonuclease assay included the
30,000 cpm 5'-y^^P-radiolabelled CRD c-myc mRNA substrate as a control, 2 pL (1-5 U) of post 
heparin-sepharose purified native enzyme, 0.5 pL of both un-induced and induced controls (cell 
lysate), 1 pL of the cell-lysate fraction, and 1 pL of the pre-nickel column Rpp35 (Figure 21, 
lanes 1-6, respectively). Four pL of each of the selected fractions were used to test for 
endoribonuclease activity. These fractions included Buffer B, pH 8.0 flow-through fractions 1, 
2, and 10, as well as Buffer C, pH 6.3 Rpp35-rich elution fractions 28, 31, 34, 43, 46, 49, 67, 70, 
and 79 (Figure 21, lanes 7-18, respectively). The solid black arrow to the left of the figure 
represents the cleavage fragments associated with the native enzyme activity, while the solid 
black arrow on the top right of the figure represents the 5'-y^^P-radiolabelled CRD c-myc mRNA 
substrate (Figure 21). The white arrows on the bottom right of the figure represent the cleavage 
fragments generated by dialyzed Rpp35 (Figure 21).
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Figure 21. Endoribonuclease assay to evaluate the endoribonucleolytic activity of dialyzed 
Rpp35-rich fractions, as visualized on a 6%  polyacrylamide/7 M urea denaturing gel. Lane 
1 represents the 5 ' radiolabelled CRD c-myc mRNA control substrate with no enzyme 
added, while lane 2 depicts 2 pL of post heparin-sepharose purified native 
endoribonuclease (1-5 U). Lanes 3 and 4 represent 0.5 pL of the cell lysate nn-indnced and 
induced controls, respectively. Lane 5 represents 1 pL of the soluble cell lysate fraction, 
and lane 6 depicts 1 pL of the pre-nickel column denatured Rpp35 sample. Lane 7, 8, and 
9 represent 4 pL of the Buffer B, pH 8.0 flow-through fractions 1, 2, and 10, respectively. 
Lanes 10-18 depict selected 4pL Rpp35-rich Buffer C, pH 6.3 elution fractions 28, 31, 34, 
43, 46, 49, 67, 70, and 79, respectively. The hlack arrow on the right represents the 5'-y^^P- 
radiolahelled CRD c-myc mRNA substrate used to test enzymatic activity, while the hlack 
arrow on the lower left indicates the typical cleavage fragments associated with native 
mammalian endoribonuclease activity (Bergstrom et al. 2006). The unfilled white arrows 
on the lower right indicate the major cleavage fragments generated hy the dialyzed Rpp35 
fractions.
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The combined buffer replacement and dialysis method resulted in Rpp35 exhibiting 
endoribonucleolytic activity, as evidenced by the cleavage fragments generated and the reduction 
of the substrate RNA in the selected Rpp35-rich fractions, as compared to that of the controls 
(Figure 21, lanes 11-17, and lanes 1, 3, 6, 7, and 10, respectively). Clearly too much of the 
dialyzed Rpp35 was used in this endoribonuclease assay, as the majority of the original RNA 
substrate has been degraded and can be seen at the bottom of the gel as small degradation 
products (Figure 21, lanes 11-17). The samples that display the characteristic Rpp35 degradation 
products the clearest are fractions 49, 67, and 70 (Figure 21, lanes 15-17, respectively). This is 
because these samples contained less Rpp35 then the earlier fractions, and were not concentrated 
enough to completely degrade their own degradation products, which is believed to be the case 
for the earlier fractions. While it is difficult to adequately compare the degradation products of 
the novel mammalian endoribonuclease to that of the dialyzed selected fractions on a 6% 
polyacrylamide/7 M urea denaturing gel, preliminary observations indicate that the cleavage 
fragments of native enzyme appear to be similar to those of the dialyzed Rpp35 (Figure 2 1, lane 
2, and lanes 11-17, respectively).
As expected, the fractions that displayed the most enzymatic activity were the same 
fractions that Rpp35 prevalence was found to be the greatest in (comparing Figures 18B and 18C 
to Figure 21). To correlate the results from this endoribonuclease assay to 12% SDS-PAGE 
Rpp35 fractions with endonucleolytic activity, both the 12% SDS-PAGE and the 6% 
polyacylamide/7 M urea gel were combined into one figure (Figure 22).
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Figure 22. Rpp35-rich fractions, visualized with 12% SDS-PAGE (top), correlated with 
their corresponding endonucleolytic activity, as visualized on a 6% polyacrylamide/7 M 
urea denaturing gel (bottom). Lane 1 represents the 5' -y^^P-radiolahelled CRD c-myc 
mRNA control substrate, lane 2 depicts 2 pL of post heparin-sepharose purifîed native 
endoribonuclease (1-5 U), and lanes 3 and 4 represent the un-induced and Induced controls, 
respectively. Lane 5 represents the soluble cell lysate fraction, and lane 6 depicts the pre­
nickel column Rpp35. Lane 7, 8, and 9 represent the Buffer B, pH 8.0 flow-thru fractions 
1, 2, and 10, respectively. Lanes 10-18 depict selected Rpp35-rich Buffer C, pH 6.3 elution 
fractions 28 ,31 ,34 ,43 ,46 ,49 , 67,70, and 79, respectively. Volumes included on the top are 
for the SDS-PAGE gel, volumes used for the endoribonuclease assay are provided in Figure 
21.
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It is important to note that while Rpp35 clearly displays nucleolytic activity, the results 
presented here do not confirm the activity to be endonucleolytic in nature. In an experiment 
conducted by another Lee lab member, dialyzed Rpp35 was tested for endonucleolytic activity 
by subjecting it to both 3'- and 5'-y^^P-radioIabelled CRD c-myc mRNA substrate. The results 
from this experiment conclusively demonstrated that the dialyzed Rpp35 endonucleolytically 
cleaved the CRD c-myc mRNA substrate (nts 1705-1792) (data not shown).
2.2 Chapter Summary;
The pUC19 DNA plasmid containing the CRD c-myc DNA sequence (nts 1705-1792) 
was effectively purified through treatment with Proteinase K, which most likely removed any 
contaminants, such as RNase A. The plasmid was successfully digested with EcoRI, the DNA in 
vitro transcribed, and the RNA quantified. The RNA was also effectively dephosphorylated, 
radiolabelled, and gel-purified.
All attempts at inducing pQE31-Rpp35 ATMD in BL21 cells were either inconclusive or 
unsuccessful. Based on the conflicting data, and uncertainties as to the actual identity of the 
pQE31-Rpp35 ATMD, efforts to induce this recombinant protein ceased, and the focus shifted to 
the use of full-length Rpp35 incorporated into a pHTT7K plasmid.
Rpp35 in pHTT7K was successfully induced in BL21 cells using a final IPTG 
concentration of 1 mM and incubating at 37 °C. Rpp35 was found to be successfully induced 
after one hour of incubation, although subsequent large-scale inductions used a constant 5-hour 
incubation period. The cell lysis conditions were optimized, and it was determined that the 
addition of sonication and 3% N-Lauroyl sarcosine made no significant difference in the yield or 
solubility of B-PER extracted Rpp35.
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Rpp35 was successfully partially purified in both small- and large-scale using Ni-NTA 
resin. A pooled and concentrated sample of Rpp35 was generated and used to determine the 
effectiveness of dialysis and the Takara re-folding kit. It was found that dialysis appeared to re­
fold Rpp35 adequately enough for Rpp35 to exhibit endoribonuclease activity. The Takara re­
folding kit procedure did not result in Rpp35 displaying significant enzymatic activity.
Aim I was a success in that the selected dialyzed Rpp35 fractions displayed 
endonucleolytic activity that correlated with the prevalence of the Rpp35 as seen in 12% SDS- 
PAGE. Preliminary observations indicate that Rpp35 enzymatic activity generates degradation 
products that appear similar to that of the native mammalian endoribonuclease.
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CHAPTER 3 - IS RECOMBINANT p35 ONE OF THE COMPONENTS OF THE 
NATIVE MAMMALIAN ENDORIBONUCLEASE?
This chapter details five main characterization experiments conducted on recombinant 
p35 (Rpp35) and/or the native endoribonuclease in an attempt to elucidate the identity of the -35 
kDa protein associated with the novel mammalian endoribonucleolytic activity. These 
characterization experiments included: i) the size-exclusion separation of the two large proteins 
that co-eluted with Rpp35, and subsequent testing of these proteins for endoribonuclease 
activity; ii) comparing the endoribonucleolytic activity of Rpp35 to that of the native mammalian 
endoribonuclease and other recombinant proteins; iii) mapping the cleavage sites and specificity 
of Rpp35 as compared to the native mammalian endoribonuclease against CRD c-myc mRNA; 
iv) investigating the specificity of Rpp35 and phosphocellulose-purified native mammalian 
endoribonuclease by Western blot analysis using Rpp35-oligopeptide generated polyclonal 
antibodies v) performing immunoprécipitation experiments on Rpp35 and phosphocellulose- 
purified native mammalian endoribonuclease, as visualized by Western blot, and then testing 
these immunoprecipitated fractions for depleted endoribonuclease activity.
3.0 Methods:
3.0.1 Size-exclusion separation of the two large proteins that co-eluted with Rpp35 and 
subsequent testing of these proteins for endoribonuclease activity.
Four hundred pL aliquots of Buffer B (pH 6.3) Rpp35-rich elution fractions 53 and 54 
were placed in 10 kDa Nanosep® centrifugal devices and subjected to the combined buffer 
replacement and dialysis steps outlined earlier (Chapter 2, Section 2.0.14). Fifty pL aliquots of 
the dialyzed Rpp35 were transferred into a 100 kDa Nanosep® and centrifuged at 4 °C for 20 
minutes at 14,000g. The flow-through sample (-45 pL), representing the fraction containing the 
<100 kDa proteins, was transferred to another eppendorf tube and stored at -20 °C. Ten pL of
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Buffer B-without urea (pH 8.0) was added to the remaining trapped liquid (<5 pL), which 
represented the fraction containing >100 kDa proteins. The solutions were pipetted up and down 
gently ten times to release any membrane-bound protein before being transferred to a clean 1.5 
mL eppendorfs and stored at -20 °C.
To test the effectiveness of the separation procedure, 6 pL of the original Rpp35-rich 
elution fractions 53 and 54, as well as 6 pL of their respective >100 kDa and <100 kDa samples 
were added to 10 pL of 2X SDS, 10 % P-Mercaptoethanol loading dye and subjected to 12% 
SDS-PAGE (as described in Chapter 2, Section 2.0.9). After the gel was finished running, it was 
fixed on the shaker for twenty minutes in a 200 mL solution containing 100 mL of methanol, 20 
mL of acetic acid, 20 mL of Bio-Rad fixative enhancer concentrate, and 60 mL of ddHzO. The 
gel was then rinsed twice in ddHzO for 10 minutes. As per the Bio-Rad Silver Stain Plus 
protocol, 35 mL of ddH20, 5.0 mL of Bio-Rad silver complex solution, 5.0 mL of Bio-Rad 
reduction moderator solution, 5.0 mL of Bio-Rad image developing reagent, and 50 mL of Bio- 
Rad development accelerator solution were added to a 250 mL erlenmeyer flask and mixed 
thoroughly. This mixture was then poured over the gel, which was then allowed to stain on the 
shaker at room temperature for -15 minutes. Once adequately stained, the gel was placed in a 
5% acetic acid solution and fixed for -15 minutes. The gel was rinsed in ddHiO for 5 minutes 
before being imaged using the Chemilmager^”^  System.
One pL of the fractions containing the >100 kDa and <100 kDa proteins, as well as 1 pL 
of the original Rpp35-rich dialyzed fractions were each added to 18 pL of endoribonuclease 
reaction cocktail and subjected to an endoribonuclease assay to test for endoribonuclease 
activity, as described earlier (Chapter 2, Section 2.0.15).
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3.0.2 Comparing the endoribonucleolytic activity of Rpp35 to that of the native 
mammalian endoribonuclease and other recombinant proteins.
The Rpp35 used for this endoribonuclease assay was a Buffer B-without urea (pH 8.0) 
dialyzed and 10 kDa Nanosep®-concentrated sample (1.125 mg/mL). The recombinant protein 
coding region determinant binding protein (RpCRD-BP) (0.17 mg/mL), recombinant protein p21 
(Rpp21) (0.26 mg/mL), and recombinant protein p40 (Rpp40) (0.21 mg/mL), were previously 
generated and quantified by another member of the Lee lab.
The appropriate volume of each of these recombinant proteins was added to 18 pL of 
endoribonuclease reaction cocktail to generate reaction solutions with final protein content of 0.5 
and 1.0 pg, with the exception of Rpp35, which also included a 0.25 pg protein sample. The 
samples were then subjected to an endoribonuclease assay to test for nucleolytic activity against 
the 5'-y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792), as described earlier 
(Chapter 2, Section 2.0.15).
3.0.3 Mapping the cleavage sites and specificity of Rpp35 as compared to the native 
mammalian endoribonuclease against CRD c-myc mRNA
The RNase T1 was partially digested under denaturing conditions in a lOX sequencing 
buffer (Ambion Inc., Austin, Texas), which contained final concentrations of 20 mM sodium 
citrate pH 5.0, 7 M urea, and 1 mM EDTA; conditions sufficient for RNase T1 to remain active 
(Ehresmann et al. 1987). The radiolabelled RNA substrate was first incubated in the lOX 
sequencing buffer for five minutes at 55 °C, and then allowed to cool to room temperature prior 
to treatment with the RNase T l. Partial digestion of 30,000 cpm of the 5'-y^^P-radiolabelled 
CRD c-myc mRNA substrate (nts 1705-1792) was accomplished in 2 pL of lOX sequencing 
buffer and 1 U of RNase Tl (Roche Diagnostic Inc., Mannheim, Germany), in a total reaction
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volume of 20 |nL made up to volume using DEPC-treated ddHzO. The digestion involved 
incubating at room temperature for five minutes, at which time the reaction was quenched by the 
addition of 1 pi of saturated RNA phenol, followed by standard ethanol precipitation, and finally, 
re-suspending the pellet in a 9 M urea/phenol loading dye.
An alkaline hydroxyl ladder was also prepared. The lOX alkaline hydrolysis buffer 
consisted of 50 mM Sodium carbonate (NaHCOs/NaaCOs) pH 9.2, and 1 mM EDTA. As was 
the case with the RNase T l procedure, the radiolabelled RNA substrate was first incubated in the 
lOX alkaline hydrolysis buffer for five minutes at 55 °C, and then allowed to cool to room 
temperature before digestion. Digestion of 30,000 cpm of the 5'-y^^P-radiolabelled CRD c-myc 
mRNA substrate (nts 1705-1792) was accomplished in 2 pL of lOX alkaline hydrolysis buffer in 
a total reaction volume of 20 pL, made up to volume using DEPC-treated ddHiO and incubated 
at 95 °C for three minutes. The reaction was quenched by the addition of 1 pi of saturated RNA 
phenol, followed by standard ethanol precipitation, and pellet re-suspension in a 9 M urea/phenol 
loading dye.
For the endoribonuclease assay, 1.5 pL of the dialyzed Rpp35 and Rpp25 samples, 
corresponding to 1.5 pg total protein, were used to test for native mammalian endoribonuclease 
activity. This assay also included two 1-5 U of post heparin-sepharose purified native 
endoribonuclease, and two other controls; input RNA without reaction mixture, and input RNA 
in reaction mixture with no enzyme added. The actual endoribonuclease assay was performed as 
described in Chapter 1, section 2.0.15.
The 12% polyacrylamide/7 M urea gel was first loaded and then pre-run for 30 minutes 
in 0.5X TBE buffer to test for leaks. One and a half pL of the above described post- 
endoribonuclease assay native mammalian endoribonuclease, Rpp35, and Rpp25 samples were
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added to 1.5 p.L of the 9 M urea/phenol loading dye; all 3 pL were loaded onto the gel. Three 
pL of the alkaline hydrolysis and RNase Tl digested 5'-y‘^ ^P-radiolabelled CRD c-myc mRNA 
substrate (nts 1705-1792) mixed with 9 M urea/phenol loading dye were also loaded onto the gel. 
The 12% polyacrylamide/7 M urea denaturing gel was run at a constant 28 mA for 
approximately 2 hours and 30 minutes, or until the bromophenol dye front was close to the 
bottom of the gel. The gel was then fixed in a 10% methanol, 10% acetic acid fixing solution for 
-15 minutes and exposed overnight (16 hours). The image was scanned using the Cyclone 
Phospholmager and visualized using the OptiQuant software.
3.0.4 Using Western blot analysis to investigate the specificity of Rpp35 and 
phosphocellulose-purified native mammalian endoribonuclease to Rpp35-oligopeptide 
generated polyclonal antibodies.
In preparation of native mammalian endoribonuclease and Rpp35-associated Western 
blot experiments, the following samples were subjected to the acetone precipitation procedure: 
12 pL of HepG2 (7.5 pg/pL); 18 pL of rat liver (5.0 pg/pL); 36 pL of bulk liver salt wash 
(LSW) (5.0 pg/pL); 90 pL of post pH-precipitated native mammalian endoribonuclease (2.591 
pg/pL); 600 pL of phosphocellulose-purified native mammalian endoribonuclease (0.0935 
pg/pL), 200 pL of reactive blue-4-purified native mammalian endoribonuclease (concentration 
unknown).
The acetone precipitation procedure involved the addition of 4 volumes of cold 100% 
acetone to the volumes of protein solutions indicated above. The solutions were gently mixed 
and allowed to incubate at -20 °C for one hour. The precipitated proteins were centrifuged at 
13,200 rpm for 10 minutes at 4 °C, the supernatant removed, and the pellet washed with 1 
volume of cold 80% acetone. The samples were centrifuged again at 13,200 rpm at 4°C, but this
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time only for 5 minutes. The acetone was gently removed through aspiration, and the pellet 
allowed to dry at room temperature for 15 minutes before being re-suspended in 10 pL of 
ddHiO. All of the acetone precipitated fractions were stored at -20 °C.
Ten pL of the acetone precipitated fractions, as well as 10 pL of the original Rpp-35 rich 
Buffer B (pH 6.3) elution fractions were each mixed with 10 pL of 2X SDS, 10% p- 
mercaptoethanol loading dye. These samples were then boiled and subjected to 12% SDS-PAGE 
as described earlier (Chapter 2 , Section 2.0.9). Instead of a protein marker, this gel included 10 
pL of Amersham rainbow marker (GE Healthcare, Montreal), mixed with 10 pL of 2X SDS, 
10% P-mercaptoethanol loading dye. The rainbow marker was not boiled prior to the loading 
and running of the 12% SDS-PAGE.
A nitrocellulose membrane and 4 filter papers were cut to size and soaked in transfer 
buffer (0.0479 M Tris, 0.0386 M glycine, 20% (v/v) MeOH) for 15 minutes. When the 12% 
SDS-polyacrylamide gel was finished running, it was separated from the glass plates and placed 
against the nitrocellulose membrane. A transfer 'sandwich' was made, which consisted of several 
items in the following order: foam spacer; two pre-soaked filter papers, pre-soaked nitrocellulose 
membrane, 12% SDS-polyacrylamide gel, two more pre-soaked filter papers, a second foam 
spacer. The 'sandwich' was placed in a Bio-Rad western blot sandwich cassette, and while 
submerged in transfer buffer, rolled with a plastic pipette to remove any trapped air bubbles. An 
ice block and stir bar were added to the Bio-Rad western blot apparatus, and the gel was 
transferred to the nitrocellulose membrane at a constant 500 mA for 90 minutes.
Once transfer was complete, the nitrocellulose membrane was gently removed from the 
gel and placed face up in 50 mL of a 5% skim milk (Nestle Carnation commercial skim milk 
powder) solution (5% (w/v) skim milk powder in 50 mL of IX TBS [0.154 M NaCl, 0.010 M
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Tris, pH 7.4]), which acted to block non-specific binding. The Western blot was shaken in the 
5% milk solution for 2 hours at room temperature on a platform shaker. The nitrocellulose 
membrane was then rinsed quickly with 20 mL of ST buffer (1% (w/v) skim milk powder, 0.1% 
(v/v) Tween 20, IX TBS) twice, and then in 50 mL of ST buffer for 15 minutes, followed by two 
more 5 minute - 50 mL ST buffer rinses. A 1/1500 dilution was made of the primary antibody, 
which in this case involved 20 pL of an Invitrogen Rpp35 oligopeptide sequence rabbit­
generated polyclonal antibody (animal #9950, week 10 bleed, Invitrogen Corporation, Carlsbad, 
CA, USA) source in 30 mL of ST buffer. A non-antibody containing pre-sera (animal #9950, 
pre-bleed) at the same dilution was used as the negative control. The primary antibody dilution 
was poured onto the Western blot and allowed to shake at room temperature for two hours. The 
blot was then rinsed using the same procedures outlined above, which included two quick rinses, 
one 15 minute rinse and two 5 minute rinses, all in ST buffer. The nitrocellulose membrane was 
then probed with a 1/2500 dilution of the secondary antibody, which in this case involved 12 pL 
of Promega anti-rabbit IgG (H-hL) horseradish-peroxidase (HR?) conjugated (Promega 
Corporation, Madison, WI, USA) secondary antibody in 30 mL of ST buffer. The blot was 
allowed to shake in the secondary antibody on the shaker at room temperature for a period of one 
hour. Once again, the series of ST buffer rinses described above were repeated. 5 ml of Pierce 
SuperSignal® West Pico Chemiluminescent (MIS BioLynx Inc., ON, Canada) luminol/enhancer 
solution was added to 5 ml of SuperSignal® West Pico Chemiluminescent stable peroxidase 
buffer solution and the mix poured over the blot, which was then shaken on the platform shaker 
for five minutes. Excess liquid was quickly removed from the corner of the blot with Kim- 
wipes, and the luminescence given off by the Western blot was immediately recorded using the 
chemiimager system.
129
3.0.5 Performing and visualizing immunoprécipitation experiments on Rpp35 and 
phosphocellulose-purified native mammalian endoribonuclease and then testing these 
immunoprecipitated fractions for depleted endoribonuclease activity.
Several different approaches were used in an attempt to immunoprecipitate Rpp35 using 
Rpp35 oligopeptide sequence-generated polyclonal antibodies. Some of these 
immunoprécipitation attempts utilized a variety of methods that were based on protocols 
obtained from the labs of Sidney Altman, Daniel Schoenberg, and Patrick Provost, outlined in 
detail in the following papers, respectively (Chernokalskaya et al. 1998; Guerrier-Takada et al. 
2002; Provost et al. 2002). Later immunoprécipitation efforts utilized a Pierce Seize X 
Immunoprécipitation kit. Only several selected representative immunoprécipitation experiments 
and subsequent endoribonuclease assays will be discussed here.
3.0.5.1 Immunoprécipitation:
Buffer replacement and dialysis was accomplished by pipetting 45 pL of previously 
dialyzed and concentrated Rpp35 (in Buffer B-without urea) (1.125 pg/pL) into a 10 kDa 
Nanosep® device containing 400 pL of 4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid 
(HEPES) buffer (50 mM HEPES, 150 mM KCl, pH 7.4). The device was centrifuged at 14,000g 
for ~1 minute, and an additional 400 pL of HEPES buffer was added. This wash/centrifugation 
step was repeated for a total of four times (1600 pL HEPES buffer total), and the volume 
brought down to -60  pL in the final centrifugation step. Eight hundred pL of HEPES buffer was 
then added and the Rpp35-rich sample stored at 4 °C.
In duplicate, 400 pL of Pierce Immunopure Immobilized Protein A (MJS BioLynx Inc., 
ON, Canada) was placed in the Pierce Seize X kit spin cup and centrifuged at 4000g for 1
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minute. The flow-through was discarded, the beads washed with 400 |uL of HEPES buffer by 
capping and gently inverting 10 times, and the mix centrifuged at 4000g for 1 minute and the 
flow-through once again discarded. These wash/centrifugation steps were repeated a total of 3 
times.
The spin cup was placed in a fresh eppendorf tube and 200 pL of HEPES buffer and 200 
pL of either pre-sera (pre-bleed) or sera (week 10 bleed) were added to their respective tubes. 
The contents were allowed to mix on a nutator at room temperature for 1 hour before being 
centrifuged at 4000g for 1 minute. The flow-through fraction from this step was saved, and 
termed flow-through fraction 1. 400 pL of HEPES buffer was added, mixed gently by inverting 
10 times, and then centrifuged at 4000g for 1 minute followed by the removal of the flow­
through fraction. These wash/centrifugation steps were repeated a total of 3 times before the 
spin cup was transferred to a new eppendorf tube and an additional 400 pL of HEPES buffer was 
added.
Immediately prior to use, 80 pL of dimethyl sulfoxide (DMSO) was used to gently 
dissolve the one-time-use packages of disuccinyl suberate (DSS) that were included in the Pierce 
Seize X Immunoprécipitation kit. Twenty-five pL of the DSS/DMSO mixture was then added to 
the spin-cup, which was mixed on the nutator at room temperature for I hour. The spin cup was 
then centrifuged at 4000g for 1 minute; the flow-through, termed flow-through 2, was saved and 
stored at 4 °C. Four hundred pL of HEPES buffer was then added, the spin cup capped, inverted 
10 times to ensure mixing, centrifuged for 1 minute, and the flow-through discarded. These 
wash/centrifugation steps were repeated a total of 5 times before the spin cup was transferred to a 
new eppendorf tune and the wash/centrifugation steps repeated an additional 2 times. Following 
the removal of the last flow-through fraction, 400 pL of the previously prepared (described
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above) Rpp35-rich HEPES buffer combination was transferred into the two spin cups, either pre­
sera or sera, and allowed to mix on the nutator at 4 °C overnight (~16 hours).
The samples were first centrifuged at 4000g for 1 minute and the flow-through fraction, 
referred to as flow-through fraction 3A, was saved and stored at 4 °C. The spin cup was 
transferred into a new eppendorf tube and the above mentioned wash/centrifugation steps were 
repeated at total of five times before the spin cup was placed in a new eppendorf tube and the 
wash/centrifugation step repeated one more time. The second centrifugation flow-through, 
referred to as flow-through fraction 3B, was also saved and refrigerated. 200 |o,l of Pierce Seize 
X Immunoprécipitation kit Immunopure® IgG Elution Buffer (pH 2.8) was added to each spin 
cup, which was then inverted ten times to ensure mixing. The mix was centrifuged at 4000g for 
1 minute, and the flow-through elution fraction saved. This elution procedure was repeated a 
total of four times (4 x 200 pL), to produce four 200 pL elution fractions 1-4. The elution 
fractions were immediately neutralized by repeating the buffer replacement/dialysis combination 
(described above), effectively removing the acidic environment of the elution buffer and 
replacing it with the HEPES (pH 7.4) buffer. The HEPES dialyzed elution fractions and flow­
through fractions were transferred to 10 kDa Nanosep® devices and centrifuged for 1.5 minutes 
at 14,000g. The volumes of all of the samples was brought up to 35 pL and then stored at 4°C.
Ten pL of all of the samples were added to 10 pL of 2X SDS, 10% p-mereaptoethanol 
loading dye, and subjected to 12% SDS-PAGE followed by Western blot analysis as described 
earlier (Chapter 2 , Section 2.0.9, and Chapter 3, section 3.0.4).
A Western blot stripping buffer (100 mM p-Mercaptoethanol, 2% SDS, 62.5 mM Tris, 
pH 6.7) was heated to 50 °C before 50 mL were poured over the nitrocellulose membrane and 
allowed to shake at room temperature for 15 minutes. The buffer was then replaced with 50 mL
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of fresh 50 °C Western blot stripping buffer and allowed to shake at room temperature for an 
additional 15 minutes. The stripping buffer was removed and the Western blot rinsed in 50 mL 
of ST buffer for five minutes. The nitrocellulose membrane was then re-blocked with the 5% 
skim milk solution, re-probed with secondary antibody only, and then subjected to Pierce 
chemiluminescent detection, all as described earlier (Section 3.0.4).
3.0.5.2 Performing endoribonuclease assays to test if the samples generated from the 
immunoprécipitation attempts effectively depleted endoribonucleolytic activity.
The two endoribonuclease assays described in this section followed the procedures 
outlined in the immunoprécipitation section. All reagents, volumes, centrifugation times, and 
procedures, unless otherwise stated, are identical to those found in the immunoprécipitation 
methods section.
The first experiment was performed using the samples generated from the 
immunoprécipitation experiment outlined in the immunoprécipitation methods section. Four pL 
of the sera and pre-sera samples was added to 18 pL of endoribonuclease reaction cocktail and 
subjected to an endoribonuclease assay to test for depleted nucleolytic activity against the 5'- 
Y^^P-radiolabelled CRD c-myc mRNA substrate, as described earlier (Chapter 2, Section 2.0.15).
The second experiment involved the addition of 250 pL (2.353 pg) of phosphocellulose- 
purified HEPES-dialyzed native mammalian endoribonuclease (9.412 ng/pL) and 250 pL (129.5 
pg) of HEPES-dialyzed Rpp35 (0.518 pg/pL). Both the flow-through and elution fractions were 
immediately subjected to the buffer replacement and dialysis procedure outlined earlier (Chapter 
3, Section 3.0.5.1)
The HEPES dialyzed 400 pL flow-through and elution samples were transferred into 10 
kDa Nanosep® devices and centrifuged at 14,000g for various times. Both the flow-through
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samples 3A for native mammalian endoribonuclease were centrifuged for 75 seconds, which 
resulted in volumes of 50 pL and 25 pL for the pre-sera and sera, respectively. The two flow­
through samples 3A for Rpp35 were centrifuged for 180 seconds, and generated volumes of 50 
pL and 20 pL, respectively. Only the first two elution fractions were centrifuged for both the 
native mammalian endoribonuclease and the Rpp35. The native mammalian endoribonuclease 
elution fractions were centrifuged for 70 seconds, which generated volumes of: 50 pL for both 
pre-sera and sera elution fractions 1, and 34 pL and 20 pL for pre-sera and sera elution fractions 
2, respectively. The Rpp35 elution fractions were centrifuged for 130 seconds, resulting in: 43 
pL and 50 pL for pre-sera and sera elution fractions 1, and <5 pL for both pre-sera and sera 
elution fractions 2. All fractions were brought up to a volume of 50 pL with the addition of 
HEPES (pH 7.4) buffer.
Four pL of these samples were then added to 18 pL of endoribonuclease reaction cocktail 
and subjected to an endoribonuclease assay to test for depleted nucleolytic activity against the 5'- 
y^^P-radiolabelled CRD c-myc mRNA substrate, as described earlier (Chapter 2, Section 2.0.15)
3.1 Results and Discussion:
3.1.1 Size-exclusion separation of the two large proteins that co-eluted with Rpp35 and 
subsequent testing of these proteins for endorihonuclease activity.
As discussed briefly in Chapter 2, Sections 2.1.9 and 2.1.10, several other proteins 
consistently co-purified with the Rpp35 Buffer B pH 6.3 elution fractions. In addition to the -44  
kDa protein band attributed to Rpp35, three other distinct protein bands were observed: two 
larger proteins at -84  and -98  kDa, and third, smaller protein at -30  kDa (review Figures 18B 
and 18C, lanes 2-10, respectively. Chapter 2, Section 2.1.10). The goal of this first
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characterization experiment was to determine whether the endonucleolytic activity of Rpp35 was 
due to the -44  kDa protein, and not due to the other three co-purifying proteins.
The separation of the two larger protein bands (-85 and -98 kDa) from the Rpp35- 
associated -44  kDa band and the smaller -30  kDa protein band was attempted through the use of 
a Pall, 100 kDa size-exclusion Nanosep® device. According to the manufacture's product guide, 
this size-exclusion separation device has a low protein-binding membrane consisting of modified 
polyethersulfone on a polyethylene substrate, and with a membrane nominal pore size of 10 nm 
it effectively retains biomolecules that are between 95 and 900 kDa. Furthermore, they report 
that the 100 kDa Nanosep® device is capable of a recovering 26% of proteins 67 kDa in size and 
91 % of proteins 97.4 kDa in size. Based on this information, it was anticipated that the 100 kDa 
Nanosep® device would effectively remove the two larger (-80 and -95  kDa) co-eluting 
proteins from the Rpp35-rich fractions efficiently enough to visualize via 12% SDS-PAGE, and 
to determine if the removal of these two proteins had an effect on the endoribonucleolytic 
activity of Rpp35.
The silver-stained 12% SDS-PAGE representation of the results of this size-exclusion 
experiment can be seen in Figure 23. This gel included a 6.5-205 kDa protein marker (Figure 23, 
lane 1) and two lanes containing 6 pL of the original dialyzed Rpp35-rich fraction (Figure 23, 
lanes 2 and 5). Lanes 3 and 4 represent 6 pL of the elution fraction 53 containing <100 kDa and 
>100 kDa proteins, respectively, while lanes 6 and 7 represent 6 pL of the elution fraction 54 
containing <100 kDa and >100 kDa proteins, respectively (Figure 23). The solid black arrow on 
the lower right indicates the -4 4  kDa Rpp35-associated protein band, while the unfilled arrows 
on the top right indicate the two co-eluting proteins (Figure 23).
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Figure 23. 100 kDa Nanosep® size-exclusion separation of the two proteins (-85 and -98  
kDa) that co-eluted with Rpp35 as visualized on silver-stained 12% SDS-PAGE. Lane 1 
represents the protein marker, with respective markers indicated on the left with arrows. 
Lane 2 depicts 6 pL of the original, Buffer B-without urea-dialyzed Rpp35-rich elution 
fraction. Lanes 3 and 4 depict 6 pL of the elution fraction 53 containing <100 kDa and 
>100 kDa proteins, respectively. Lanes 6 and 7 represent 6 pL of the elution fraction 54 
containing <100 kDa and >100 kDa proteins, respectively. The unfîlled white arrows on 
the top right indicate the two larger co-eluting proteins, while the solid black arrow on the 
right indicates Rpp35.
The -85 and -98  kDa proteins that co-eluted with the -44  kDa Rpp35 were partially 
separated from the Rpp35 using the 100 kDa Nanosep® device. This conclusion was made 
based on the disappearance of the two protein bands in both the 53 and 54 <100 kDa fractions 
(Figure 23, lanes 3 and 6, respectively), as compared to the presence of the two co-eluting bands 
in the original Rpp35-rich fractions (Figure 23, lanes 2 and 5) and the faintly visible bands in
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both the 53 and 54 >100 kDa fractions (Figure 23, lanes 4 and 7, respectively), which are 
indicated by white arrows on the top right of the figure.
This teehnique does have limitations, however, and it is readily apparent that Rpp35 was 
retained in the >100 kDa protein fraetions (Figure 23, lanes 4 and 7). It was anticipated that 
Rpp35 would be present in the >100 kDa protein fraetions, but only at very low levels. While it 
is possible that the Rpp35 eould be assoeiating with one or both of the larger co-eluting proteins, 
thus preventing it from passing through the membrane, the most plausible explanation for the 
relatively intense Rpp35 band observed in the >100 kDa protein fractions is that the inherent 
properties of the Nanosep® device prevented Rpp35 from completely passing through the 
membrane. If the 100 kDa Nanosep® deviee is eapable of recovering 26% of a 61 kDa protein, 
it is most likely capable of recovering 10-15% of a -44  kDa protein. As the volume of the 
trapped >100 kDa protein fraetions decreased during centrifugation, the concentration of the 
trapped Rpp35 would increase drastically compared to the <100 kDa protein flow-through 
fractions.
The same fractions used to generate Figure 23 were also used to test for Rpp35 
endoribonuclease activity, as shown in Figure 24. This gel included the 5'-y^^P-radiolabelled 
CRD c-myc mRNA substrate (nts 1705-1792) with no enzyme added as a control (Figure 24, 
lane 1), as well as the original Rpp35-rich fraetions 53 and 54 (Figure 24, lanes 2 and 5, 
respectively). Lanes 3 and 6 of this gel depict the <100 kDa protein fractions 53 and 54, 
respectively, while the >100 kDa protein samples from elution fraetions 53 and 54 are 
represented in lanes 4 and 7, respectively (Figure 24).
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Figure 24. Endoribonuclease assay to test for activity of the 100 kDa Nanosep® size- 
exclusion-generated 53 and 54 elution fractions >100 kDa and <100 kDa protein samples. 
Lane 1 represents the radiolahelled c-myc mRNA control substrate. Lanes 2 and 5 depicts 
1 pL of the original, Buffer B-without urea-dialyzed Rpp35-rich elution fractions 53 and 
54, respectively. Lanes 3 and 6 represents 1 pL of the >100 kDa flow-through samples 
from elution fractions 53 and 54, respectively, while lanes 4 and 7 depicts 1 pL of the <100 
kDa retained fraction. The solid black arrow indicates the 5 -y^^P-radiolahelled CRD c- 
myc mRNA substrate while the white arrow indicates the major products associated with 
Rpp35 endonucleolytic cleavage.
As was expected, both of the <100 kDa protein fractions generated cleavage fragments 
typical of Rpp35 endonucleolytic cleavage (Figure 24, lanes 3 and 6, as indicated by the white 
arrow) and match up to those generated by both of the original Rpp35-rich fractions used as 
controls (Figure 24, lanes 2 and 5). Typical Rpp35 endoribonucleolytic cleavage is also visible 
in both of the >100 kDa protein fractions (Figure 24, lanes 4 and 7), which does not come as a
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surprise as both of these fractions were confirmed, via SDS-PAGE, to contain Rpp35. Both of 
the <100 kDa protein fractions, which did not show the presence of the -85  and -98  kDa 
proteins in the 12% SDS-PAGE analysis, endonucleolytically cleaved c-myc mRNA and 
generated cleavage products typical of Rpp35. These observations led to the conclusion that the 
-85  and -98 kDa proteins that co-eluted with the -44  kDa Rpp35 are not likely to be associated 
with Rpp35 endonucleolytic cleavage.
3.1.2 Comparing the endoribonucleolytic activity of Rpp35 to that of the native 
mammalian endoribonuclease and other recombinant proteins.
To determine if all recombinant proteins posses nucleolytic cleavage activity against 
CRD c-myc mRNA, an endoribonuclease assay was performed on four recombinant proteins: 
Rpp35, RpCRD-BP, Rpp21, and Rpp40. CRD-BP, as was discussed earlier (Chapter 1, Section 
1.1.4), is a binding protein that is involved in the protection of the CRD of c-myc mRNA 
(Prokipcak et al. 1994; Lemm and Ross 2002). p21 and p40 are known protein sub-units of 
human RNase P, required for the removal of the 5' leader sequences of precursor tRNAs to 
generate mature 5' termini (Chapter 1, Section 1.3.1 - vi) (Guerrier-Takada et al. 2002; Li and 
Altman 2003).
This gel generated from this endoribonuclease assay included 2 pL (1-5 U) of native 
mammalian endoribonuclease and the 5 '-y^^P-radi olabelled CRD c-myc mRNA substrate (nts 
1705-1792) as controls (Figure 25, lanes 1 and 2 respectively). Three different samples of 
Rpp35, 0.25, 0.5, and 1.0 pg samples, are represented in lanes 3, 4, and 5, respectively (Figure 
25). RpCRD-BP samples of 0.5 and 1.0 pg are depicted in lanes 6 and 7, respectively, while 
lanes 8 and 9 represent the enzymatic activity of Rpp21 0.5 and 1.0 pg samples, respectively 
(Figure 25). The Rpp40 0.5 and 1.0 pg samples are represented in lanes 10 and 11, respectively.
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The 5'-y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792) is indicated by the solid 
black arrow to the top right of the figure (Figure 25).
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Figure 25. Endoribonuclease assay to test for, and compare, the enzymatic activity of the 
native mammalian endoribonuclease, Rpp35, RpCRD-BP, Rpp21, and Rpp40. Lane 1 
represents 2 pL (1-5 U) of heparin-sepharose purified native endoribonuclease. Lane 2 
depicts the 5 ' -y^^P-radiolahelled CRD c-myc mRNA substrate with no enzyme as a control. 
Lanes 3-5 represent 0.25, 0.5, and 1.0 pg of dialyzed Rpp35, respectively. Lanes 6 and 7 
depict 0.5 and 1.0 pg of RpCRD-BP, respectively, while lanes 8 and 9 represent 0.5 and 1.0 
pg of Rpp21, respectively. Lanes 10 and 11 represent the cleavage generated by 0.5 and 1.0 
pg of Rpp40, respectively. The solid black arrow indicates the 5 -y^^P-radiolabelled CRD c- 
myc mRNA substrate.
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From Figure 25, it is fairly clear that RpCRD-BP, Rpp21, and Rpp40 do not posses the 
same enzymatic cleavage properties of Rpp35 (Figure 25, lanes 3-5 as compared to lanes 6-7, 8- 
9, and 10-11). Instead, it appears as if the RpCRD-BP and Rpp21 are generating very faint 
bands that are similar to the bands generated by the native mammalian endoribonuclease (Figure 
25, lanes 6-7 and 8-9, as compared to lane 1).
Caution must be used when coming to conclusions based on these observations. While it 
is true that cleavage fragments appear to be generated in all of the recombinant proteins, the 
input substrate control also includes faint cleavage products (Figure 25, lane 2). This 
observation suggests that RNase A may have slightly contaminated this experiment, as it has 
been shown that the native mammalian endoribonuclease and RNase A display very similar 
cleavage products against the 5 '-y^^P-radiolabelled CRD c-myc mRNA substrate (Bergstrom et 
al. 2006). Furthermore, it is difficult to come to conclusions based on the size of the input 
substrate remaining as several of the recombinant samples exhibited streaking in the lanes, which 
is a typical indication of protein precipitation in the wells. Nevertheless, this experiment 
effectively distinguished the unique endoribonucleolytic activity of Rpp35 from that of other 
recombinant proteins.
The most significant observation to be made from this experiment was that the novel 
mammalian endonucleolytic cleavage fragments do not appear to correlate with that of Rpp35. 
This conclusion was made based on comparisons of the cleavage fragments generated by the 
native mammalian endoribonuclease and Rpp35 (Figure 25, lane 1 compared to lanes 3, 4, and 
5). These results prompted the use of a larger sequencing gel to better resolve the cleavage 
differences observed between the novel mammalian endoribonuclease and Rpp35.
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3.1.3 Mapping the cleavage sites generated by Rpp35 endonucleolytic cleavage of CRD c- 
myc mRNA and comparing it to those of the native mammalian endoribonuclease.
To map and compare the cleavage sites generated by Rpp35 and the native mammalian 
endoribonuclease, a 12% polyacrylamide/7 M urea sequencing gel was used. The sequencing 
gel also included a hydroxyl ladder, which cleaves 3' after every nucleotide, and an RNase T1 
digestion, which cleaves 3' to single-stranded (ss) guanosines; the hydroxyl ladder and RNase T1 
digest were utilized to map cleavage sites generated by the dialyzed Rpp35 as compared to that 
of the native endoribonuclease complex.
The sequencing gel included three controls, the input S'-y^^P-radiolabelled CRD c-myc 
mRNA substrate, the substrate in reaction cocktail but with no enzyme, and 1.5 qg of another 
recombinant protein, p25 (Rpp25) (Figure 26, lanes 1, 4, and 7, respectively). As mentioned, 
this gel also included 3 qL of both a hydroxyl ladder and RNase T1 digest (Figure 26, lanes 2 
and 3, respectively), as well as the endonucleolytic cleavage fragments generated by 2 qL (1-5 
U) of heparin-sepharose purified native endoribonuclease and 1.5 qg of dialyzed Rpp35 (Figure 
26, lanes 5 and 6, respectively).
The cleavage fragments generated by Rpp35 are distinct and clearly not the same as that 
of the native mammalian endoribonuclease (Figure 26, lanes 6 and 5, respectively). In addition, 
Rpp35 does not appear to have the same cleavage specificity as the native mammalian 
endoribonuclease, which is known to preferentially cleave UA and CA di nucleotides, and to a 
lesser extent, UG di nucleotides (Tafech 2006) (Figure 26, lane 5, and Figure 5). There are 
eleven distinct cleavage fragments generated by Rpp35, and based on the mapping methods and 
MFOLD (Zuker et al. 1999) secondary structure determination utilized for the native 
endoribonuclease (Figure 27) (Tafech 2006), it was determined that Rpp35 cleaves at the
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following ss loop region dinucleotides: AA (nt 1758, 1733, 1732, 1725, 1724), AG (nt 1748, 
1731, 1717), GU (nt 1746) (Figure 26, lane 5, and Figure 27). Interestingly, Rpp35 also seems 
capable of cleaving double-stranded stem regions, which occurs twice between the di nucleotide 
GG (nt 1745 and 1721) (Figure 26, lane 5, and Figure 27). The 1.5 pg of Rpp25 did not appear 
to possess any enzymatic activity against the c-myc mRNA substrate (Figure 26, lane 7).
In summary, Rpp35 does not generate the same eleavage fragments as the native 
mammalian endoribonuclease against the 5'-y^^P-radiolabelled CRD c-myc mRNA substrate, and 
does not appear to share the same cleavage specificity. The differences in cleavage fragments 
and specifieity eould be due to the fact that: a) Rpp35 is not part of the native endoribonuclease 
complex, b) Rpp35 was not correctly refolded when dialyzed so exhibits altered activity, or c) 
Rpp35 is only one sub-unit of the native endoribonuelease complex (Bergstrom et al. 2006), and 
so exhibits altered cleavage action when expressed independently.
Nevertheless, Rpp35 possess' endoribonucleolytic activity against c-myc mRNA; a very 
exciting discovery in itself, as the Rpp35 trafficking protein, to our knowledge, has not been 
previously identified as having any nucleolytic properties.
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Figure 26. 12% polyacrylamide/7 M urea denaturing gel illustrating the differences
between the cleavage fragments of the native endoribonuclease and Rpp35. Lanes 1,4, and 
7 are negative controls, representing input substrate, input substrate in reaction m ixture, 
and 1.5 pg of Rpp25, respectively. Lanes 2 and 3 depict 3 pL samples of the hydroxyl 
ladder and RNase T1 digest, respectively. The cleavage fragments generated by 2 pL (1-5 
U) of heparin-sepharose purified native endoribonuclease and 1.5 pg of Rpp35 can he 
compared in lanes 5 and 6, respectively. The mapped cleavage sites are indicated on the 
left for the native endoribonuclease, and on the right for Rpp35. The RNA substrate is 
marked with a large solid black arrow on the top right.
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Figure 27. MFOLD predicted secondary structure of CRD c-myc mRNA (nts 1705-1792) 
(Zuker et a l  1999) with cleavage sites of both the native endoribonuelease (Tafech 2006) 
and Rpp35 indicated. The cleavage sites of the native mammalian endoribonuclease are 
indicated by thin black arrows, while the cleavage sites of Rpp35 are indicated with circles, 
unfilled white arrows, and underlined text.
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3.1.4 Using Western blot analysis to investigate the specificity of Rpp35 and 
phosphocellulose-purified native mammalian endoribonuclease to Rpp35-oligopeptide 
generated polyclonal antibodies.
Western blots rely on the highly-specific recognition of glycoproteins called antibodies to 
their complimentary antigen-binding sites, referred to as the epitope (Harlow and Lane 1999). A 
polyclonal source of antibodies was generated by Invitrogen (Invitrogen Corporation, Carlsbad, 
CA, USA), who injected rabbits with an oligopeptide sequence corresponding to Rpp35. 
Invitrogen supplied our lab with pre-bleed samples for negative controls, as well as polyclonal 
antibody sources from various weeks of the study. The polyclonal antibody source used for all 
experiments in this thesis was from a week 10 bleed. As the antibodies were developed from the 
Rpp35 oligopeptide sequence, it was anticipated that they would bind to the purified Rpp35, and 
this could then be used as a positive control to test to see if the antibodies also bound to the 
native mammalian endoribonuclease. If the antibodies cross-reacted with the native 
endoribonuclease it would be a very strong indication that Rpp35 is part of the active novel 
mammalian endoribonuclease complex.
A Western blot was performed on selected elution fractions from a Rpp35-purification 
procedure to evaluate the specificity of the antibody. The Western blot analysis included 10 pL 
of rainbow marker, 90 pg of HepG2 cell lysate, and 90 pg of bulk rat liver cell lysate (Figure 28 
(TOP), lanes 1, 2, and 3, respectively). The Western blot also included 0.168 pg of a pre-nickel 
column Rpp35-rich sample and 10 pL of Buffer B, pH 6.3 elution fractions 20, 28, 46, 49, 70, 
and 79 (Figure 28 (TOP), lane 4 and lanes 5, 6, 7, 8, 9, and 10, respectively). The corresponding 
12% SDS-PAGE analysis of the same fractions (review Figure 22, Chapter 2, Section 2.1.12) 
was also included in Figure 28.
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Figure 28. Western blot analysis of Rpp335-rich Buffer B, pH 6.3 elution fractions against 
Rpp35 oligopeptide generated polyclonal antibodies correlated with corresponding 12% 
SDS-PAGE. (TOP) Western blot: Lane 1 depicts the rainbow marker with respective 
molecular weight markers indicated on the left with black arrows. Lanes 2 and 3 represent 
90 pg of HepG2 and rat liver cell lysates, respectively, while lane 4 depicts 0.168 pg of pre­
nickel column Rpp35. 10 pL of Buffer B, pH 6.3 elution fractions 20, 28, 46, 49, 70, and 79 
are represented in lanes 5-10, respectively. (BOTTOM) 12% SDS-PAGE: Lane 1 depicts 
the protein marker, lane 2 depicts 5 pL of pre-nickel column Rpp35, and lanes 3-7 
represent 10 pL samples of Buffer B, pH 6.3 elution fractions 20, 28, 46, 49, 70, and 79, 
respectively. The white arrow on the right indicates the ~44 kDa protein associated with 
Rpp35 endoribonuclease activity.
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As was expected, the Rpp35 oligopeptide sequence-generated polyclonal antibody source 
contained an antibody specific for Rpp35; a conclusion based on the presence of the -4 4  kDa 
Rpp35 protein band seen in the Buffer B, pH 6.3 elution fractions 28, 46, 49, and 70, indicated 
by the white arrow to the right of the figure (Figure 28 (TOP), lanes 6, 7, 8, and 9, respectively). 
The primary antibody also detected and bound to Rpp35 present in the pre-nickel column 
sample, as evidenced by the presence of the -44  kDa band in this sample (Figure 28 (TOP), lane 
4). These data illustrate that the Rpp35 oligopeptide sequence-generated polyclonal antibody 
source contains an antibody that is specific to Rpp35.
When comparing the sizes of the protein bands generated by the rat liver and human 
HepG2 cell lysates, the question arose as to how similar the Rpp35 sequences would be in these 
two species. Using the Clustal W multiple sequence alignment program (NCBI), it was found 
that the human {Homo sapiens) Rpp35 amino acid sequence shares 96% (322/335 positive amino 
acid matches) sequence homology to the amino acid sequence of Rattus norvegicus (Altschul et 
al. 1997). According to the ExPASy uniPROT/Swiss database, human Rpp35-equivalent is a 
335 amino acid long protein with a calculated molecular weight of 38.674 kDa, while Rpp35- 
equivalent in Rattus norvegicus (334 amino acids long) has a calculated molecular weight of 
38.512 kDa (Gasteiger et al. 2003). For SDS-PAGE purposes, these very similar molecular 
weights can effectively be considered the same. When comparing these molecular weights with 
that of the -44  kDa human Rpp35 discussed here, it is important to keep in mind that this Rpp35 
protein also included an additional 20 amino acids, including a 6X-histidine tag, which most 
likely accounts for the discrepancies in the molecular weights.
The antibody appeared to cross-react with proteins in both the human HepG2 cell lysate 
and rat liver cell lysate, with multiple bands being detected in each sample (Figure 28, lanes 2
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and 3, respectively). The polyclonal antibody source cross-reacted with two bands in the HepG2 
cell lysate, with R / calculated molecular weights of -58  and -30  kDa (Figure 28, lane 2). 
Several possibilities exist to explain the unexpected size of these cross-reacting proteins. It is 
possible that the -58  kDa band in the HepG2 cell lysate is due to a dimer of two -30  kDa 
proteins, as the bonds formed by SNARE proteins have been demonstrated to be exceedingly 
stable, parallel coiled-coil complexes that can actually be SDS-resistant (Pfeffer 1999; Duman 
and Forte 2003). It is also possible that the -58  kDa protein band is larger then expected due to 
post-translational modifications. Another possibility is that the smaller molecular weight band 
(-30  kDa) in the HepG2 cell lysate could represent an alternatively spliced isoform that possess' 
a similar epitope, a proteolytically digested form of the original antigen, or even a different 
member of the same protein family.
The polyclonal antibody source also cross-reacted with the rat liver cell lysate, detecting 
three bands with R/calculated molecular weights of -56, -42, and -14  kDa (Figure 28, lane 3). 
The -56  kDa band is similar to that of the HepG2 -59  kDa band, in that the same possibilities 
exist to explain the molecular weight discrepancies. The rat liver cell lysate also contained a 
protein of -42  kDa, which is believed to be the Rpp35 equivalent in rats, although it could also 
represent an alternatively spliced isoform, a proteolytically digested form of the original antigen, 
or a different member of the same protein family. The third cross-reacting protein appears to be 
-14  kDa in size, which could represent one protein, explaining the other two larger protein bands 
as tri- and tetrameric isoforms.
Nevertheless, proteins were present in both the human HepG2 and rat liver cell lysates 
that cross-reacted with the Rpp35-specific polyclonal antibody source. While many possibilities 
exist to explain the size of the cross-reacting protein bands, the most plausible explanation for
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the discrepancies in the expected molecular weight of the bands observed in human HepG2 and 
rat liver cell lysates is that the Rpp35-equivalent protein in these cells is most likely bound to 
other proteins in a complex, hypothesized to be the native mammalian endoribonuclease 
complex.
A Western blot was also performed on the native mammalian endoribonuclease samples 
obtained throughout its purification procedure to test to see if the Rpp35-specific polyclonal 
antibody source would cross-react with the novel endoribonuclease. This Western blot included 
10 pL of rainbow marker, 90 pg of HepG2 cell lysate, and 90 pg of bulk rat liver cell lysate 
(Figure 29, lanes 1, 2, and 3, respectively). Also included was 130 pg of bulk liver salt wash 
(LSW), 233 pg of post-pH precipitated native mammalian endoribonuclease, and 56 pg of post- 
phosphocellulose (PC) purified native mammalian endoribonuclease (Figure 29, lanes 4, 5, and 
6, respectively). The last two samples were a 200 pL-10 pL acetone-precipitated aliquot of un­
quantified post-reactive blue-4 (RB4) purified native mammalian endoribonuclease and a 20 pL- 
10 pL acetone-precipitated aliquot of un-quantified Rpp35-rich Buffer B, pH 6.3 elution fraction 
50 (Figure 29, lanes 7 and 8, respectively).
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Figure 29. Western blot analysis of purified native endoribonnclease fractions against 
Rpp35 oligopeptide sequence-generated polyclonal antibodies. Lane 1 depicts the rainbow 
marker with respective molecular weight markers indicated on the left with black arrows. 
Lanes 2 and 3 represent 90 pg of HepG2 and rat liver cell lysates, respectively, while lane 4 
depicts 132 pg of bulk liver salt wash. Lane 5 represents 233 pg of post-pH precipitated 
native endoribonuclease while lane 6 depicts 56 pg of phosphocellulose purified native 
endoribonuclease. Lanes 7 and 8 represent 200 pL of reactive blue 4 purified native 
endoribonuclease and 20 pi of Rpp35-rich Buffer B, pH 6.3 elution fraction 50, 
respectively. The white arrow on the right indicates the ~44 kDa protein associated with 
Rpp35 endoribonuclease activity while the black arrow indicates the native 
endoribonuclease.
The Rpp35-specific antibody was found to cross-react and detect the native mammalian 
endoribonuclease, as illustrated by the -35 kDa band present in the post-phosphocellulose 
purified native endoribonuclease sample (Figure 29, lane 6, indicated by black arrow to the right 
of figure). The native endoribonuclease band (-35 kDa) is not visible in the post-pH precipitated
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or post-reactive blue 4 fractions (Figure 29, lanes 5 and 7, respectively). It is believed that the 
-35  kDa protein is still bound to the native mammalian endoribonuclease complex in the post- 
pH precipitated sample, which explains the absence of the -35  kDa protein band in this sample 
(Figure 29, lane 5). It is also believed that the reactive blue 4-purified native endoribonuclease 
failed to cross-react with the antibody because there was simply not enough of this protein 
loaded onto the gel. Unfortunately, this pitfall could not be avoided as this Western blot used the 
last remaining aliquot of the reactive blue 4 purified native endoribonuclease. This experiment 
was also previously attempted by another Lee lab member, and their results indicated that the 
purified native endoribonuclease fractions, up to reactive blue 4, were all detected by an antibody 
specific to Rpp35, provided to us from the same collaborators in Japan who provided us with the 
original Rpp35ATMD in the pQE31 plasmid (data not shown).
As was the case with the Rpp35 Western blot, the HepG2 and rat liver cell lysates in the 
native mammalian endoribonuclease Western blot generated the same protein bands, as was 
discussed earlier. The bulk liver salt wash and pH precipitated native endoribonuclease fractions 
both generated protein bands with R / calculated molecular weights of -46  kDa, and appeared to 
be slightly larger than the Rpp35-rich Buffer B, pH 6.3 elution fraction 50 indicated by the white 
arrow to the right of the figure (Figure 29, lanes 3 and 5, respectively). The two smaller proteins 
that also cross-reacted in the bulk liver salt wash and pH precipitated native endoribonuclease 
fractions have an apparent molecular weight of -10  kDa. One possibility to explain these 
smaller bands is that perhaps these small proteins dissociated from the novel mammalian 
endoribonuclease complex, and in doing so, lowered the molecular weight of the complex from 
-56  kDa to -46  kDa.
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Due to the technique used to determine the approximate molecular weights of these 
protein bands, in association with the large number of possible explanations for the discrepancies 
observed in the expected molecular weights of these bands, it is difficult to come to any firm 
conclusions regarding some of the data presented in these Western blots. Nevertheless, the 
polyclonal antibody source that was generated in rabbits from the oligopeptide sequence of 
Rpp35 successfully reacted with Rpp35 and cross-reacted with the native mammalian 
endoribonuclease (up to post reactive blue-4 native enzyme samples), indicating that these two 
proteins are similar enough to each other that the highly specific antibody can recognize and bind 
to both of their epitopes. While this fact alone does not definitively prove that they are the same 
protein, it provides support for the notion that Rpp35 is present in the successively purified 
native mammalian endoribonuclease fractions, and further strengthens the hypothesis that 
cellular Rpp35 is associated with other proteins in a complex, believed to be the native 
mammalian endoribonuclease complex.
3.1.5 Performing and visualizing immunoprécipitation experiments on Rpp35 and native 
mammalian endoribonuclease, and then testing these immunoprecipitated fractions for 
depleted endoribonuclease activity.
Immunoprécipitation experiments were conducted in an attempt to further support the 
hypothesis that the Rpp35 is a protein sub-unit of the native mammalian endoribonuclease 
complex. If the polyclonal antibody source could precipitate both the Rpp35 and the native 
mammalian endoribonuclease and then demonstrate depleted endoribonucleolytic activity in the 
immunoprecipitated fractions, we would be able to conclude with more confidence that Rpp35 
does, in fact, represent a sub-unit of the native endoribonuclease complex.
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3.1.5.1 Immunoprécipitation:
Immunoprécipitation of Rpp35 was attempted using a Pieree Seize X Protein A 
Immunoprécipitation kit. As the components of this kit are not compatible with primary amine 
buffers, such as Tris-based buffers, it was necessary to first dialyze the Rpp35 out of the Tris- 
based Buffer B-without urea and into a non-primary amine based buffer. This was aceomplished 
by using the same buffer replacement/dialysis eombination that was used to successfully dialyze 
the original Rpp35-rich elution fractions (Chapter 2, Section 2.0.14), except the buffer used here 
was a HEPES buffer (detailed earlier in methods). The general methods used for these two 
immunoprécipitation experiments are summarized on the next page (Figure 30).
The first gel of this immunoprécipitation experiment included 10 pL of rainbow marker, 
and 10 pL (3.850 pg) of HEPES-dialyzed Rpp35 as a control (Figure 31 A, lanes 1 and 2, 
respectively). Ten pL of the 10 kDa Nanosep®-centrifuged pre-sera and sera flow-through 
fractions I, 2, and 3 were also included (Figure 31 A, lanes 3 and 4, 5 and 6, and 7 and 8, 
respectively). The second gel represented the elution fractions generated in this 
immunoprécipitation experiment. This gel included 10 pL of rainbow marker, and 10 pL (3.850 
pg) of HFPFS-dialyzed Rpp35 as a control (Figure 3 IB, lanes 1 and 4, respectively). Ten pL 
samples of HFPFS-dialyzed pre-sera and sera elution fractions 1, 2, and 3 were also included 
(Figure 3 IB, lanes 2 and 3, 5 and 6, and 7 and 8, respectively).
154
W ash Steps
Elution Fraction 2Elution Fraction 1 Elution Fraction 3
Wash Steps
Wash Steps
Rpp35 (in Tris)
250 pL (129.5 pg)
Rpp35 (in Hepes)
Nutated at 4"C O/N
Flow-through  
Fraction 3
Flow-through  
Fraction 1
Flow-through  
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Protein A Sepharose (400 pL)
N utated at RT for I hr
+ 200 pL Pre- 
Sera in 200 pL 
H epes Buffer
+ 200 pL Sera  
in 200 pL 
H epes Buffer
C rosslinked Ab with DSS  
resuspended in DM SO
Pooled elution fractions 
concentrated by Nanosep  
to <50 pL
Eluted Ab-bound proteins 
Four X 200 pL elution fractions
5 pL used for endoribonuclease  
assay to test for depleted  
enzym e activity
Figure 30. Immunoprécipitation procedure outline. Note that the volumes and total 
protein indicated in this scheme are those used in the second immunoprécipitation attempt.
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Figure 31. Western blot visualization of attempted immunoprécipitation of Rpp35 using 
Pierce Seize X kit with HEPES buffer. ^  Lane 1 represents 10 pL of rainbow marker, 
while lane 2 depicts 10 pL (3.850 pg) of HEPES-dialyzed Rpp35. Lanes 3 and 4, 5 and 6, 
and 7 and 8 represent 10 pL of the pre-sera and sera flow-through fractions 1, 2, and 3, 
respectively. ^  Lane 1 represents 10 pL of rainbow marker, while lane 4 depicts 10 pL 
(3.850 pg) of HEPES-dialyzed Rpp35. Lanes 2 and 3 ,5  and 6, and 7 and 8, represent 10 pL 
samples of HEPES-dialyzed pre-sera and sera elution fractions 1, 2, and 3, respectively. 
The white arrow on the left indicates the -44 kDa Rpp35 while the black arrow on the right 
indicates the suspected -55 kDa IgG heavy chain.
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The larger number of protein bands detected in both the pre-sera and sera flow-through 
fractions 1 (Figure 31 A, lanes 3 and 4) were expected, as these fractions represent any excess 
proteins and/or antibodies present in the polyclonal antibody source that did not get bound by the 
poly(A) sepharose beads. It was anticipated that the pre-sera of flow-through fraction 3 would 
have more Rpp35 than the sera fraction, because the sera sample should contain Rpp35-specific 
antibodies that bind and sequester the protein. This was not the case for the flow-through 3 
samples, however, and it was the sera samples that appeared to react with the antibodies in both 
flow-through fractions 2 and 3 (Figure 31 A, 5 and 6, and 7 and 8, respectively). Furthermore, it 
was anticipated that the sera elution fractions would contain more Rpp35 than their pre-sera 
counterparts, and while this was the case, the molecular weights of the reacting proteins did not 
correspond to the -44  kDa molecular weight of Rpp35 (Figure 3 IB, lanes 2 and 3, 5 and 6, and 7 
and 8, as compared to lane 4). To summarize, the immunoprécipitation of Rpp35 was not 
successful under these conditions; a conclusion based on the lack of detection of the -44  kDa 
Rpp35 protein band in any of the elution fractions (Figure 3 IB, lanes 2 and 3, and 5-8).
Antibodies are composed of both heavy and light chain regions; the IgG heavy chain in 
humans is known to have an SDS-PAGE molecular weight of -55 kDa while the light chain of 
IgG in humans can vary, but usually migrates at -22.5-28 kDa (Harlow and Lane 1999). The 
protein bands detected in the sera flow-through and elution fractions appear to have molecular 
weights that correlate with the heavy chain of IgG (-55 kDa), and not the -4 4  kDa Rpp35 band 
(Figures 31 A, lanes 6 and 8, and Figure 3 IB, lanes 5, 6, and 8, indicated by black arrow to the 
right of the figure as compared to white arrow to the left). To confirm this suspicion and 
evaluate the effectiveness of this approach for the visualization of immunoprécipitation, the two 
gels were stripped, and then re-probed with only the IgG HR? secondary antibody in an effort to
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determine if the observed bands were due to the detection by the primary or secondary antibody 
(Figures 32A and 32B).
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Figure 32. Visualization of the re-probing of the immunoprécipitation Western blot of 
Rpp35 with secondary antibody only. ^  Lane 1 represents 10 pL of rainbow marker, 
while lane 2 depicts 10 pL (3.850 pg) of HEPES-dialyzed Rpp35. Lanes 3 and 4, 5 and 6, 
and 7 and 8 represent 10 pL of the pre-sera and sera flow-through fractions 1, 2, and 3, 
respectively. ^  Lane 1 represents 10 pL of rainbow marker, while lane 4 depicts 10 pL 
(3.850 pg) of HEPES-dialyzed Rpp35. Lanes 2 and 3 ,5  and 6, and 7 and 8, represent 10 pL 
samples of HEPES-dialyzed pre-sera and sera elution fractions 1, 2, and 3, respectively. 
The white arrow on the left indicates the normal migration position of the -44 kDa Rpp35 
while the black arrow on the right indicates the -55 kDa IgG heavy chain.
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The results from the re-probing of the immunoprécipitation Western blot with only the 
secondary antibody indicated that all of the protein bands detected in both the flow-through 
fractions and elution fractions were due to the secondary antibody source, which can be seen by 
comparing Figures 32A and 32B to 31A and 3 IB. The only protein band missing in both of the 
re-probed blots was the -44 kDa Rpp35 control (Figures 32A and 32B, lanes 2 and 4, 
respectively), which can clearly be seen in the original blots (Figures 31A and 3 IB, lanes 2 and 
4, respectively).
These results bring about several conclusions. First, the fact that the Rpp35 protein was 
not detected by the secondary antibody confirmed that the primary antibody source contains an 
antibody specific to Rpp35. Second, the fact that the -55 kDa bands, among others, persisted in 
the secondary antibody-only probed Western blot confirms our suspicions that these protein 
bands were due to the secondary antibody, most likely the heavy chain of IgG, and not due to 
proteins within the pre-sera or sera fractions associating with Rpp35. Finally, these results 
indicate that for our purposes, due to high background detection of heavy chain IgG, Western 
blot may not be a sensitive enough technique for evaluating immunoprécipitation efficiency. 
Based on these conclusions, we shifted our efforts, and concentrated on directly testing the 
immunoprecipitated fractions for depleted endoribonucleolytic activity.
3.1.5.2 Performing endoribonuclease assays to test if the samples generated from the 
immunoprécipitation attempts effectively depleted endoribonucleolytic activity.
Two endoribonuclease assays were conducted in an attempt to determine if the 
endoribonuclease activity of Rpp35 was depleted using the Rpp35 oligopeptide sequence­
generated polyclonal antibodies. These two experiments were carried out as outlined in the 
methods section.
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The gel generated from this endoribonuclease assay included the radiolahelled c-myc 
mRNA input substrate, 1.5 pL (1-5 U) of heparin-sepharose purified native mammalian 
endoribonuclease, and 3 pL (1.554 pg) of HEPES-dialyzed Rpp35 as controls (Figure 33, lanes 
1, 6, and 7, respectively). This gel also included 4 pL of pre-sera and sera flow-through fractions 
3A and 3B (Figure 33, lanes 2 and 3, and 4 and 5, respectively). Four pL of the pre-sera and sera 
elution fractions 1, 2, and 3, were also included (Figure 33, lanes 8 and 9, 10 and 11, and 12 and 
13, respectively). The y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792) is 
indicated by the solid black arrow to the top right of the figure (Figure 33).
It was anticipated that the first set of flow-through fractions (flow-through fractions 3A) 
depicted would exhibit a small amount of Rpp35 activity, and that the pre-sera activity would be 
more prevalent than that of the sera sample. This was based on the expectation that Rpp35 
would bind to the Rpp35 antibody-containing sera, and the majority of the Rpp35 would remain 
in the spin cup and not elute in the first centrifugation step. Conversely, it was anticipated that 
the Rpp35 would not bind to the pre-sera, and would then wash out in the first centrifugation 
step. Furthermore, it was expected that the sera elution fractions would exhibit Rpp35 activity, 
and the pre-sera elution fractions would show little or depleted activity.
The results from this enzyme activity depletion experiment were not as expected, as 
Rpp35 endoribonuclease activity was not observed in any of the flow-through fractions (Figure 
33, lanes 2-5) or in elution fractions 2 or 3 (Figure 33, lanes 10-13), as compared to that of the 
Rpp35 control (Figure 33, lane 7). Differences can be seen, however, between the pre-sera and 
sera samples from elution fraction 1 (Figure 33, lanes 8 and 9, respectively). It is difficult to 
attribute the darkened lane of the sera elution fraction 1 to the activity of Rpp35, as there does 
not appear to be any clear, distinct protein bands characteristic of Rpp35 cleavage (Figure 33,
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lane 9 as compared to lane 7). The very faint cleavage products observed in the sera elution 1 
sample are the same bands observed in the RNA substrate control, and the same faint bands 
observed in almost all of the samples. As discussed earlier, these faint background bands are 
most likely due to slight contamination with RNase A.
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Figure 33. Endoribonuclease assay depicting attempted depletion of Rpp35 activity using 
Rpp35-specific polyclonal antibodies. Lane 1 represents the control RNA substrate, while 
lanes 6 and 7 represent the other two controls: 1.5 pL (1-5 U) of heparin-sepharose purified 
native endoribonuclease and 3 pL (1.554 pg) of HEPES-dialyzed Rpp35, respectively. 
Lanes 2 and 3 depict 4 pL of the pre-sera and sera flow-through fractions 3A, while lanes 4 
and 5 represent 4 pL of the pre-sera and sera flow-through fractions 3B. Lanes 8 and 9 
depict 4 pL samples of the pre-sera and sera elution fractions 1, lanes 10 and 11 represent 4 
pL samples of the pre-sera and sera elution fractions 2, and lanes 12 and 13 depict the 4 pL 
samples of pre-sera and sera elution fractions 3. The solid black arrow to the right 
indicates the radiolahelled input RNA substrate.
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At this time it was believed that the laek of observable enzyme activity was due to the 
fact that not enough protein was loaded, therefore not enough of the protein was present to 
cleave the RNA. Based on this hypothesis, the second attempt at depleting enzymatic activity 
involved both the phosphocellulose-purified native mammalian endoribonuclease (9.412 ng/pL) 
and HEPES dialyzed-Rpp35 (0.518 pg/pL), but at the much higher protein concentrations of 2.4 
pg (250 pL) and 129.5 pg (250 pL), respectively.
The gel generated from this endoribonuclease assay included the radiolahelled c-myc 
mRNA input substrate, 1.5 pL (1-5 U) of heparin-sepharose purified native mammalian 
endoribonuclease, and 3 pL (1.554 pg) of HEPES-dialyzed Rpp35 as controls (Figure 34, lanes 
1, 2 and 15, and 3, respectively). Four pL of the Rpp35 pre-sera and sera flow-through fractions 
3A (Figure 34, lanes 4 and 5), as well as 4 pL of the Rpp35 pre-sera and sera elution fractions 1 
and 2 (Figure 34, lanes 6 and 7, and 8 and 9, respectively) were also added. This gel also 
included 2 pL (1-5 U) of phosphocellulose purified native mammalian endoribonuclease as a 
control (Figure 38, lane 10), and 4 pL of the native mammalian endoribonuclease pre-sera and 
sera elution fractions 1 and 2 (Figure 38, lanes 11 and 12, and 13 and 14, respectively). The 
y^^P-radiolabelled CRD c-myc mRNA substrate (nts 1705-1792) is indicated by the solid black 
arrow to the top right of the figure (Figure 34).
The expectations of this gel were the same as the first attempt discussed earlier, as the 
only differences were the amount of protein loaded. Unfortunately this experiment was 
unsuccessful at depleting the activity of Rpp35 using the Rpp35 oligopeptide sequence-generated 
polyclonal antibody source; a conclusion based on the fact that no detectable obvious differences 
were observed between any of the pre-sera and sera samples (Figure 34, lanes 4-9).
162
Furthermore, no distinct cleavage products characteristic of Rpp35 were observed in any of the 
Rpp35-generated samples (Figure 34, lanes 4-9).
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Figure 34. Endoribonuclease assay depicting attempted depletion of the enzymatic activity 
of Rpp35 and the native mammalian endorihonuclease using Rpp35-specific polyclonal 
antibodies. Lane 1 represents the control RNA substrate, lanes 2 and 15 represent 1.5 pL 
(1-5 U) of heparin-sepharose purified native endorihonuclease, and lane 3 depicts 3 pL 
(1.554 pg) of HEPES-dialyzed Rpp35. Lanes 4 and 5 depict 4 pL of the Rpp35 pre-sera 
and sera flow-through fractions 3A. Lanes 6 and 7 depict 4 pL samples of the Rpp35 pre­
sera and sera elution fractions 1, while lanes 8 and 9 represent 4 pL samples of the Rpp35 
pre-sera and sera elution fractions 2. Lane 10 represents 2 pL (1-5 U) o f phosphocellulose- 
purifled native endorihonuclease. Lanes 11 and 12 depict 4 pL samples of the native 
endorihonuclease pre-sera and sera elution fractions 1, while lanes 13 and 14 represent 4 
pL samples of the native endorihonuclease pre-sera and sera elution fractions 2. The solid 
black arrow to the right indicates the radiolahelled input RNA substrate. The white 
arrows to the right indicate the cleavage fragments generated by the native 
endorihonuclease sera elution fraction 1.
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Excitingly, the novel mammalian endoribonuclease sera elution fraction 1 appeared to 
exhibit some nucleolytic activity, where its pre-sera counterpart contained none (Figure 34, lanes 
11 and 12, respectively). Some of the cleavage fragments generated by this sera sample appear 
to correlate with those produced by the novel mammalian endoribonuclease controls (Figure 34, 
lane 12 compared to lanes 2, 10, and 15, indicated by the two upper white arrows). However, 
some cleavage fragments were also generated that appear to correlate with those produced by 
Rpp35 (Figure 34, lane 12 compared to lane 3, indicated by the bottom white arrow). It is 
difficult to come to any firm conclusions regarding these interesting, yet somewhat conflicting 
data. Based on these results, it is believed that future immunoprécipitation experiments using 
much more native mammalian endoribonuclease protein could effectively and convincingly 
deplete the activity of the native mammalian endoribonuclease. Unfortunately this experiment 
exhausted all supplies of phosphocellulose-purified native mammalian endoribonuclease, so the 
experiment could not be repeated.
In summary, all attempts at immunoprecipitating and/or depleting the activity of Rpp35 
were unsuccessful. It was determined earlier that Rpp35 was ~90% insoluble and -10%  soluble 
when lysed from the BL21 cells (Chapter 2, Section 2.1.8). While it was acknowledged that 
immunoprécipitation experiments generally can not be conducted on insoluble proteins (Harlow 
and Lane 1999; Qiagen 2003), it was hoped that enough of the Rpp35 protein would be soluble 
to effectively visualize immunoprécipitation and/or the depletion of Rpp35 activity. It had also 
been observed that the Rpp35 precipitated out of solution during dialysis out of the urea-based 
buffer, and that upon gently suspending the Rpp35 precipitate in solution, the homogenous 
Rpp35 mixture exhibited endoribonuclease activity. Based on these facts, and in association 
with the results obtained in the immunoprécipitation and enzymatic activity-depletion
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experiments, it is believed that these two experiments were unsuceessful due to the relative 
insolubility of the protein. While the native mammalian endoribonuclease also failed to be 
immunoprecipitated as visualized by Western blot analysis, and was found to generate 
inconclusive data in its respective enzymatic activity-depletion experiment, it is believed that the 
Rpp35 ol i gopep tide-sequence generated polyclonal antibody source could effectively 
immunoprecipitate and deplete the enzymatic activity of the soluble native mammalian 
endoribonuclease. For such an experiment to be a success, however, would require a sufficient 
amount of native endoribonuclease, and significantly higher endoribonuclease protein content 
than the experiments outlined here.
3.2 Chapter Summary:
This chapter outlined several characterization experiments conducted on Rpp35, as well 
the native endoribonuclease enzyme complex, in an effort to further characterize the novel 
mammalian endoribonuclease, and in an attempt to determine whether Rpp35 is, in fact, a sub­
unit of the native endoribonuclease complex.
The first characterization experiment involved the size-exclusion separation of two 
proteins (-85 and -98  kDa) that were found to co-elute with Rpp35 in the Buffer B, pH 6.3 
elution fractions. 12% SDS-PAGE analysis confirmed the successful removal of these two 
proteins from the Rpp35 fraction, and subsequent endoribonuclease assay testing of this fraction 
against the radiolabelled CRD c-myc mRNA substrate confirmed that the endoribonucleolytic 
activity observed was due to the -44  kDa Rpp35, and not associated with the two removed 
proteins.
The endoribonuclease activity of Rpp35 was demonstrated to be unique by comparing its 
activity against the radiolabelled CRD c-myc mRNA substrate to that of three other recombinant
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proteins, RpCRD-BP, Rpp21, and Rpp40, as well as to the cleavage activity of the native 
mammalian endoribonuclease. Only Rpp35 generated conclusive cleavage fragments, 
illustrating that not any recombinant protein is capable of cleaving the CRD of c-myc mRNA. 
More significantly, the results from this experiment indicated that Rpp35 was generating distinct 
cleavage fragments from that of the native mammalian endoribonuclease.
These results prompted the use of a larger sequencing gel, in association with a hydroxyl 
ladder and an RNase T1 digest, to allow for a better comparison of the cleavage fragments of 
Rpp35 and the native endoribonuclease. This experiment also permitted the mapping of the 
cleavage fragments, and based on the MFOLD-predicted secondary structure of the CRD c-myc 
mRNA substrate, allowed for the determination of cleavage specificity. It was determined that 
the cleavage fragments generated by Rpp35 are unique, and clearly not the same as that of the 
native endoribonuclease. There are eleven distinct cleavage fragments generated by Rpp35, and 
based on the mapping methods and secondary structure determination utilized for the native 
endoribonuclease (Tafech 2006), it was determined that Rpp35 cleaves at the following single­
stranded loop region dinucleotides AA, AG, and GU, as well as the double-stranded stem region 
dinucleotide GG. This is in direct contrast to the cleavage specificity of the native 
endoribonuclease, which is known to preferentially cleave UA and CA dinucleotides, and to a 
lesser extent, UG dinucleotides (Bergstrom et al. 2006).
To further evaluate the similarities between Rpp35 and the native mammalian 
endoribonuclease, Western blot experiments were conducted on both proteins using a polyclonal 
antibody source generated in rabbits against the Rpp35 oligopeptide-sequence generated antigen. 
The polyclonal antibody source was confirmed to be specific to Rpp35. The antibody was also
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found to cross-react with the native mammalian endoribonuclease, indicating that Rpp35 is likely 
to be present in the native endoribonuclease complex.
Immunoprécipitation and enzyme activity-depletion of Rpp35 were not successful under 
any of the conditions used. One possibility to explain this is the general insolubility of Rpp35. It 
is believed that the novel mammalian endoribonuclease was not conclusively shown to have its 
endoribonucleolytic activity depleted because too little of the native endoribonuclease was used. 
It is hypothesized that subsequent immunoprécipitation and enzyme activity-depletion 
experiments conducted on the native mammalian endoribonuclease could be successful using a 
much higher total novel endoribonuclease protein content.
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CHAPTER 4 - GENERAL DISCUSSION
4.0 General Overview
The main goal of this thesis was to characterize the human recombinant protein p35 
(Rpp35) in an effort to identify the native mammalian endoribonuclease capable of degrading the 
CRD of c-myc mRNA in vitro. Five proteins were found to co-purify with the native 
endoribonuclease activity (Bergstrom et at. 2006), with one of these proteins having a molecular 
weight of -35 kDa. Trypsin digestion of this -35  kDa protein, followed by MALDI-mass 
spectroscopy and subsequent database searching, found a protein, referred to here as Rpp35, that 
matched four of the -35 kDa protein's tryptic peptides. The first aim of this thesis was to 
generate, purify, re-fold, and then test human Rpp35 for endoribonuclease activity. The second 
aim of this thesis was to perform five main characterization experiments on Rpp35 in an attempt 
to elucidate the identity of the -35  kDa protein that co-purified with the novel mammalian 
endoribonuclease.
The scientific community's current lack of overall knowledge regarding 
endoribonucleases, in association with the emerging role of endoribonucleases as key players in 
post-transcriptional regulation of gene expression, including c-myc gene expression, emphasizes 
the importance of studying and identifying this novel group of enzymes. Considering that c-myc 
has been demonstrated to be a key player in neoplasia (Facchini and Penn 1998; Catapano et al. 
2000; Hermeking 2003; Wang et al. 2005), and currently contributes to -1 /7  of all cancer 
fatalities annually (Dang 1999; Dang et al. 1999), finding ways to control and regulate c-myc 
expression is paramount in the battle against cancer.
To date, there are only four known previously described endoribonucleases capable of 
degrading c-myc mRNA in vitro: the 52 kDa RasGap-associated G3BP (Tourriere et al. 2001;
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Barnes et al. 2002), a -65  kDa RNase E-like endoribonuclease (Wennborg et al. 1995), a -39  
kDa endoribonuclease (Lee et al. 1998), and the novel mammalian endoribonuclease (Bergstrom 
et al. 2006), which is the focus of this thesis. While we know that these four reported 
endoribonucleases can cleave c-myc mRNA, do they possess other similarities as well?
4.1 Comparison of native mammalian endoribonuclease to Rpp35
While the endoribonucleolytic activity of the native mammalian endoribonuclease is 
associated with 5 proteins, it has been hypothesized that it is the -35  kDa protein that is 
responsible for the cleavage event. Is Rpp35 the -35  kDa protein that makes up a component of 
the native mammalian endoribonuclease complex? The following sections compare support for 
and against this hypothesis.
4.1.1 Evidence that supports the hypothesis that Rpp35 makes up a component of the 
native mammalian endoribonuclease
Gel-purification of the -35 kDa protein component of the novel mammalian 
endoribonuclease complex, followed by trypsin digestion, MALDI mass spectroscopy, and 
subsequent NCBI database comparisons of the masses of the 22 generated peptide fragments 
found a protein in Mus musculus, referred to as Rpp35, that had four matching peptide 
fragments, with an overall sequence homology of 16% (Altschul et al. 1997). NCBI protein 
sequence BLAST comparisons (Altschul et al. 1997) of these four individual peptide fragments 
were found to have 100% sequence homology to Mus musculus Rpp35. Significant sequence 
homology (>86% sequence homology, with conserved amino acid substitutions) was also found 
in Homo sapiens and Rattus Norvegicus Rpp35. No putative conserved domains were found in 
any of these short peptide fragments.
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Unfortunately the original SDS-PAGE gel that was used for the gel-purification of the 
-35 kDa protein was stained with silver-stain, which is known to interfere with the peptide 
identification strategy discussed above, so the exact amino acid sequence of the native 
mammalian endoribonuclease -35 kDa protein was unable to be determined. Nevertheless, the 
fact that four peptide matches were made, with all four sharing 100% sequence homology to Mus 
musculus Rpp35 and >86% sequence homology to the Rpp35 of Homo sapiens and Rattus 
norvegicus, supports the notion that the -35 kDa protein of the native mammalian 
endoribonuclease complex is Rpp35.
Adding further support to the hypothesis that Rpp35 is a part of the native mammalian 
endoribonuclease complex is the fact that both Rpp35 and the native mammalian 
endoribonuclease have both been demonstrated to endonucleolytically degrade single- and 
double-stranded c-myc mRNA in vitro. Furthermore, Western blot analysis demonstrated that 
the Rpp35 oligopeptide sequence-generated polyclonal antibody source was not only specific to 
Rpp35, but also cross-reacted with human HepG2 cell lysate, rat liver cell lysate, and the pH- 
precipitated and phosphocellulose-purified native mammalian endoribonuclease. This 
demonstrates that a protein, believed to be the -35  kDa protein of the native mammalian 
endoribonuclease complex, that cross-reacted with the Rpp35 polyclonal antibody source was 
present in each subsequent step of the native endoribonuclease purification procedure. While 
this does not provide definitive proof that the -35  kDa protein and Rpp35 are the same protein, it 
does provide support for the notion that either Rpp35 or a related family member (with similar 
epitope) makes up a component of the native mammalian endoribonuclease complex.
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4.1.2 Evidence that does not support the hypothesis that Rpp35 makes up a component of 
the native mammalian endoribonuclease
It has been determined that the native mammalian endoribonuclease is capable of 
degrading single- and double-stranded CA dinucleotides, as well as single-stranded UA, UG, and 
CA dinucleotides within the CRD of c-myc mRNA (Bergstrom et al. 2006; Tafech 2006). In 
addition, this enzyme was found to cleave mRNAs other then CRD c-myc, including (3-globin 
RNA (nts 50-169), multi-drug resistance 1 (M DRl) RNA (nts 745-922), and the 5'-UTR of c- 
myc RNA (nts 1-217), which suggests that the endoribonuclease is sequence-specific, and not 
substrate-specific (Bergstrom et al. 2006). While Rpp35 has also been demonstrated to cleave 
both single- and double-stranded CRD c-myc mRNA, it's cleavage specificity is very different 
than that of the native mammalian endoribonuclease. It was determined that Rpp35 specifically 
cleaves single-stranded AA, AG, and GU dinucleotides, as well as GG dinucleotides found in 
double-stranded stem loop regions. Rpp35 has not yet been tested against other RNAs, so it is 
difficult to state whether Rpp35 is sequence or substrate-specific.
The calculated molecular weight of human Rpp35 is 38.674 kDa (Gasteiger et al. 2003), 
but with a 6XHistidine tag, has been demonstrated to have a 12% SDS-PAGE molecular weight 
of ~44 kDa. The calculated molecular weights of the Mus musculus and Rattus norvegicus 
Rpp35-equivalents are 35.512 kDa and 38.512 kDa, respectively (Gasteiger et al. 2003). In 
contrast, the molecular weight of the novel mammalian endoribonuclease protein isolated from 
rats has been found to be -35 kDa on SDS-PAGE. While the differences between these 
molecular weights is not significant, it does suggest that these two proteins may not be the same.
Immunoprécipitation experiments using Rpp35-specific antibody were also unable to 
support the hypothesis that Rpp35 is the -35  kDa protein component of the native mammalian
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endoribonuclease complex, as immunoprécipitation of both Rpp35 and the native mammalian 
endoribonuclease were unsuccessful. Subsequent testing of these immunoprecipitated fractions 
for depleted enzyme activity also failed to generate conclusive data, although it is worth noting 
that slight enzymatic activity was observed in the sera elution sample of the native mammalian 
endoribonuclease that was not seen in its respective pre-sera fraction.
Table 4, on the next page, compares the evidence supporting and not supporting the 
hypothesis that Rpp35 is the same protein as the ~35 kDa protein component of the native 
mammalian endoribonuclease complex. Clearly more experimental work needs to be conducted 
in order to definitively conclude whether or not the -35  kDa protein component of the native 
mammalian endoribonuclease complex is Rpp35. Table 5, on page 174, summarizes the 
characteristics of the novel mammalian endoribonuclease and Rpp35, and illustrates the large 
number of characterization experiments that still need to be conducted on Rpp35 in order to 
come to any firm conclusion regarding the identity of the -35 kDa protein component of the 
native mammalian endoribonuclease complex.
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Table 4. Evidence supporting and not supporting the hypothesis that Rpp35 is the same 
protein as the ~35 kDa protein component of the native mammalian endorihonuclease 
complex.
Evidence supporting hypothesis Evidence not supporting hypothesis
Trypsin digest and MALDI-MS followed by 
subsequent database searching found significant 
sequence homology matches to the peptide 
fragments of the ~35 kDa protein component of 
the native mammalian endoribonuclease to 
Rpp35 in several species
Rpp35 and the native mammalian endoribonuclease 
have been demonstrated to have zero sequence 
specificity overlap
Both the native mammalian endoribonuclease 
and Rpp35 can endonucleolytically degrade 
single- and double-stranded CRD c-myc mRNA 
in vitro
The molecular weight of the native mammalian 
endoribonuclease protein isolated from rats has been 
found to be ~35 kDa on SDS-PAGE, which does not 
correlate with the calculated molecular weight of either 
Rpp35 in Homo sapiens (38.674 kDa) or in Rattus 
norvegicus (38.512 kDa), or to the Homo sapiens 
6XHis-Rpp35 that has a SDS-PAGE molecular weight 
of -44  kDa.
Western blot analysis confirmed that the Rpp35- 
specific polyclonal antibody source detected 
Rpp35 and cross-reacted with a protein that is 
present in each subsequent step of the native 
endoribonuclease purification procedure.
All immunoprécipitation experiments and subsequent 
testing for depleted enzymatic activity failed to 
generate any conclusive data that supports the notion 
that Rpp35 and the -35  kDa protein of the native 
mammalian endoribonuclease complex are the same
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Table 5. Comparison of native mammalian endoribonuclease and Rpp35 characteristics
and properties tested to date.
Characteristic NativeEndoribonuclease Rpp35 Summary
RNA Cleaved c-myc, P-globin, MDRl c-myc, (no others tested) Both cleave c-myc RNA
c-myc Cleavage Sites
CA: nts 1727, 1742, 1766, 
1758, 1771, & 1775; UA: 
1751, 1757, % 1773; UG: 
1730; others: CC: 1740 & 
1741; UU; 1750
AA: nts 1724, 1725, 1732, 
1733 & 1758; AG: nts 
1717, 1731, & 1748; GU: 
nt 1746; GG: nts 1721 & 
1745
No cleavage site 
similarities
Cleavage Specificity ss CA, UA, and UG dinucleotides in coding region
ss AA, AG, and GU and 
ds GG dinucleotides in the 
coding region
No cleavage specificity 
overlap
Cleaves DNA-RNA duplexes No unknown -
Size 5 proteins, 1 at -35 kDa, 4 at 
10-25 kDa
1 protein, calculated: 38.6 
kDa in humans, 6XHis- 
Rpp35: -44 kDa
Molecular weights do 
not match
Rpp35 antibody-specific Yes Yes Both specific to same antibody
Immunoprecipitated Inconclusive No (solubility issues) Neither
immunoprecipitated
Soluble in 50 mM HEPES Yes Partially, suspended particulate -
Endoribonucleolytically activity in 
HEPES Buffer Yes Yes
Both active in HEPES 
buffer
Endoribonucleolytically active in 
Phosphate Buffer Yes No
Rpp35 inactive in 
phosphate buffer
Mg* -Dependence Mg^*-Independent Mg^*-Dependent Different Mg *^- 
dependence
Resistance to RNasin Yes unknown -
Protein Complex Suspected 5 protein complex unknown -
Sequence known No Yes -
Tryptic peptide Maldi-MS 
sequence matches
Yes, 4 peptide matches to 
Rpp35
N/A -
Contains transmembrane domain Unknown - unlikely as soluble Yes -
Requires RNA co-factor for activity No unknown -
Heat tolerances for enzymatic 
activity
Enzymatically active up to 
60“C, completely inactivated at 
70”C
unknown -
Generates cleavage fragments with 
3' hydroxyls Yes unknown -
Resistant to EDTA Yes unknown -
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4.2 Comparison of native mammalian endoribonuclease to other previously described
endoribonucleases also capable of degrading c-myc mRNA
The native mammalian endoribonuclease can also be shown to be distinct from the other 
three c-myc mRNA degrading endoribonucleases. The 52 kDa RasGap-associated G3BP has 
been demonstrated to endonucleolytically cleave single-stranded CA dinucleotides only in the 3'- 
UTR of c-myc mRNA in vitro (Guitard et al. 2001; Tourriere et al. 2001; Barnes et al. 2002), 
while the native mammalian endoribonuclease has been shown to cleave both single- and 
double-stranded CA dinucleotides located anywhere along the c-myc mRNA, independent of 
consensus elements. The native mammalian endoribonuclease can also be distinguished from 
the -65  kDa RNase E-like endoribonuclease, which has been demonstrated to cleave only within 
the 5'-AUUUA-3' motif found in the 3'-UTR of c-myc mRNA (Wennborg et al. 1995). The 
native mammalian endoribonuclease can also be distinguished from the previously described -39  
kDa enzyme, which was found to specifically cleave CRD c-myc mRNA (nts 1705-1792) at nts 
1743-1745 within the sequence AAGG (Lee et al. 1998). Similarities do exist between these two 
endoribonucleases, however, in that they both appear to be sequence-specific (Lee et al. 1998; 
Bergstrom et al. 2006; Tafech 2006). It was also determined that the while the -39  kDa 
endoribonuclease cleaved between nts 1727 and 1736 within the sequence 5 -CAAUGAAAAG- 
3' (Lee et al. 1998), the native mammalian endoribonuclease cleaved at nts 1727-1732 within the 
sequence 5'-CAAUGAA-3' (Bergstrom et al. 2006). The cleavage event at nt 1727 (CA) was 
generated by both endoribonucleases, a site that precisely corresponds to a c-myc cleavage 
product generated by murine erythroleukemia cells using ligation-mediated PCR method 
(Hanson and Schoenberg 2001); a fact that supports the role of these two endoribonucleases in 
the post-transcriptional control of c-myc mRNA in cells.
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4.3 Comparisons of native mammalian endoribonuclease to other previously described 
endoribonucleases capable of degrading mRNA.
The novel mammalian endoribonuclease also appears to be distinct from the other 
previously described endoribonucleases that are also capable of endonucleolytically cleaving 
mRNA. Recall that the native mammalian endoribonuclease is capable of degrading single- and 
double-stranded CA dinucleotides, as well as single-stranded UA and UG dinucleotides within 
the CRD of c-myc mRNA (Bergstrom et al. 2006; Tafech 2006).
None of the six discussed prokaryotic endoribonucleases (review Table 1, page 30) share 
cleavage specificity or have similar molecular weights to that of the native mammalian 
endoribonuclease. Both RNase E (~118 kDa) and G (-50  kDa) preferentially cleave only 5' to 
single-stranded AU-rich regions (Feng et al. 2002; Callaghan et al. 2003; Lee et al. 2003; 
Kaberdin and Bizebard 2005), while RNase III (26 kDa) cleaves only double-stranded stem-loop 
regions in the 5-UTR (Nicholson 1999; Condon and Putzer 2002; Conrad and Rauhut 2002). 
MazF (12.1 kDa) and PemK (-12 kDa) have both been determined to cleave only single­
stranded dinucleotides, and only when present within a consensus element (Hols et al. 1997; 
Engelberg-Kulka and Glaser 1999; Zhang et al. 2004b; Zhang et al. 2005). The last of the 
prokaryotic endoribonucleases, RNase P (RNA subunit -120 kDa, protein subunit -12.5 kDa), 
specifically cleaves single-stranded tna operon mRNA between the UG (nts 47-48) dinucleotide 
(Hartmann and Hartmann 2003; Kazantsev et al. 2003; Li and Altman 2003).
Neither of the two identified endoribonucleases known to exist in yeast, R ntlp  and 
RNase MRP, share cleavage specificity or have similar molecular weights to that of the native 
mammalian endoribonuclease (review Table 2, page 32). R ntlp (-55 kDa) has been 
demonstrated to cleave only double-stranded RNA hairpins, and cleaves regions that are capped
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by tetraloop consensus elements (Nagel and Ares 2000; Fortin e t  a l  2002; Lee e t  a l  2005). 
RNase MRP (1 protein subunit at 100.5 kDa, the other 8 at <32.5 kDa) has been found to cleave 
the 5 -UTR of CLB2 mRNA with, as of yet, undetermined cleavage specificity (Cai et a l  1999; 
Gill et a l  2004).
The cleavage specificity of the novel mammalian endoribonuclease is also distinct from 
all of the known and previously discussed vertebrate endoribonucleases (review Table 3, page 
56). The majority of the vertebrate endoribonucleases require consensus elements for cleavage, 
and are capable of cleaving either single-stranded or double-stranded mRNAs, but not both. The 
cleavage specificity of the native mammalian endoribonuclease is further distinguished from the 
other known vertebrate endoribonucleases in that none of the discussed endoribonucleases 
cleaved all three of the dinueleotides cleaved by the native mammalian endoribonuclease (UA, 
CA, and UG).
4.4 R p d 35
Rpp35 has been identified as a member of the SNARE family of proteins (Teng et a l  
2001). All Rpp35-family members, with one exception, are transmembrane proteins that are 
anchored by their carboxy-terminal tails, while their amino terminus and the majority of the 
polypeptide chain faces towards the cytoplasm (Teng et a l 2001). Rpp35 has been identified as 
a t-SNARE that is localized in the endoplasmic reticulum (ER), and is believed to play roles in 
ER-Golgi transport (Teng et a l  2001).
Extensive bioinformatic searches were conducted in an effort to putatively identify the 
nucleolytic domain of Rpp35. Rpp35 in Homo sapiens has been determined to be a 335 amino 
acid protein, with a calculated molecular weight of 38.7 kDa (Gasteiger et a l  2003). NCBI 
BLAST sequence homology searches found that the amino acid sequence of Rpp35 in Rattus
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Norvegicus and Mus musculus share 86% sequence homology to the amino acid sequence of 
human Rpp35 (Altschul et al. 1997). The amino acids that differed in these sequences were 
found to be conserved amino acid substitutions (Altschul et al. 1997). NCBI BLAST database 
conserved domain searches of the Homo sapiens Rpp35 amino acid sequence matched the t- 
SNARE complex subunit conserved domain with 32.5% overall sequence alignment homology 
(Marchler-Bauer et al. 2003). The t-SNARE eonserved domain of Rpp35 was predicted to be 
between amino acids 238-323 (Marchler-Bauer et al. 2003). As was expected, the t-SNARE 
conserved domain was also found in the Rpp35 of Mus musculus and Rattus norvegicus using 
the SUPERFAMILY database (Madera et al. 2004). Two predicted coiled-coil regions and a 
hydrophobic region were found by subjecting the primary amino acid sequence of Rpp35 to a 
variety of secondary structure prediction servers and algorithms. These servers included Jpred 
(Cuff et al. 1998), PSIPRED (McGuffin et al. 2000), SAM T99 (Krogh et al. 1994), SCRATCH 
(SSPro) (Cheng et al. 2005), and PredictProtein (Rost et al. 2003). The two coiled-coil regions 
of Rpp35 were found between amino aeids 230-266 and 276-312. The hydrophobic putative 
transmembrane domain of Rpp35 was predicted to be between amino acids 313-330. The coiled- 
coil regions (in the amino-terminal domain), the SNARE domain, and the transmembrane 
domain of Rpp35 are depicted below, in Figure 35.
\
Amino-terminal
d om ain
SNARE Transmembrane 
dom ain domain
Figure 35. Schematic representation of SNARE protein (Teng et al. 2001).
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The amino acid residue and predicted secondary structure composition of Rpp35 were 
also determined using the PHDsec PredictProtein program (Rost et al. 2003), and can be seen 
below, in Tables 6 and 7, respectively.
Table 6. Amino acid residue composition of Rpp35 (Rost et al. 2003).
%A: 5 . 1 %C: 0 . 9 %D: 6 . 3 %E: 11 . 9 %F: 4 . 2
%G: 5.1 %H: 2.1 %I : 6 . 6 %K: 6 . 6 %L: 7 . 8
%M: 2.1 %N: 3 . 0 %P : 2 . 7 %Q: 5 . 4 %R: 8 . 4
%S : 7 . 8 %T : 5 .1 %V: 6 . 6 %W: 0 . 9 %Y: 1 . 8
Table 7. Predicted secondary structure of Rpp35. H = Helix, E = extended (sheet), L 
Loop (Rost et at. 2003).
sec ,str type H E L
% in protein 6 4 . 4 8 3 . 8 8 3 1 . 6 4
To our knowledge, Rpp35 is the first protein of the SNARE family known to exhibit 
endoribonucleolytic activity. This exciting discovery generates more questions than it does 
answers. Several immediate questions need to be answered, and these questions correlate to the 
characterization tests that still need to be conducted, as outlined in Table 5. For example, is the 
endoribonucleolytic activity of Rpp35 substrate- or sequence-specific? If substrate-specific, is it 
specific only to the CRD of c-myc mRNA, or can it cleave other mRNAs as well? There are also 
deeper probing questions, which highlight the direction this research will most likely take; 
questions such as; is Rpp35 the ~35 kDa protein component of the native mammalian 
endoribonuclease complex?; are all five of the proteins that co-purified with the native 
mammalian endoribonuclease activity necessary for cleavage?; do the individual protein 
components display enzymatic activity, and does the specificity change?; which of the novel
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mammalian protein components are necessary for endoribonucleolytic cleavage?; will Rpp35 
retain endoribonuclease activity in vivol
Currently little is known about the true functions of SNARE proteins in regards to their 
role in growth, physiology, and development (Teng et a l  2001). Clearly there is much more to 
learn about the Rpp35 t-SNARE protein and its role as an endoribonuclease in everyday vital 
cellular processes.
As was briefly mentioned earlier (Chapter 1, Section 1.0.4), mRNA decay in yeast and 
mammals is now believed to occur at localized distinct cytoplasmic foci, referred to as 
processing bodies (P-bodies) or GW bodies (GWBs) (Sheth and Parker 2003; Cougot et a i  2004; 
Stinton et a l  2004). A 182 kDa human GWB protein has been discovered, called GW 182, that 
is characterized by multiple glycine/tryptophan (G/W) repeats as well as a classic RNA 
recogntition motif (RRM) (Eystathioy et a l  2002; Stinton et a l  2004; Jakymiw et a l  2005). In 
addition, it was found that in yeast, 5-3 ' mRNA degradation factors such as Dcpl/Dcp2, Xrnl,  
Ccr4, and LSm proteins were found to localize in discrete cytoplasmic foci, referred to a P- 
bodies (Sheth and Parker 2003; Lian et a l  2006). Since it was demonstrated that D cpla and 
LSm4 proteins colocalized with the GW182 in GWBs in mammalian cells (Eystathioy et a l  
2003), GWBs are now considered the mammalian anologue of P-bodies (Eystathioy et a l  2003; 
Cougot et a l  2004; Lian et a l  2006).
Proteins that are associated with GWBs, such as GW 182, are believed to play roles in 
mRNA degradation (Jakymiw et a l  2005). For example, it has been demonstrated that in human 
cells, Argonaute2 (Ago2) interacts with GW182 (Jakymiw et a l  2005; Liu et a l  2005). A 
GW182 knockdown experiment demonstrated that not only is GW182 essential for the formation 
of GWBs, but that the localization of Ago2 to the cytoplasmic foci was found to be completely
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abolished under these eonditions, indieating that the loealization of Ago2 to GWBs is dependent 
on GW182 (Jakymiw et al. 2005). This data also suggests that GWBs play a role in RNA 
intereference, as Ago2 is known to be a key player in this process (Liu et al. 2005).
While there is currently no direct evidence linking Rpp35 to GWBs, it is interesting to 
note that Rpp35 is known to localize within the ER. As other endoribonucleases have been 
implicated with GWBs, such as Argonaute2, it is not unreasonable to hypothesize that Rpp35 
could also be associating with GWBs. Perhaps the native mammalian endoribonuclease complex 
discussed here is also associated with, or a component of GWBs. Obviously there are many 
unanswered questions regarding Rpp35 and the native mammalian endoribonuclease, and future 
experimental work should help to clarify the role(s) they play in mRNA degradation.
4.5 Concluding Statement
The main goal of this thesis was to characterize human Rpp35 in an attempt to identify 
the -35  kDa protein that co-purified with the native mammalian endoribonuclease capable of 
endonucleolytically cleaving the CRD of c-myc mRNA in vitro. It was proposed, based on 
trypsin digest and MALDI-MS data analysis, that the -35 kDa protein component of the native 
mammalian endoribonuclease complex was Rpp35. To test this theory, Rpp35 was successfully 
generated, purified, and tested for endoribonuclease activity. It was determined that Rpp35 is 
capable of endoribonucleolytically degrading the CRD of c-myc mRNA (nts 1705-1792) in vitro, 
specifically cleaving single-stranded AA, AG, and GU dinucleotides, as well as GG 
dinucleotides found in double-stranded stem loop regions. While evidence exists to indicate that 
the -35  kDa protein component of the native mammalian endoribonuclease is in fact Rpp35, 
there is also some contradictory evidence to discount this theory. In short, more characterization 
tests must be completed before any firm conclusions can be made regarding the identity of the
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-35  kDa protein. To our knowledge, Rpp35 is the first t-SNARE protein to exhibit 
endoribonuclease activity, an exciting discovery in its own right.
Future characterization experiments should be able to definitively determine if the -35 
kDa protein is Rpp35. Long-term research that follows up this thesis should attempt to address 
two main questions: i) why would a t-SNARE protein that is involved in vesicular transport in 
the ER have endoribonuclease activity, and do other family members also exhibit similar 
activity? and ii) if Rpp35 is the active component of the native mammalian endoribonuclease 
complex, how can it be regulated in vivo so as to be useful for future cancer-related therapeutic 
applications?
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